<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01241591</url>
  </required_header>
  <id_info>
    <org_study_id>A3921080</org_study_id>
    <nct_id>NCT01241591</nct_id>
  </id_info>
  <brief_title>A Phase 3, Multi Site, Randomized, Double Blind, Placebo Controlled Study Of The Efficacy And Safety Comparing CP- 690,550 And Etanercept In Subjects With Moderate To Severe Chronic Plaque Psoriasis</brief_title>
  <official_title>A Phase 3, Multi Site, Randomized, Double Blind, Placebo Controlled, Parallel Group Study Of The Efficacy And Safety Of 2 Oral Doses Of CP- 690,550 And 1 Subcutaneous Dose Of Etanercept In Subjects With Moderate To Severe Chronic Plaque Psoriasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the efficacy of CP-690,550 as compared to etanercept and the safety of CP-690,550
      for treatment of moderate to severe chronic plaque psoriasis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2010</start_date>
  <completion_date type="Actual">January 2013</completion_date>
  <primary_completion_date type="Actual">January 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With a Physician's Global Assessment (PGA) Response of &quot;Clear&quot; or &quot;Almost Clear&quot; at Week 12</measure>
    <time_frame>Week 12</time_frame>
    <description>The PGA of psoriasis is scored on a 5-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling are scored separately over the whole body according to a 5-point severity scale (0 to 4). The severity scores are summed and averaged after which the total average is rounded to the nearest whole number score to determine the PGA score and category (0=clear; 1=almost clear; 2=mild; 3=moderate; and 4=severe). PGA response was defined as 0 (clear) or 1 (almost clear).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With a Psoriasis Area and Severity Index 75 (PASI75) Response at Week 12</measure>
    <time_frame>Week 12</time_frame>
    <description>The PASI quantifies the severity of a participant's psoriasis based on both lesion severity and the percent of body surface area (BSA) affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk [including axillae and groin], and lower limbs [including buttocks), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI75 response was defined as at least a 75 percent (%) reduction in PASI relative to baseline/Day 1.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a PGA Response of &quot;Clear&quot; or &quot;Almost Clear&quot; During the 12-Week Double-Blind Treatment</measure>
    <time_frame>Weeks 2, 4, and 8</time_frame>
    <description>The PGA of psoriasis is scored on a 5-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling are scored separately over the whole body according to a 5-point severity scale (0 to 4). The severity scores are summed and averaged after which the total average is rounded to the nearest whole number score to determine the PGA score and category (0=clear; 1=almost clear; 2=mild; 3=moderate; and 4=severe). PGA response is defined as 0 (clear) or 1 (almost clear).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants in Each PGA Category During the 12-Week Double-Blind Treatment</measure>
    <time_frame>Baseline and Weeks 2, 4, 8, and 12</time_frame>
    <description>The PGA of psoriasis is scored on a 5-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling are scored separately over the whole body according to a 5-point severity scale (0 to 4). The severity scores are summed and averaged after which the total average is rounded to the nearest whole number score to determine the PGA score and category (0=clear; 1=almost clear; 2=mild; 3=moderate; and 4=severe).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a PASI75 Response During the 12-Week Double-Blind Treatment</measure>
    <time_frame>Weeks 2, 4, and 8</time_frame>
    <description>The PASI quantifies the severity of a participant's psoriasis based on both lesion severity and the percent of BSA affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk [including axillae and groin], and lower limbs [including buttocks), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI75 response was defined as at least a 75% reduction in PASI relative to baseline/Day 1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean PASI Score During the 12-Week Double-Blind Treatment</measure>
    <time_frame>Baseline and Weeks 2, 4, 8, and 12</time_frame>
    <description>Combined assessment of lesion severity and area affected into single score; range=0(no disease)-72(maximal disease). Body divided into 4 sections=head, upper/lower limbs, trunk; each area scored by itself and scores combined for final PASI. For each section percent area of skin involved was estimated:0(0%)-6(90-100%) and severity estimated by clinical signs of erythema, induration, scaling; ranged 0-4: 0=none, 1=slight, 2=moderate, 3=marked, 4=very marked. Final PASI=sum of severity parameters for each section*area score*weighing factor (head=0.1, upper limbs=0.2, trunk=0.3, lower limbs=0.4). PASI score can vary in increments of 0.1; higher scores represent greater severity of psoriasis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in PASI Score During the 12-Week Double-Blind Treatment</measure>
    <time_frame>Weeks 2, 4, 8, and 12</time_frame>
    <description>Combined assessment of lesion severity and area affected into single score; range=0(no disease)-72(maximal disease). Body divided into 4 sections=head, upper/lower limbs, trunk; each area scored by itself and scores combined for final PASI. For each section percent area of skin involved was estimated:0(0%)-6(90-100%) and severity estimated by clinical signs of erythema, induration, scaling; ranged 0-4: 0=none, 1=slight, 2=moderate, 3=marked, 4=very marked. Final PASI=sum of severity parameters for each section*area score*weighing factor (head=0.1, upper limbs=0.2, trunk=0.3, lower limbs=0.4). PASI score can vary in increments of 0.1; higher scores represent greater severity of psoriasis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean PASI Component Scores by Body Region During the 12-Week Double Blind Treatment</measure>
    <time_frame>Baseline and Weeks 2, 4, 8, and 12</time_frame>
    <description>Combined assessment of lesion severity and area affected into single score; range=0(no disease)-72(maximal disease). Body divided into 4 sections=head, upper/lower limbs, trunk; each area scored by itself and scores combined for final PASI. For each section percent area of skin involved was estimated:0(0%)-6(90-100%) and severity estimated by clinical signs of erythema, induration, scaling; ranged 0-4: 0=none, 1=slight, 2=moderate, 3=marked, 4=very marked. Final PASI=sum of severity parameters for each section*area score*weighing factor (head=0.1, upper limbs=0.2, trunk=0.3, lower limbs=0.4). PASI score can vary in increments of 0.1; higher scores represent greater severity of psoriasis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in PASI Component Scores by Body Region During the 12-Week Double Blind Treatment</measure>
    <time_frame>Weeks 2, 4, 8, and 12</time_frame>
    <description>Combined assessment of lesion severity and area affected into single score; range=0(no disease)-72(maximal disease). Body divided into 4 sections=head, upper/lower limbs, trunk; each area scored by itself and scores combined for final PASI. For each section percent area of skin involved was estimated:0(0%)-6(90-100%) and severity estimated by clinical signs of erythema, induration, scaling; ranged 0-4: 0=none, 1=slight, 2=moderate, 3=marked, 4=very marked. Final PASI=sum of severity parameters for each section*area score*weighing factor (head=0.1, upper limbs=0.2, trunk=0.3, lower limbs=0.4). PASI score can vary in increments of 0.1; higher scores represent greater severity of psoriasis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Percentage of Total Psoriatic BSA During the 12-Week Double-Blind Treatment</measure>
    <time_frame>Baseline and Weeks 2, 4, 8, and 12</time_frame>
    <description>Assessment of BSA with psoriasis performed separately for 4 body regions: head and neck, upper limbs, trunk (including axillae and groin), and lower limbs (including buttocks). The % surface area with psoriasis was estimated by means of the handprint method, where the full palmar hand of the participant (fully extended palm, fingers and thumb together) represented approximately 1% of the total BSA. The number of handprints of psoriatic skin in a body region was used to determine the extent (%) to which a body region was involved with psoriasis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Percent Change From Baseline in Total Psoriatic BSA During the 12-Week Double-Blind Treatment</measure>
    <time_frame>Weeks 2, 4, 8, and 12</time_frame>
    <description>Assessment of BSA with psoriasis performed separately for 4 body regions: head and neck, upper limbs, trunk (including axillae and groin), and lower limbs (including buttocks). The %surface area with psoriasis was estimated by means of the handprint method, where the full palmar hand of the participant(fully extended palm, fingers and thumb together) represented approximately 1% of the total BSA. The number of handprints of psoriatic skin in a body region was used to determine the extent (%) to which a body region was involved with psoriasis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Achieved a 50% Reduction in PASI Relative to Baseline (PASI50) During the 12-Week Double-Blind Treatment</measure>
    <time_frame>Weeks 2, 4, 8, and 12</time_frame>
    <description>PASI quantifies severity of psoriasis based on both lesion severity and percent of BSA affected. PASI is a composite score by the investigator of degree of erythema, induration, and scaling (scored separately) for each of 4 body regions (head and neck, upper limbs, trunk [including axillae and groin], and lower limbs [including buttocks), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0; higher scores represent greater severity of psoriasis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Time to PASI50 Response During the 12-Week Double-Blind Treatment</measure>
    <time_frame>Baseline up to Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Achieved a 90% Reduction in PASI Relative to Baseline (PASI90) During the 12-Week Double-Blind Treatment</measure>
    <time_frame>Weeks 2, 4, 8, and 12</time_frame>
    <description>PASI quantifies severity of psoriasis based on both lesion severity and percent of BSA affected. PASI is a composite score by the investigator of degree of erythema, induration, and scaling (scored separately) for each of 4 body regions (head and neck, upper limbs, trunk [including axillae and groin], and lower limbs [including buttocks), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0; higher scores represent greater severity of psoriasis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Time to Achieve PASI75 Response During the 12-Week Double-Blind Treatment</measure>
    <time_frame>Baseline up to Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a PASI Score Greater Than or Equal to (≥)125% of the Baseline PASI Score During the 12-Week Double-Blind Treatment</measure>
    <time_frame>Weeks 2, 4, 8, and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Itch Severity Item (ISI) Score During the 12-Week Double-Blind Treatment</measure>
    <time_frame>Baseline, Weeks 2, 4, 8, and 12</time_frame>
    <description>ISI assessed severity of itch (pruritus) due to psoriasis. ISI is a single item, horizontal numeric rating scale. Participants were asked to rate &quot;your worst itching due to psoriasis over the past 24 hours&quot; on a numeric rating scale anchored by the terms &quot;No itching&quot; (0) and &quot;Worst possible itching&quot; (10) at the ends.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in ISI Score During the 12-Week Double-Blind Treatment</measure>
    <time_frame>Weeks 2, 4, 8, and 12</time_frame>
    <description>ISI assessed severity of itch (pruritus) due to psoriasis. ISI is a single item, horizontal numeric rating scale. Participants were asked to rate &quot;your worst itching due to psoriasis over the past 24 hours&quot; on a numeric rating scale anchored by the terms &quot;No itching&quot; (0) and &quot;Worst possible itching&quot; (10) at the ends.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving an ISI Score of 0 During the 12-Week Double-Blind Treatment</measure>
    <time_frame>Weeks 2, 4, 8, and 12</time_frame>
    <description>ISI assessed severity of itch (pruritus) due to psoriasis. ISI is a single item, horizontal numeric rating scale. Participants were asked to rate &quot;your worst itching due to psoriasis over the past 24 hours&quot; on a numeric rating scale anchored by the terms &quot;No itching&quot; (0) and &quot;Worst possible itching&quot; (10) at the ends.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Dermatology Life Quality Index (DLQI) Score During the 12-Week Double-Blind Treatment</measure>
    <time_frame>Baseline and Weeks 4 and 12</time_frame>
    <description>The DLQI is a general dermatology questionnaire that consists of 10 items that assess health related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI questions are rated by the participant as 0 (not at all/not relevant) to 3 (very much) with a total score range of 0 (best) to 30 (worst); higher scores indicate poor quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in DLQI Score During the 12-Week Double-Blind Treatment</measure>
    <time_frame>Weeks 4 and 12</time_frame>
    <description>The DLQI is a general dermatology questionnaire that consists of 10 items that assess health related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI questions are rated by the participant as 0 (not at all/not relevant) to 3 (very much) with a total score range of 0 (best) to 30 (worst); higher scores indicate poor quality of life. The minimally important difference for the DLQI has been estimated as a 2 to 5 point change from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean DLQI Subscale Scores During the 12-Week Double-Blind Treatment</measure>
    <time_frame>Baseline and Weeks 4 and 12</time_frame>
    <description>The DLQI is a general dermatology questionnaire that consists of 10 items that assess health related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI questions are rated by the participant as 0 (not at all/not relevant) to 3 (very much); higher scores indicate poor quality of life. The DLQI can be analyzed under 6 subscales by combining questions and is categorized as follows: symptoms and feelings (maximum score=6); daily activities (maximum score=6); leisure (maximum score=6); work and school (maximum score=3); personal relationships (maximum score=6); and treatment (maximum score=3).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in DLQI Subscale Scores During the 12-Week Double-Blind Treatment</measure>
    <time_frame>Weeks 4 and 12</time_frame>
    <description>The DLQI is a general dermatology questionnaire that consists of 10 items that assess health related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI questions are rated by the participant as 0 (not at all/not relevant) to 3 (very much); higher scores indicate poor quality of life. The DLQI can be analyzed under 6 subscales by combining questions and is categorized as follows: symptoms and feelings (maximum score=6); daily activities (maximum score=6); leisure (maximum score=6); work and school (maximum score=3); personal relationships (maximum score=6); and treatment (maximum score=3). The minimally important difference for the DLQI has been estimated as a 2 to 5 point change from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving DLQI Response ≥5 During the 12-Week Double-Blind Treatment</measure>
    <time_frame>Weeks 4 and 12</time_frame>
    <description>The DLQI is a general dermatology questionnaire that consists of 10 items that assess health related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI questions are rated by the participant as 0 (not at all/not relevant) to 3 (very much) with a total score range of 0 (best) to 30 (worst); higher scores indicate poor quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving DLQI Response ≤1 During the 12-Week Double-Blind Treatment</measure>
    <time_frame>Weeks 4 and 12</time_frame>
    <description>The DLQI is a general dermatology questionnaire that consists of 10 items that assess health related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI questions are rated by the participant as 0 (not at all/not relevant) to 3 (very much) with a total score range of 0 (best) to 30 (worst); higher scores indicate poor quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Time to DLQI Response</measure>
    <time_frame>Weeks 4 and 12</time_frame>
    <description>The DLQI is a general dermatology questionnaire that consists of 10 items that assess health related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI questions are rated by the participant as 0 (not at all/not relevant) to 3 (very much) with a total score range of 0 (best) to 30 (worst); higher scores indicate poor quality of life. DLQI Response was defined as a 5-point reduction in the total DLQI score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Short Form 36 (SF-36) Mental Component Summary (MCS) and Physical Component Summary (PCS) Scores at Baseline and Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>The SF-36 is a general health status questionnaire that assesses 8 domains of functional health and well being: Physical Functioning, Role Limitations due to Physical Health Problems, Bodily Pain, Social Functioning, Mental Health, Role Limitations due to Emotional Problems, Vitality, and General Health Perceptions. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning). A PCS score and MCS score are based on a normalized sum of the 8 scale scores; PCS/MCS summary concept score = (raw score*10) plus 50. Higher scores indicate a better health related quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean SF-36 Domain Scores at Baseline and Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>The SF-36 is a general health status questionnaire that assesses 8 domains of functional health and well being: Physical Functioning, Role Limitations due to Physical Health Problems, Bodily Pain, Social Functioning, Mental Health, Role Limitations due to Emotional Problems, Vitality, and General Health Perceptions. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning). Higher scores indicate a better health related quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in SF-36 MCS and PCS Scores</measure>
    <time_frame>Week 12</time_frame>
    <description>The SF-36 is a general health status questionnaire that assesses 8 domains of functional health and well being: Physical Functioning, Role Limitations due to Physical Health Problems, Bodily Pain, Social Functioning, Mental Health, Role Limitations due to Emotional Problems, Vitality, and General Health Perceptions. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning). A PCS score and MCS score are based on a normalized sum of the 8 scale scores; PCS/MCS summary concept score = (raw score*10) plus 50. Higher scores indicate a better health related quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in SF-36 Domain Scores</measure>
    <time_frame>Week 12</time_frame>
    <description>The SF-36 is a general health status questionnaire that assesses 8 domains of functional health and well being: Physical Functioning, Role Limitations due to Physical Health Problems, Bodily Pain, Social Functioning, Mental Health, Role Limitations due to Emotional Problems, Vitality, and General Health Perceptions. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning). Higher scores indicate a better health related quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants in Each Patient Global Assessment of Psoriasis (PtGA) Category During the 12-Week Double-Blind Treatment</measure>
    <time_frame>Baseline and Weeks 2, 4, and 8</time_frame>
    <description>The PtGA asks the participant to evaluate the overall cutaneous disease at that point in time on a single item, 5-point scale (0=clear; 1=almost clear; 2=mild; 3=moderate; 4=severe).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a PtGA Response During the 12-Week Double-Blind Treatment</measure>
    <time_frame>Weeks 2, 4, 8, and 12</time_frame>
    <description>The PtGA asks the participant to evaluate the overall cutaneous disease at that point in time on a single item, 5-point scale (0=clear; 1=almost clear; 2=mild; 3=moderate; 4=severe). Response defined as score of 0 or 1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants in Each Patient Satisfaction With Study Medication (PSSM) Category During the 12-Week Double-Blind Treatment</measure>
    <time_frame>Week 12</time_frame>
    <description>The PSSM is a single, 7 point item that evaluates overall participant satisfaction with the study treatment. Response options range from &quot;very dissatisfied&quot; to &quot;very satisfied&quot; with the study medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving PSSM Response of 'Very Satisfied' or 'Somewhat Satisfied' at Week 12</measure>
    <time_frame>Week 12</time_frame>
    <description>The PSSM is a single, 7 point item that evaluates overall participant satisfaction with the study treatment. Response options range from &quot;very dissatisfied&quot; to &quot;very satisfied&quot; with the study medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean European Quality of Life 5 Dimension (EQ-5D) Health State Utility Score During the 12-Week Double-Blind Treatment</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problems); 3 indicates worst health state (&quot;confined to bed&quot;). Scoring formula developed by EuroQol Group assigns a utility value for each domain in the profile. Score is transformed and results in a total score range -0.594 to 1.000; higher score indicates a better health state.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Least Squares (LS) Mean Change From Baseline in EQ-5D Health State Utility Score During the 12-Week Double-Blind Treatment</measure>
    <time_frame>Week 12</time_frame>
    <description>EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problems); 3 indicates worst health state (&quot;confined to bed&quot;). Scoring formula developed by EuroQol Group assigns a utility value for each domain in the profile. Score is transformed and results in a total score range -0.594 to 1.000; higher score indicates a better health state.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean EQ-5D Visual Analog Score (VAS) During the 12-Week Double-Blind Treatment</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single index value. The VAS component rates current health state on a scale from 0 mm (worst imaginable health state) to 100 mm (best imaginable health state); higher scores indicate a better health state.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in EQ-5D VAS at Week 12</measure>
    <time_frame>Week 12</time_frame>
    <description>EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single index value. The VAS component rates current health state on a scale from 0 mm (worst imaginable health state) to 100 mm (best imaginable health state); higher scores indicate a better health state.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dimension Health State EQ-5D Score During the 12-Week Double-Blind Treatment</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 dimensions: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression. The score for each of the 5 dimensions can range from 1 to 3; 1 indicates better health state (no problems); 3 indicates worst health state (&quot;confined to bed&quot;).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in EQ-5D Dimension Health State Score at Week 12</measure>
    <time_frame>Week 12</time_frame>
    <description>EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 dimensions: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression. The score for each of the 5 dimensions can range from 1 to 3; 1 indicates better health state (no problems); 3 indicates worst health state (&quot;confined to bed&quot;).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Interacting With Healthcare Professionals During the 12-Week Double-Blind Treatment</measure>
    <time_frame>Baseline (BL) and Week 12</time_frame>
    <description>The Psoriasis Health Care Resource Utilization (Ps-HCRU) questionnaire is a short questionnaire designed to assess healthcare resource use and the impact of psoriasis on work. The first section assesses direct costs associated with healthcare resource use (interactions with healthcare providers such as general practitioners [GPs], primary care physicians [PCPs], or family medicine physicians [FMP], emergency room visits, and hospitalizations), and the second section assesses indirect costs associated with absenteeism due to psoriasis and the impact of psoriasis on productivity at work.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Reporting Healthcare Resource Use Events During the 12-Week Double-Blind Treatment</measure>
    <time_frame>Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Employed or Not Employed and the Impact of Psoriasis on Work</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>Psoriasis Health Care Resource Utilization Questionnaire is a short questionnaire designed to assess healthcare resource use and the impact of psoriasis on work. The questionnaire assesses employment status of participant (employed: yes or no) and if currently employed it asks the participant if they were absent or on sick leave from work due to psoriasis; if unemployed it asks the participant if the unemployment is due to psoriasis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Reporting Work-Impacted Events During the 12-Week Double-Blind Treatment</measure>
    <time_frame>Week 12</time_frame>
    <description>Psoriasis Health Care Resource Utilization Questionnaire is a short questionnaire designed to assess healthcare resource use and the impact of psoriasis on work.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Psoriasis Quality of Life 12 (PQOL-12) Score During the 12-Week Double-Blind Treatment</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>The PQOL-12 is a 12-item questionnaire; 8 of the items on the Koo-Menter Psoriasis Index 12-item Quality of Life Questionnaire (PQOL-12) focus on emotional issues associated with psoriasis (self conscious, helpless, embarrassed, ability to enjoy life). The last 4 items deal with physical symptoms (pain or soreness, itch, physical irritation) and choice of clothing. The recall period is over the past month. The questions are answered on a scale from 0 to 10 with 0 being best and 10 being worst. Scores from each question are summed to give a total score (range 0 -120); higher scores indicate greater impairment to quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in PQOL-12 Score During the 12-Week Double-Blind Treatment</measure>
    <time_frame>Week 12</time_frame>
    <description>The PQOL-12 is a 12-item questionnaire; 8 of the items on the PQOL-12) focus on emotional issues associated with psoriasis (self conscious, helpless, embarrassed, ability to enjoy life). The last 4 items deal with physical symptoms (pain or soreness, itch, physical irritation) and choice of clothing. The recall period is over the past month. The questions are answered on a scale from 0 to 10 with 0 being best and 10 being worst. Scores from each question are summed to give a total score (range 0 -120); higher scores indicate greater impairment to quality of life.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">1101</enrollment>
  <condition>Psoriasis</condition>
  <arm_group>
    <arm_group_label>CP 690,550 5 mg BID+Placebo BIW</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>CP 690,550 10 mg BID+Placebo BIW</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo BID+Etanercept 50 mg BIW</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo BID+Placebo BIW</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CP 690,550 5 mg</intervention_name>
    <description>CP-690,550 5 mg orally dosed twice daily and placebo subcutaneously dosed twice weekly for 12 weeks</description>
    <arm_group_label>CP 690,550 5 mg BID+Placebo BIW</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CP 690,550 10 mg</intervention_name>
    <description>CP-690,550 10 mg orally dosed twice daily and placebo subcutaneously dosed twice weekly for 12 weeks</description>
    <arm_group_label>CP 690,550 10 mg BID+Placebo BIW</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Etanercept 50 mg</intervention_name>
    <description>Placebo orally dosed twice daily and etanercept 50 mg subcutaneously dosed twice weekly for 12 weeks</description>
    <arm_group_label>Placebo BID+Etanercept 50 mg BIW</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo orally dosed twice daily and placebo subcutaneously dosed twice weekly for 12 weeks.</description>
    <arm_group_label>Placebo BID+Placebo BIW</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Have had a diagnosis of plaque type psoriasis (psoriasis vulgaris);

          -  Have plaque-type psoriasis covering at least 10% of total body surface area

          -  Considered by dermatologist investigator to be a candidate for systemic therapy or
             phototherapy of psoriasis

        Exclusion Criteria:

          -  Non-plaque or drug induced forms of psoriasis

          -  Cannot discontinue current systemic and/or topical therapies for the treatment of
             psoriasis

          -  Cannot discontinue phototherapy

          -  Any uncontrolled significant medical condition
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centro de Investigaciones Dermatologicas</name>
      <address>
        <city>Ciudad Autonoma de Buenos Aires</city>
        <state>C1114aap</state>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Investigaciones Dermatologicas</name>
      <address>
        <city>Ciudad Autonoma de Buenos Aires</city>
        <zip>C1114AAP</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IMAI (Instituto Medico de Asistencia e Investigaciones)</name>
      <address>
        <city>Ciudad Autonoma de Buenos Aires</city>
        <zip>C1425AWC</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LKH Feldkirch Abteilung fuer Dermatologie und Venerologie</name>
      <address>
        <city>Feldkirch</city>
        <zip>A-6807</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LKH Innsbruck Universitaetsklinik fuer Dermatologie und Venerologie</name>
      <address>
        <city>Innsbruck</city>
        <zip>A-6020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LKH Salzburg, Landesklinik fuer Dermatologie</name>
      <address>
        <city>Salzburg</city>
        <zip>5020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krankenhaus Hietzing mit Neurologischem Zentrum Rosenhuegel</name>
      <address>
        <city>Wien</city>
        <zip>1130</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cliniques universitaires Saint-Luc</name>
      <address>
        <city>Bruxelles</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Gent</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department for skin and venerial diseases, Clinical Center University of Sarajevo</name>
      <address>
        <city>Sarajevo</city>
        <zip>71000</zip>
        <country>Bosnia and Herzegovina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitetska Mnogoprofilna Bolnitsa Za Aktivno Lechenie- Dr Georgi Stranski- Pleven</name>
      <address>
        <city>Pleven</city>
        <zip>5800</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tsentar za kozhno-venericheski zaboliavania&quot; EOOD</name>
      <address>
        <city>Sofia</city>
        <zip>1404</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mnogoprofilna Bolnitsa Za Aktivno Lechenie- Tokuda Bolnitsa Sofia- Sofia</name>
      <address>
        <city>Sofia</city>
        <zip>1407</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitetska mnogoprofilna bolnitsa za aktivno lechenie- Alexandrovska- Sofia</name>
      <address>
        <city>Sofia</city>
        <zip>1431</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MBAL na Voennomeditsinska akademia- Sofia</name>
      <address>
        <city>Sofia</city>
        <zip>1606</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica Davila</name>
      <address>
        <city>Santiago, Rm 8431657</city>
        <state>RM</state>
        <zip>8420383</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Especialidades Dermatologicas</name>
      <address>
        <city>Vina del Mar</city>
        <state>V Region</state>
        <zip>00000</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica Dermovein S.A.</name>
      <address>
        <city>Santiago</city>
        <zip>7640881</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universidad de Chile, Departamento Dermatologia</name>
      <address>
        <city>Santiago</city>
        <zip>8380456</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Reumalab S.A.S.</name>
      <address>
        <city>Medellin</city>
        <state>Antioquia</state>
        <zip>0</zip>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Integral de Reumatología del Caribe Circaribe S.A</name>
      <address>
        <city>Barranquilla</city>
        <state>Atlantico</state>
        <zip>0000</zip>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Investigacion Clinica de la Universidad del Rosario</name>
      <address>
        <city>Bogota</city>
        <state>Cundinamarca</state>
        <zip>0000</zip>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Riesgo de Fractura S.A.</name>
      <address>
        <city>Bogota</city>
        <state>Cundinamarca</state>
        <zip>0000</zip>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medicity S.A.S</name>
      <address>
        <city>Bucaramanga</city>
        <state>Santander</state>
        <zip>0000</zip>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Dermatovenerology, University Hospital Center Osijek</name>
      <address>
        <city>Osijek</city>
        <zip>31000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatovenerological Clinic, University hospital center &quot;Sestre milosrdnice&quot;</name>
      <address>
        <city>Zagreb</city>
        <zip>10 000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of dermatovenerology, University Hospital Center Zagreb</name>
      <address>
        <city>Zagreb</city>
        <zip>10000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nemocnice Ceske Budejovice, a.s.</name>
      <address>
        <city>Ceske Budejovice</city>
        <zip>37001</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FN Kradec Kralove</name>
      <address>
        <city>Hradec Kralove</city>
        <zip>50005</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fakultni nemocnice Plzen</name>
      <address>
        <city>Plzen - Bory</city>
        <zip>30599</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kozni ordinace</name>
      <address>
        <city>Praha 1</city>
        <zip>11000</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kralska zdravotni a.s., Masarykovy nemocnice o.z.</name>
      <address>
        <city>Usti nad Labem</city>
        <zip>40113</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kralska zdravotni</name>
      <address>
        <city>Usti nad Labem</city>
        <zip>40113</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Dermatology, Aarhus University Hospital</name>
      <address>
        <city>Aarhus C</city>
        <zip>8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bispebjerg Hospital, University of Copenhagen</name>
      <address>
        <city>Copenhagen NV</city>
        <zip>2400</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hudklinikken Herning</name>
      <address>
        <city>Herning</city>
        <zip>7400</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHG Le Mans</name>
      <address>
        <city>Le Mans</city>
        <state>Cedex 09</state>
        <zip>72037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Besancon - Hopital Saint Jacques</name>
      <address>
        <city>Besancon</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Ambroise Pare, Service de Dermatologie</name>
      <address>
        <city>Boulogne</city>
        <zip>92104</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu Morvan</name>
      <address>
        <city>BREST Cédex</city>
        <zip>29609</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Dupuytren</name>
      <address>
        <city>Limoges</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Fournier</name>
      <address>
        <city>NANCY Cédex</city>
        <zip>54035</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Nantes - Hotel Dieu</name>
      <address>
        <city>Nantes Cedex 1</city>
        <zip>44035</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de NICE - Hôpital de l'Archet II</name>
      <address>
        <city>Nice</city>
        <zip>06200</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Saint-Louis</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Bichat</name>
      <address>
        <city>Paris</city>
        <zip>75018</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Lyon Sud</name>
      <address>
        <city>Pierre-Benite</city>
        <zip>69310</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>C.H.U. de Poitiers</name>
      <address>
        <city>Poitiers</city>
        <zip>86000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Robert Debre</name>
      <address>
        <city>Reims</city>
        <zip>51100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Nord</name>
      <address>
        <city>Saint Priest En Jarez</city>
        <zip>42270</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Larrey</name>
      <address>
        <city>Toulouse cedex 9</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital de Brabois / Bâtiment Philippe Canton</name>
      <address>
        <city>Vandoeuvre-les-Nancy</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charite - Universitaetsmedizin Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hautarztpraxis</name>
      <address>
        <city>Berlin</city>
        <zip>13507</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dres.Kirsten Prepeneit und Volker Streit</name>
      <address>
        <city>Buchholz</city>
        <zip>21244</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinik Carl Gustav Carus</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hautzentrum Duelmen</name>
      <address>
        <city>Duelmen</city>
        <zip>48249</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Erlangen Hautklinik im Internistischen Zentrum</name>
      <address>
        <city>Erlangen</city>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der Johann Wolfgang Goethe Universitaet</name>
      <address>
        <city>Frankfurt/Main</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Hamburg-Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hautklinik der Ruprecht-Karls-Universitaet Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <zip>69115</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaets- Hautklinik Koeln</name>
      <address>
        <city>Koeln</city>
        <zip>50924</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hautarztpraxis Dres. Scholz, Sebastian, Schilling</name>
      <address>
        <city>Mahlow</city>
        <zip>15831</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz KoeR</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Technische Universitaet Muenchen</name>
      <address>
        <city>Muenchen</city>
        <zip>80802</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dres. med. Bredlich/PD Rosenbach/Thiele</name>
      <address>
        <city>Osnabrueck</city>
        <zip>49078</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eberhard-Karls-Universitaet Tuebingen</name>
      <address>
        <city>Tuebingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hautarztpraxis</name>
      <address>
        <city>Witten</city>
        <zip>58453</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Hong Kong (HKU)-Queen Mary Hospital (QMH)</name>
      <address>
        <city>Hong Kong</city>
        <zip>0</zip>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus Magyarorszag Kft.</name>
      <address>
        <city>Budapest</city>
        <zip>1036</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Debreceni Egyetem Orvos- es Egeszsegtudomanyi Centrum/Bor- es Nemikortani Klinika</name>
      <address>
        <city>Debrecen</city>
        <zip>4032</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Miskolci Semmelweis Ignac Korhaz-Rendelointezet/Borgyogyaszat</name>
      <address>
        <city>Miskolc</city>
        <zip>3529</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SZTE Szentgyorgyi Albert Klinikai Kozpont/Borgyogyaszati es Allergologiai Klinika</name>
      <address>
        <city>Szeged</city>
        <zip>6720</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ALLERGO-DERM BAKOS Kft.</name>
      <address>
        <city>Szolnok</city>
        <zip>5000</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology Department</name>
      <address>
        <city>Afula</city>
        <zip>18101</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center / Department of Dermatology</name>
      <address>
        <city>Gangnam-Gu</city>
        <state>Seoul</state>
        <zip>135-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Severance Hospital, Yonsei University College of Medicine/Department of Dermatology</name>
      <address>
        <city>Seoul</city>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Academic Medical Centre (AMC)</name>
      <address>
        <city>Amsterdam</city>
        <state>Noord Holland</state>
        <zip>1105 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PT &amp; R</name>
      <address>
        <city>Beek</city>
        <zip>6191 JW</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Amphia Hospital Location Molengracht / Department Dermatology</name>
      <address>
        <city>Breda</city>
        <zip>4800 RK</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Erasmus MC</name>
      <address>
        <city>Rotterdam</city>
        <zip>3015 CA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NZOZ Osteo-Medic s.c. Artur Racewicz, Jerzy Supronik</name>
      <address>
        <city>Bialystok</city>
        <zip>05-354</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinika Dermatologii, Wenerologii i Alergologii, Uniwersyteckie Centrum Kliniczne</name>
      <address>
        <city>Gdansk</city>
        <zip>80-952</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krakowskie Centrum Medyczne NZOZ</name>
      <address>
        <city>Krakow</city>
        <zip>31-501</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novum Instytut Dermatologii Leczniczej i Estetycznej</name>
      <address>
        <city>Opole</city>
        <zip>45-080</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Solumed S.C.</name>
      <address>
        <city>Poznan</city>
        <zip>60-539</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Korolev Dermatovenerologic Dispensary</name>
      <address>
        <city>Korolev</city>
        <state>Moscow region</state>
        <zip>141070</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Research Center of Dermatovenerology, Department of clinical dermatology</name>
      <address>
        <city>Moscow</city>
        <zip>107076</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Research Center of Dermatovenerology, Department of dermatology</name>
      <address>
        <city>Moscow</city>
        <zip>107076</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatovenerologic dispensary #7</name>
      <address>
        <city>Moscow</city>
        <zip>121614</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rostov-on-Don regional dermatovenerologic dispensary</name>
      <address>
        <city>Rostov-on-Don</city>
        <zip>344007</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ryazan regional clinical dermatovenerologic dispensary</name>
      <address>
        <city>Ryazan</city>
        <zip>390046</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatovenerologic dispensary #10 of Vyborg region</name>
      <address>
        <city>Saint-Petersburg</city>
        <zip>194021</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Military medical academy S.M. Kirov</name>
      <address>
        <city>Saint-Petersburg</city>
        <zip>194044</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North-Western State Medical University I.I. Mechnikov, Dermatovenerology Department</name>
      <address>
        <city>Saint-Petersburg</city>
        <zip>195067</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinic of dermatovenerologic diseases</name>
      <address>
        <city>Saratov</city>
        <zip>410028</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Smolensk State Medical Academy</name>
      <address>
        <city>Smolensk</city>
        <zip>214019</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical hospital of emergency care N.V. Soloviev</name>
      <address>
        <city>Yaroslavl</city>
        <zip>150003</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Skin Centre</name>
      <address>
        <city>Singapore</city>
        <zip>308205</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Changi General Hospital</name>
      <address>
        <city>Singapore</city>
        <zip>529889</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatologicka klinika SZU, Fakultna nemocnica s poliklinikou F.D. Roosevelta</name>
      <address>
        <city>Banska Bystrica</city>
        <zip>975 17</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Narodny ustav reumatickych chorob</name>
      <address>
        <city>Piestany</city>
        <zip>921 12</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DOST-Dermatovenerologicke oddelenie sanatorneho typu, SANARE, spol. s r.o.</name>
      <address>
        <city>Svidnik</city>
        <zip>089 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Fundacion Alcorcon</name>
      <address>
        <city>Alcorcon</city>
        <state>Madrid</state>
        <zip>28922</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Puerta de Hierro Majadahonda</name>
      <address>
        <city>Majadahonda</city>
        <state>Madrid</state>
        <zip>28222</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario de Alicante</name>
      <address>
        <city>Alicante</city>
        <zip>03010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de La Princesa</name>
      <address>
        <city>Madrid</city>
        <zip>28006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Consorcio Hospital General Universitario de Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Falu lasarett, Hudkliniken</name>
      <address>
        <city>Falun</city>
        <zip>791 82</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hermelinen Forskning AB</name>
      <address>
        <city>Lulea</city>
        <zip>972 33</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Skanes Universitetssjukhus i Malmo, Hudkliniken</name>
      <address>
        <city>Malmo</city>
        <zip>205 02</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sodersjukhuset, Hudkliniken</name>
      <address>
        <city>Stockholm</city>
        <zip>118 83</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karolinska Universitetssjukhuset Solna</name>
      <address>
        <city>Stockholm</city>
        <zip>171 76</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital St. Gallen</name>
      <address>
        <city>St. Gallen</city>
        <zip>9007</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gazi University Medical Faculty</name>
      <address>
        <city>Besevler</city>
        <state>Ankara</state>
        <zip>06500</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istanbul university Istanbul Medical Faculty</name>
      <address>
        <city>Capa</city>
        <state>Istanbul</state>
        <zip>34390</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>T.C. Saglik Bakanligi Marmara Universitesi Egitim ve Arastirma Hastanesi Dermatoloji Anabilim Dali</name>
      <address>
        <city>Pendik</city>
        <state>Istanbul</state>
        <zip>34890</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mersin University Medical Faculty</name>
      <address>
        <city>Akdeniz</city>
        <state>Mersin</state>
        <zip>33070</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dokuz Eylul Universitesi Tip Fakultesi Dermatoloji Anabilim Dali</name>
      <address>
        <city>Izmir</city>
        <zip>35340</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Whipps Cross University Hospital</name>
      <address>
        <city>London</city>
        <state>Leytonstone</state>
        <zip>E11 1NR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leicester Royal Infirmary, Balmoral building, Clinic 3, Dermatology</name>
      <address>
        <city>Leicester</city>
        <zip>LE1 5WW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Bosnia and Herzegovina</country>
    <country>Bulgaria</country>
    <country>Chile</country>
    <country>Colombia</country>
    <country>Croatia</country>
    <country>Czech Republic</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hong Kong</country>
    <country>Hungary</country>
    <country>Israel</country>
    <country>Korea, Republic of</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Singapore</country>
    <country>Slovakia</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Switzerland</country>
    <country>Turkey</country>
    <country>United Kingdom</country>
  </location_countries>
  <removed_countries>
    <country>Italy</country>
  </removed_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A3921080&amp;StudyName=A%20Phase%203%2C%20Multi%20Site%2C%20Randomized%2C%20Double%20Blind%2C%20Placebo%20Controlled%20Study%20Of%20The%20Efficacy%20And%20Safety%20Comparing%20CP-%20690%2C550%20And</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>May 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 12, 2010</study_first_submitted>
  <study_first_submitted_qc>November 12, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 16, 2010</study_first_posted>
  <results_first_submitted>January 27, 2014</results_first_submitted>
  <results_first_submitted_qc>April 4, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 7, 2014</results_first_posted>
  <last_update_submitted>May 8, 2014</last_update_submitted>
  <last_update_submitted_qc>May 8, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 19, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CP-690,550</keyword>
  <keyword>Etanercept</keyword>
  <keyword>Moderate</keyword>
  <keyword>Severe</keyword>
  <keyword>Chronic</keyword>
  <keyword>Plaque</keyword>
  <keyword>Psoriasis</keyword>
  <keyword>Efficacy</keyword>
  <keyword>Safety</keyword>
  <keyword>Tofacitinib</keyword>
  <keyword>Xeljanz</keyword>
  <keyword>OPT Compare</keyword>
  <keyword>OPT</keyword>
  <keyword>head-to-head</keyword>
  <keyword>non-inferiority</keyword>
  <keyword>Psoriasis vulgaris</keyword>
  <keyword>short-term</keyword>
  <keyword>Itch</keyword>
  <keyword>Pruritus</keyword>
  <keyword>Plaque psoriasis</keyword>
  <keyword>DLQI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Etanercept</mesh_term>
    <mesh_term>Tofacitinib</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>CP-690,550 5 mg Twice Daily (BID)+Placebo Twice Weekly (BIW)</title>
          <description>Participants received CP-690,550 5 mg tablets, orally, BID, at approximately 12-hour intervals and placebo subcutaneous (SC) injections BIW at approximately 3- to 4-day intervals for 12 weeks.</description>
        </group>
        <group group_id="P2">
          <title>CP-690,550 10 mg BID + Placebo BIW</title>
          <description>Participants received CP-690,550 10 mg tablets, orally, BID, at approximately 12-hour intervals and placebo SC injections BIW at approximately 3- to 4-day intervals for 12 weeks.</description>
        </group>
        <group group_id="P3">
          <title>Placebo BID + Etanercept 50 mg BIW</title>
          <description>Participants received matching placebo tablets, orally, BID, at approximately 12-hour intervals and etanercept 50 mg SC injections BIW at approximately 3- to 4-day intervals for 12 weeks.</description>
        </group>
        <group group_id="P4">
          <title>Placebo BID + Placebo BIW</title>
          <description>Participants received matching placebo tablets, orally, BID, at approximately 12-hour intervals and placebo SC injections BIW at approximately 3- to 4-day intervals for 12 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="329"/>
                <participants group_id="P2" count="330"/>
                <participants group_id="P3" count="335"/>
                <participants group_id="P4" count="107"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="306"/>
                <participants group_id="P2" count="306"/>
                <participants group_id="P3" count="313"/>
                <participants group_id="P4" count="95"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="24"/>
                <participants group_id="P3" count="22"/>
                <participants group_id="P4" count="12"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Screen Failure</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not specified</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="12"/>
                <participants group_id="P4" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Full Analysis Set (FAS): included all participants who were randomized to the study and received at least 1 dose of the randomized investigational drug (CP-690,550, etanercept, or placebo).</population>
      <group_list>
        <group group_id="B1">
          <title>CP-690,550 5 mg Twice Daily (BID)+Placebo Twice Weekly (BIW)</title>
          <description>Participants received CP-690,550 5 mg tablets, orally, BID, at approximately 12-hour intervals and placebo subcutaneous (SC) injections BIW at approximately 3- to 4-day intervals for 12 weeks.</description>
        </group>
        <group group_id="B2">
          <title>CP-690,550 10 mg BID + Placebo BIW</title>
          <description>Participants received CP-690,550 10 mg tablets, orally, BID, at approximately 12-hour intervals and placebo SC injections BIW at approximately 3- to 4-day intervals for 12 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Placebo BID + Etanercept 50 mg BIW</title>
          <description>Participants received matching placebo tablets, orally, BID, at approximately 12-hour intervals and etanercept 50 mg SC injections BIW at approximately 3- to 4-day intervals for 12 weeks.</description>
        </group>
        <group group_id="B4">
          <title>Placebo BID + Placebo BIW</title>
          <description>Participants received matching placebo tablets, orally, BID, at approximately 12-hour intervals and placebo SC injections BIW at approximately 3- to 4-day intervals for 12 weeks.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="329"/>
            <count group_id="B2" value="330"/>
            <count group_id="B3" value="335"/>
            <count group_id="B4" value="107"/>
            <count group_id="B5" value="1101"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44.4" spread="12.1"/>
                    <measurement group_id="B2" value="43.6" spread="12.6"/>
                    <measurement group_id="B3" value="43.3" spread="12.2"/>
                    <measurement group_id="B4" value="46.1" spread="13.4"/>
                    <measurement group_id="B5" value="44.0" spread="12.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="93"/>
                    <measurement group_id="B2" value="92"/>
                    <measurement group_id="B3" value="102"/>
                    <measurement group_id="B4" value="36"/>
                    <measurement group_id="B5" value="323"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="236"/>
                    <measurement group_id="B2" value="238"/>
                    <measurement group_id="B3" value="233"/>
                    <measurement group_id="B4" value="71"/>
                    <measurement group_id="B5" value="778"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With a Physician's Global Assessment (PGA) Response of &quot;Clear&quot; or &quot;Almost Clear&quot; at Week 12</title>
        <description>The PGA of psoriasis is scored on a 5-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling are scored separately over the whole body according to a 5-point severity scale (0 to 4). The severity scores are summed and averaged after which the total average is rounded to the nearest whole number score to determine the PGA score and category (0=clear; 1=almost clear; 2=mild; 3=moderate; and 4=severe). PGA response was defined as 0 (clear) or 1 (almost clear).</description>
        <time_frame>Week 12</time_frame>
        <population>Full Analysis Set (FAS): all participants who were randomized to the study and received at least 1 dose of the randomized investigational drug (CP-690,550, etanercept, or placebo); Non-Responder Imputation (NRI) method: participants with missing values were considered to be non-responders.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg Twice Daily (BID)+Placebo Twice Weekly (BIW)</title>
            <description>Participants received CP-690,550 5 mg tablets, orally, BID, at approximately 12-hour intervals and placebo subcutaneous (SC) injections BIW at approximately 3- to 4-day intervals for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg BID + Placebo BIW</title>
            <description>Participants received CP-690,550 10 mg tablets, orally, BID, at approximately 12-hour intervals and placebo SC injections BIW at approximately 3- to 4-day intervals for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo BID + Etanercept 50 mg BIW</title>
            <description>Participants received matching placebo tablets, orally, BID, at approximately 12-hour intervals and etanercept 50 mg SC injections BIW at approximately 3- to 4-day intervals for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Placebo BID + Placebo BIW</title>
            <description>Participants received matching placebo tablets, orally, BID, at approximately 12-hour intervals and placebo SC injections BIW at approximately 3- to 4-day intervals for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a Physician's Global Assessment (PGA) Response of &quot;Clear&quot; or &quot;Almost Clear&quot; at Week 12</title>
          <description>The PGA of psoriasis is scored on a 5-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling are scored separately over the whole body according to a 5-point severity scale (0 to 4). The severity scores are summed and averaged after which the total average is rounded to the nearest whole number score to determine the PGA score and category (0=clear; 1=almost clear; 2=mild; 3=moderate; and 4=severe). PGA response was defined as 0 (clear) or 1 (almost clear).</description>
          <population>Full Analysis Set (FAS): all participants who were randomized to the study and received at least 1 dose of the randomized investigational drug (CP-690,550, etanercept, or placebo); Non-Responder Imputation (NRI) method: participants with missing values were considered to be non-responders.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="329"/>
                <count group_id="O2" value="330"/>
                <count group_id="O3" value="335"/>
                <count group_id="O4" value="107"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.11"/>
                    <measurement group_id="O2" value="68.18"/>
                    <measurement group_id="O3" value="66.27"/>
                    <measurement group_id="O4" value="14.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Difference from Etanercept (Active-Etanercept)</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The a priori threshold for non-inferiority was -15% and a step-down approach was used to adjust for multiple comparisons. Non-inferiority of CP-690,550 5 mg to etanercept was concluded if the 95% lower confidence intervals (LCIs) of the difference for PGA and Psoriasis Area and Severity Index 75 (PASI75) responses at Week 12 were greater than -15%, and CP-690,550 10 mg was superior to placebo for PGA response and PASI75 at Week 12.</non_inferiority_desc>
            <param_type>Mean Difference</param_type>
            <param_value>-19.16</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.77</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-26.55</ci_lower_limit>
            <ci_upper_limit>-11.76</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Difference from Placebo (Active-Placebo); the a priori threshold for superiority was 0 and a step-down approach was used to adjust for multiple comparisons. Superiority of CP-690,550 5 mg to placebo was concluded if the lower bounds of the 95% LCIs of the difference for PGA and PASI75 responses at Week 12 were greater than 0, and non-inferiority of CP-690,550 5 mg was concluded to be non-inferior to etanercept.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference</param_type>
            <param_value>32.16</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.41</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>23.51</ci_lower_limit>
            <ci_upper_limit>40.81</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Difference from Etanercept (Active-Etanercept)</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The a priori threshold for non-inferiority was -15% and a step-down approach was used to adjust for multiple comparisons. Non-inferiority of CP-690,550 10 mg to etanercept was concluded if the 95% LCIs of the difference for PGA and PASI75 responses at Week 12 were greater than -15%.</non_inferiority_desc>
            <param_type>Mean Difference</param_type>
            <param_value>1.91</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.64</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.22</ci_lower_limit>
            <ci_upper_limit>9.05</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Difference from Placebo (Active-Placebo); the a priori threshold for superiority was 0 and a step-down approach was used to adjust for multiple comparisons. Superiority of CP-690,550 10 mg to placebo was concluded if the 95% LCIs of the difference for PGA and PASI75 responses at Week 12 were greater than 0, and non-inferiority of CP-690,550 10 mg was concluded to be non-inferior to etanercept.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference</param_type>
            <param_value>53.23</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.30</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>44.81</ci_lower_limit>
            <ci_upper_limit>61.65</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With a Psoriasis Area and Severity Index 75 (PASI75) Response at Week 12</title>
        <description>The PASI quantifies the severity of a participant's psoriasis based on both lesion severity and the percent of body surface area (BSA) affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk [including axillae and groin], and lower limbs [including buttocks), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI75 response was defined as at least a 75 percent (%) reduction in PASI relative to baseline/Day 1.</description>
        <time_frame>Week 12</time_frame>
        <population>FAS; NRI</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg Twice Daily (BID)+Placebo Twice Weekly (BIW)</title>
            <description>Participants received CP-690,550 5 mg tablets, orally, BID, at approximately 12-hour intervals and placebo subcutaneous (SC) injections BIW at approximately 3- to 4-day intervals for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg BID + Placebo BIW</title>
            <description>Participants received CP-690,550 10 mg tablets, orally, BID, at approximately 12-hour intervals and placebo SC injections BIW at approximately 3- to 4-day intervals for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo BID + Etanercept 50 mg BIW</title>
            <description>Participants received matching placebo tablets, orally, BID, at approximately 12-hour intervals and etanercept 50 mg SC injections BIW at approximately 3- to 4-day intervals for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Placebo BID + Placebo BIW</title>
            <description>Participants received matching placebo tablets, orally, BID, at approximately 12-hour intervals and placebo SC injections BIW at approximately 3- to 4-day intervals for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a Psoriasis Area and Severity Index 75 (PASI75) Response at Week 12</title>
          <description>The PASI quantifies the severity of a participant's psoriasis based on both lesion severity and the percent of body surface area (BSA) affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk [including axillae and groin], and lower limbs [including buttocks), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI75 response was defined as at least a 75 percent (%) reduction in PASI relative to baseline/Day 1.</description>
          <population>FAS; NRI</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="329"/>
                <count group_id="O2" value="330"/>
                <count group_id="O3" value="335"/>
                <count group_id="O4" value="107"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.51"/>
                    <measurement group_id="O2" value="63.64"/>
                    <measurement group_id="O3" value="58.81"/>
                    <measurement group_id="O4" value="5.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Difference from Etanercept (Active-Etanercept)</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The a priori threshold for non-inferiority was -15% and a step-down approach was used to adjust for multiple comparisons. Non-inferiority of CP-690,550 5 mg to etanercept was concluded if the 95% LCIs of the difference for PGA and PASI75 responses at Week 12 were greater than -15%, and CP-690,550 10 mg was superior to placebo for PGA and PASI75 response at Week 12.</non_inferiority_desc>
            <param_type>Mean Difference</param_type>
            <param_value>-19.29</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.81</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-26.75</ci_lower_limit>
            <ci_upper_limit>-11.83</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Difference from Placebo (Active-Placebo); the a priori threshold for superiority was 0 and a step-down approach was used to adjust for multiple comparisons. Superiority of CP-690,550 5 mg to placebo was concluded if the 95% LCIs of the difference for PGA and PASI75 responses at Week 12 were greater than 0, and non-inferiority of CP-690,550 5 mg was concluded to be non-inferior to etanercept.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference</param_type>
            <param_value>33.91</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.49</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>27.06</ci_lower_limit>
            <ci_upper_limit>40.76</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Difference from Etanercept (Active-Etanercept)</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The a priori threshold for non-inferiority was -15% and a step-down approach was used to adjust for multiple comparisons. Non-inferiority of CP-690,550 10 mg to etanercept was concluded if the 95% LCIs of the difference for PGA and PASI75 responses at Week 12 were greater than -15%.</non_inferiority_desc>
            <param_type>Mean Difference</param_type>
            <param_value>4.83</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.77</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.57</ci_lower_limit>
            <ci_upper_limit>12.23</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Difference from Placebo (Active-Placebo); the a priori threshold for superiority was 0 and a step-down approach was used to adjust for multiple comparisons. Superiority of CP-690,550 10 mg to placebo was concluded if the 95% LCIs of the difference for PGA and PASI75 responses at Week 12 were greater than 0, and non-inferiority of CP-690,550 10 mg was concluded to be non-inferior to etanercept.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference</param_type>
            <param_value>58.03</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.46</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>51.25</ci_lower_limit>
            <ci_upper_limit>64.81</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With a PGA Response of &quot;Clear&quot; or &quot;Almost Clear&quot; During the 12-Week Double-Blind Treatment</title>
        <description>The PGA of psoriasis is scored on a 5-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling are scored separately over the whole body according to a 5-point severity scale (0 to 4). The severity scores are summed and averaged after which the total average is rounded to the nearest whole number score to determine the PGA score and category (0=clear; 1=almost clear; 2=mild; 3=moderate; and 4=severe). PGA response is defined as 0 (clear) or 1 (almost clear).</description>
        <time_frame>Weeks 2, 4, and 8</time_frame>
        <population>FAS; Observed Case (OC): no imputation</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg Twice Daily (BID)+Placebo Twice Weekly (BIW)</title>
            <description>Participants received CP-690,550 5 mg tablets, orally, BID, at approximately 12-hour intervals and placebo subcutaneous (SC) injections BIW at approximately 3- to 4-day intervals for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg BID + Placebo BIW</title>
            <description>Participants received CP-690,550 10 mg tablets, orally, BID, at approximately 12-hour intervals and placebo SC injections BIW at approximately 3- to 4-day intervals for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo BID + Etanercept 50 mg BIW</title>
            <description>Participants received matching placebo tablets, orally, BID, at approximately 12-hour intervals and etanercept 50 mg SC injections BIW at approximately 3- to 4-day intervals for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Placebo BID + Placebo BIW</title>
            <description>Participants received matching placebo tablets, orally, BID, at approximately 12-hour intervals and placebo SC injections BIW at approximately 3- to 4-day intervals for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a PGA Response of &quot;Clear&quot; or &quot;Almost Clear&quot; During the 12-Week Double-Blind Treatment</title>
          <description>The PGA of psoriasis is scored on a 5-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling are scored separately over the whole body according to a 5-point severity scale (0 to 4). The severity scores are summed and averaged after which the total average is rounded to the nearest whole number score to determine the PGA score and category (0=clear; 1=almost clear; 2=mild; 3=moderate; and 4=severe). PGA response is defined as 0 (clear) or 1 (almost clear).</description>
          <population>FAS; Observed Case (OC): no imputation</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="325"/>
                <count group_id="O2" value="326"/>
                <count group_id="O3" value="331"/>
                <count group_id="O4" value="107"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2 (n=325,326,331,107)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.77"/>
                    <measurement group_id="O2" value="10.74"/>
                    <measurement group_id="O3" value="7.85"/>
                    <measurement group_id="O4" value="1.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (n=320,323,328,102)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.25"/>
                    <measurement group_id="O2" value="35.91"/>
                    <measurement group_id="O3" value="28.35"/>
                    <measurement group_id="O4" value="3.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (n=314,316,322,100)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.45"/>
                    <measurement group_id="O2" value="63.61"/>
                    <measurement group_id="O3" value="60.87"/>
                    <measurement group_id="O4" value="13.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants in Each PGA Category During the 12-Week Double-Blind Treatment</title>
        <description>The PGA of psoriasis is scored on a 5-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling are scored separately over the whole body according to a 5-point severity scale (0 to 4). The severity scores are summed and averaged after which the total average is rounded to the nearest whole number score to determine the PGA score and category (0=clear; 1=almost clear; 2=mild; 3=moderate; and 4=severe).</description>
        <time_frame>Baseline and Weeks 2, 4, 8, and 12</time_frame>
        <population>FAS; OC</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg Twice Daily (BID)+Placebo Twice Weekly (BIW)</title>
            <description>Participants received CP-690,550 5 mg tablets, orally, BID, at approximately 12-hour intervals and placebo subcutaneous (SC) injections BIW at approximately 3- to 4-day intervals for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg BID + Placebo BIW</title>
            <description>Participants received CP-690,550 10 mg tablets, orally, BID, at approximately 12-hour intervals and placebo SC injections BIW at approximately 3- to 4-day intervals for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo BID + Etanercept 50 mg BIW</title>
            <description>Participants received matching placebo tablets, orally, BID, at approximately 12-hour intervals and etanercept 50 mg SC injections BIW at approximately 3- to 4-day intervals for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Placebo BID + Placebo BIW</title>
            <description>Participants received matching placebo tablets, orally, BID, at approximately 12-hour intervals and placebo SC injections BIW at approximately 3- to 4-day intervals for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants in Each PGA Category During the 12-Week Double-Blind Treatment</title>
          <description>The PGA of psoriasis is scored on a 5-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling are scored separately over the whole body according to a 5-point severity scale (0 to 4). The severity scores are summed and averaged after which the total average is rounded to the nearest whole number score to determine the PGA score and category (0=clear; 1=almost clear; 2=mild; 3=moderate; and 4=severe).</description>
          <population>FAS; OC</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="329"/>
                <count group_id="O2" value="330"/>
                <count group_id="O3" value="335"/>
                <count group_id="O4" value="107"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline, Clear (n=329,330,335,107)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline, Almost Clear (n=329,330,335,107)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline, Mild (n=329,330,335,107)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8"/>
                    <measurement group_id="O2" value="1.2"/>
                    <measurement group_id="O3" value="1.2"/>
                    <measurement group_id="O4" value="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline, Moderate (n=329,330,335,107)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.2"/>
                    <measurement group_id="O2" value="83.3"/>
                    <measurement group_id="O3" value="80.9"/>
                    <measurement group_id="O4" value="82.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline, Severe (n=329,330,335,107)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.9"/>
                    <measurement group_id="O2" value="15.5"/>
                    <measurement group_id="O3" value="17.9"/>
                    <measurement group_id="O4" value="15.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2, Clear (n=325,326,331,107)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2, Almost Clear (n=325,326,331,107)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.8"/>
                    <measurement group_id="O2" value="10.7"/>
                    <measurement group_id="O3" value="7.9"/>
                    <measurement group_id="O4" value="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2, Mild (n=325,326,331,107)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.5"/>
                    <measurement group_id="O2" value="47.9"/>
                    <measurement group_id="O3" value="42.6"/>
                    <measurement group_id="O4" value="25.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2, Moderate (n=325,326,331,107)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.9"/>
                    <measurement group_id="O2" value="38.3"/>
                    <measurement group_id="O3" value="45.6"/>
                    <measurement group_id="O4" value="64.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2, Severe (n=325,326,331,107)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.8"/>
                    <measurement group_id="O2" value="3.1"/>
                    <measurement group_id="O3" value="3.9"/>
                    <measurement group_id="O4" value="8.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4, Clear (n=320,323,328,102)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9"/>
                    <measurement group_id="O2" value="2.5"/>
                    <measurement group_id="O3" value="0.6"/>
                    <measurement group_id="O4" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4, Almost Clear (n=320,323,328,102)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.4"/>
                    <measurement group_id="O2" value="33.4"/>
                    <measurement group_id="O3" value="27.7"/>
                    <measurement group_id="O4" value="3.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4, Mild (n=320,323,328,102)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.3"/>
                    <measurement group_id="O2" value="44.3"/>
                    <measurement group_id="O3" value="51.5"/>
                    <measurement group_id="O4" value="34.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4, Moderate (n=320,323,328,102)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.0"/>
                    <measurement group_id="O2" value="17.6"/>
                    <measurement group_id="O3" value="19.5"/>
                    <measurement group_id="O4" value="55.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4, Severe (n=320,323,328,102)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5"/>
                    <measurement group_id="O2" value="2.2"/>
                    <measurement group_id="O3" value="0.6"/>
                    <measurement group_id="O4" value="5.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8, Clear (n=314,316,322,100)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.4"/>
                    <measurement group_id="O2" value="14.2"/>
                    <measurement group_id="O3" value="9.0"/>
                    <measurement group_id="O4" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8, Almost Clear (n=314,316,322,100)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.0"/>
                    <measurement group_id="O2" value="49.4"/>
                    <measurement group_id="O3" value="51.9"/>
                    <measurement group_id="O4" value="13.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8, Mild (n=314,316,322,100)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.4"/>
                    <measurement group_id="O2" value="25.0"/>
                    <measurement group_id="O3" value="30.1"/>
                    <measurement group_id="O4" value="35.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8, Moderate (n=314,316,322,100)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.9"/>
                    <measurement group_id="O2" value="10.8"/>
                    <measurement group_id="O3" value="8.1"/>
                    <measurement group_id="O4" value="49.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8, Severe (n=314,316,322,100)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2"/>
                    <measurement group_id="O2" value="0.6"/>
                    <measurement group_id="O3" value="0.9"/>
                    <measurement group_id="O4" value="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12, Clear (n=314,316,322,100)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.8"/>
                    <measurement group_id="O2" value="27.0"/>
                    <measurement group_id="O3" value="21.0"/>
                    <measurement group_id="O4" value="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12, Almost Clear (n=313,311,309,95)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.7"/>
                    <measurement group_id="O2" value="45.3"/>
                    <measurement group_id="O3" value="50.8"/>
                    <measurement group_id="O4" value="14.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12, Mild (n=313,311,309,95)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.5"/>
                    <measurement group_id="O2" value="19.3"/>
                    <measurement group_id="O3" value="21.4"/>
                    <measurement group_id="O4" value="36.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12, Moderate (n=313,311,309,95)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.7"/>
                    <measurement group_id="O2" value="7.4"/>
                    <measurement group_id="O3" value="5.5"/>
                    <measurement group_id="O4" value="42.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12, Severe (n=313,311,309,95)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3"/>
                    <measurement group_id="O2" value="1.0"/>
                    <measurement group_id="O3" value="1.3"/>
                    <measurement group_id="O4" value="4.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With a PASI75 Response During the 12-Week Double-Blind Treatment</title>
        <description>The PASI quantifies the severity of a participant's psoriasis based on both lesion severity and the percent of BSA affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk [including axillae and groin], and lower limbs [including buttocks), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI75 response was defined as at least a 75% reduction in PASI relative to baseline/Day 1.</description>
        <time_frame>Weeks 2, 4, and 8</time_frame>
        <population>FAS; OC</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg Twice Daily (BID)+Placebo Twice Weekly (BIW)</title>
            <description>Participants received CP-690,550 5 mg tablets, orally, BID, at approximately 12-hour intervals and placebo subcutaneous (SC) injections BIW at approximately 3- to 4-day intervals for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg BID + Placebo BIW</title>
            <description>Participants received CP-690,550 10 mg tablets, orally, BID, at approximately 12-hour intervals and placebo SC injections BIW at approximately 3- to 4-day intervals for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo BID + Etanercept 50 mg BIW</title>
            <description>Participants received matching placebo tablets, orally, BID, at approximately 12-hour intervals and etanercept 50 mg SC injections BIW at approximately 3- to 4-day intervals for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Placebo BID + Placebo BIW</title>
            <description>Participants received matching placebo tablets, orally, BID, at approximately 12-hour intervals and placebo SC injections BIW at approximately 3- to 4-day intervals for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a PASI75 Response During the 12-Week Double-Blind Treatment</title>
          <description>The PASI quantifies the severity of a participant's psoriasis based on both lesion severity and the percent of BSA affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk [including axillae and groin], and lower limbs [including buttocks), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI75 response was defined as at least a 75% reduction in PASI relative to baseline/Day 1.</description>
          <population>FAS; OC</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="326"/>
                <count group_id="O2" value="327"/>
                <count group_id="O3" value="331"/>
                <count group_id="O4" value="106"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2 (n=326,327,331,106)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.53"/>
                    <measurement group_id="O2" value="2.75"/>
                    <measurement group_id="O3" value="0.91"/>
                    <measurement group_id="O4" value="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (n=319,323,328,102)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.34"/>
                    <measurement group_id="O2" value="19.81"/>
                    <measurement group_id="O3" value="8.23"/>
                    <measurement group_id="O4" value="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (n=315,319,323,99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.57"/>
                    <measurement group_id="O2" value="52.35"/>
                    <measurement group_id="O3" value="42.72"/>
                    <measurement group_id="O4" value="3.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean PASI Score During the 12-Week Double-Blind Treatment</title>
        <description>Combined assessment of lesion severity and area affected into single score; range=0(no disease)-72(maximal disease). Body divided into 4 sections=head, upper/lower limbs, trunk; each area scored by itself and scores combined for final PASI. For each section percent area of skin involved was estimated:0(0%)-6(90–100%) and severity estimated by clinical signs of erythema, induration, scaling; ranged 0-4: 0=none, 1=slight, 2=moderate, 3=marked, 4=very marked. Final PASI=sum of severity parameters for each section*area score*weighing factor (head=0.1, upper limbs=0.2, trunk=0.3, lower limbs=0.4). PASI score can vary in increments of 0.1; higher scores represent greater severity of psoriasis.</description>
        <time_frame>Baseline and Weeks 2, 4, 8, and 12</time_frame>
        <population>FAS; OC</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg Twice Daily (BID)+Placebo Twice Weekly (BIW)</title>
            <description>Participants received CP-690,550 5 mg tablets, orally, BID, at approximately 12-hour intervals and placebo subcutaneous (SC) injections BIW at approximately 3- to 4-day intervals for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg BID + Placebo BIW</title>
            <description>Participants received CP-690,550 10 mg tablets, orally, BID, at approximately 12-hour intervals and placebo SC injections BIW at approximately 3- to 4-day intervals for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo BID + Etanercept 50 mg BIW</title>
            <description>Participants received matching placebo tablets, orally, BID, at approximately 12-hour intervals and etanercept 50 mg SC injections BIW at approximately 3- to 4-day intervals for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Placebo BID + Placebo BIW</title>
            <description>Participants received matching placebo tablets, orally, BID, at approximately 12-hour intervals and placebo SC injections BIW at approximately 3- to 4-day intervals for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean PASI Score During the 12-Week Double-Blind Treatment</title>
          <description>Combined assessment of lesion severity and area affected into single score; range=0(no disease)-72(maximal disease). Body divided into 4 sections=head, upper/lower limbs, trunk; each area scored by itself and scores combined for final PASI. For each section percent area of skin involved was estimated:0(0%)-6(90–100%) and severity estimated by clinical signs of erythema, induration, scaling; ranged 0-4: 0=none, 1=slight, 2=moderate, 3=marked, 4=very marked. Final PASI=sum of severity parameters for each section*area score*weighing factor (head=0.1, upper limbs=0.2, trunk=0.3, lower limbs=0.4). PASI score can vary in increments of 0.1; higher scores represent greater severity of psoriasis.</description>
          <population>FAS; OC</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="329"/>
                <count group_id="O2" value="330"/>
                <count group_id="O3" value="335"/>
                <count group_id="O4" value="107"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n=329,330,335,107)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.13" spread="0.48"/>
                    <measurement group_id="O2" value="23.29" spread="0.53"/>
                    <measurement group_id="O3" value="22.73" spread="0.53"/>
                    <measurement group_id="O4" value="22.78" spread="0.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2 (n=326,327,328,102)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.16" spread="0.47"/>
                    <measurement group_id="O2" value="16.81" spread="0.53"/>
                    <measurement group_id="O3" value="17.29" spread="0.49"/>
                    <measurement group_id="O4" value="21.26" spread="0.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (n=319,323,328,102)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.46" spread="0.46"/>
                    <measurement group_id="O2" value="12.13" spread="0.52"/>
                    <measurement group_id="O3" value="12.73" spread="0.44"/>
                    <measurement group_id="O4" value="20.06" spread="0.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (n=315,319,323,99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.63" spread="0.44"/>
                    <measurement group_id="O2" value="7.59" spread="0.48"/>
                    <measurement group_id="O3" value="7.70" spread="0.38"/>
                    <measurement group_id="O4" value="17.91" spread="0.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (n=313,311,309,95)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.80" spread="0.43"/>
                    <measurement group_id="O2" value="5.77" spread="0.45"/>
                    <measurement group_id="O3" value="5.42" spread="0.36"/>
                    <measurement group_id="O4" value="17.39" spread="1.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in PASI Score During the 12-Week Double-Blind Treatment</title>
        <description>Combined assessment of lesion severity and area affected into single score; range=0(no disease)-72(maximal disease). Body divided into 4 sections=head, upper/lower limbs, trunk; each area scored by itself and scores combined for final PASI. For each section percent area of skin involved was estimated:0(0%)-6(90–100%) and severity estimated by clinical signs of erythema, induration, scaling; ranged 0-4: 0=none, 1=slight, 2=moderate, 3=marked, 4=very marked. Final PASI=sum of severity parameters for each section*area score*weighing factor (head=0.1, upper limbs=0.2, trunk=0.3, lower limbs=0.4). PASI score can vary in increments of 0.1; higher scores represent greater severity of psoriasis.</description>
        <time_frame>Weeks 2, 4, 8, and 12</time_frame>
        <population>FAS; OC</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg Twice Daily (BID)+Placebo Twice Weekly (BIW)</title>
            <description>Participants received CP-690,550 5 mg tablets, orally, BID, at approximately 12-hour intervals and placebo subcutaneous (SC) injections BIW at approximately 3- to 4-day intervals for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg BID + Placebo BIW</title>
            <description>Participants received CP-690,550 10 mg tablets, orally, BID, at approximately 12-hour intervals and placebo SC injections BIW at approximately 3- to 4-day intervals for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo BID + Etanercept 50 mg BIW</title>
            <description>Participants received matching placebo tablets, orally, BID, at approximately 12-hour intervals and etanercept 50 mg SC injections BIW at approximately 3- to 4-day intervals for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Placebo BID + Placebo BIW</title>
            <description>Participants received matching placebo tablets, orally, BID, at approximately 12-hour intervals and placebo SC injections BIW at approximately 3- to 4-day intervals for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in PASI Score During the 12-Week Double-Blind Treatment</title>
          <description>Combined assessment of lesion severity and area affected into single score; range=0(no disease)-72(maximal disease). Body divided into 4 sections=head, upper/lower limbs, trunk; each area scored by itself and scores combined for final PASI. For each section percent area of skin involved was estimated:0(0%)-6(90–100%) and severity estimated by clinical signs of erythema, induration, scaling; ranged 0-4: 0=none, 1=slight, 2=moderate, 3=marked, 4=very marked. Final PASI=sum of severity parameters for each section*area score*weighing factor (head=0.1, upper limbs=0.2, trunk=0.3, lower limbs=0.4). PASI score can vary in increments of 0.1; higher scores represent greater severity of psoriasis.</description>
          <population>FAS; OC</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="326"/>
                <count group_id="O2" value="327"/>
                <count group_id="O3" value="331"/>
                <count group_id="O4" value="106"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2 (n=326,327,331,106)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.03" spread="0.31"/>
                    <measurement group_id="O2" value="-6.47" spread="0.31"/>
                    <measurement group_id="O3" value="-5.48" spread="0.29"/>
                    <measurement group_id="O4" value="-1.58" spread="0.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (n=319,323,328,102)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.83" spread="0.42"/>
                    <measurement group_id="O2" value="-11.30" spread="0.43"/>
                    <measurement group_id="O3" value="-10.14" spread="0.39"/>
                    <measurement group_id="O4" value="-2.58" spread="0.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (n=315,319,323,99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.62" spread="0.52"/>
                    <measurement group_id="O2" value="-15.81" spread="0.51"/>
                    <measurement group_id="O3" value="-15.20" spread="0.51"/>
                    <measurement group_id="O4" value="-4.82" spread="0.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (n=313,311,309,95)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.55" spread="0.60"/>
                    <measurement group_id="O2" value="-17.54" spread="0.54"/>
                    <measurement group_id="O3" value="-17.55" spread="0.57"/>
                    <measurement group_id="O4" value="-5.33" spread="0.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean PASI Component Scores by Body Region During the 12-Week Double Blind Treatment</title>
        <description>Combined assessment of lesion severity and area affected into single score; range=0(no disease)-72(maximal disease). Body divided into 4 sections=head, upper/lower limbs, trunk; each area scored by itself and scores combined for final PASI. For each section percent area of skin involved was estimated:0(0%)-6(90–100%) and severity estimated by clinical signs of erythema, induration, scaling; ranged 0-4: 0=none, 1=slight, 2=moderate, 3=marked, 4=very marked. Final PASI=sum of severity parameters for each section*area score*weighing factor (head=0.1, upper limbs=0.2, trunk=0.3, lower limbs=0.4). PASI score can vary in increments of 0.1; higher scores represent greater severity of psoriasis.</description>
        <time_frame>Baseline and Weeks 2, 4, 8, and 12</time_frame>
        <population>FAS; OC</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg Twice Daily (BID)+Placebo Twice Weekly (BIW)</title>
            <description>Participants received CP-690,550 5 mg tablets, orally, BID, at approximately 12-hour intervals and placebo subcutaneous (SC) injections BIW at approximately 3- to 4-day intervals for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg BID + Placebo BIW</title>
            <description>Participants received CP-690,550 10 mg tablets, orally, BID, at approximately 12-hour intervals and placebo SC injections BIW at approximately 3- to 4-day intervals for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo BID + Etanercept 50 mg BIW</title>
            <description>Participants received matching placebo tablets, orally, BID, at approximately 12-hour intervals and etanercept 50 mg SC injections BIW at approximately 3- to 4-day intervals for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Placebo BID + Placebo BIW</title>
            <description>Participants received matching placebo tablets, orally, BID, at approximately 12-hour intervals and placebo SC injections BIW at approximately 3- to 4-day intervals for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean PASI Component Scores by Body Region During the 12-Week Double Blind Treatment</title>
          <description>Combined assessment of lesion severity and area affected into single score; range=0(no disease)-72(maximal disease). Body divided into 4 sections=head, upper/lower limbs, trunk; each area scored by itself and scores combined for final PASI. For each section percent area of skin involved was estimated:0(0%)-6(90–100%) and severity estimated by clinical signs of erythema, induration, scaling; ranged 0-4: 0=none, 1=slight, 2=moderate, 3=marked, 4=very marked. Final PASI=sum of severity parameters for each section*area score*weighing factor (head=0.1, upper limbs=0.2, trunk=0.3, lower limbs=0.4). PASI score can vary in increments of 0.1; higher scores represent greater severity of psoriasis.</description>
          <population>FAS; OC</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="329"/>
                <count group_id="O2" value="329"/>
                <count group_id="O3" value="335"/>
                <count group_id="O4" value="107"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Head/Neck Erythema, Baseline (n=329,329,335,107)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.28" spread="0.05"/>
                    <measurement group_id="O2" value="2.36" spread="0.05"/>
                    <measurement group_id="O3" value="2.32" spread="0.05"/>
                    <measurement group_id="O4" value="2.40" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Head/Neck Erythema, Week 2 (n=326,326,331,106)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.82" spread="0.05"/>
                    <measurement group_id="O2" value="1.65" spread="0.05"/>
                    <measurement group_id="O3" value="1.76" spread="0.06"/>
                    <measurement group_id="O4" value="2.27" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Head/Neck Erythema, Week 4 (n=320,323,328,102)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.48" spread="0.05"/>
                    <measurement group_id="O2" value="1.18" spread="0.05"/>
                    <measurement group_id="O3" value="1.23" spread="0.05"/>
                    <measurement group_id="O4" value="2.03" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Head/Neck Erythema, Week 8 (n=315,319,323,99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.19" spread="0.06"/>
                    <measurement group_id="O2" value="0.78" spread="0.05"/>
                    <measurement group_id="O3" value="0.69" spread="0.05"/>
                    <measurement group_id="O4" value="1.89" spread="0.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Head/Neck Erythema, Week 12 (n=313,311,309,95)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.04" spread="0.06"/>
                    <measurement group_id="O2" value="0.65" spread="0.05"/>
                    <measurement group_id="O3" value="0.48" spread="0.04"/>
                    <measurement group_id="O4" value="1.74" spread="0.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Head/Neck Induration, Baseline (n=329,329,335,107)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.04" spread="0.05"/>
                    <measurement group_id="O2" value="2.08" spread="0.05"/>
                    <measurement group_id="O3" value="1.96" spread="0.06"/>
                    <measurement group_id="O4" value="2.12" spread="0.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Head/Neck Induration, Week 2 (n=326,326,331,106)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.60" spread="0.05"/>
                    <measurement group_id="O2" value="1.44" spread="0.05"/>
                    <measurement group_id="O3" value="1.46" spread="0.06"/>
                    <measurement group_id="O4" value="1.97" spread="0.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Head/Neck Induration, Week 4 (n=320,323,328,102)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.21" spread="0.05"/>
                    <measurement group_id="O2" value="0.94" spread="0.05"/>
                    <measurement group_id="O3" value="1.01" spread="0.05"/>
                    <measurement group_id="O4" value="1.69" spread="0.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Head/Neck Induration, Week 8 (n=315,319,323,99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.96" spread="0.05"/>
                    <measurement group_id="O2" value="0.59" spread="0.05"/>
                    <measurement group_id="O3" value="0.54" spread="0.05"/>
                    <measurement group_id="O4" value="1.57" spread="0.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Head/Neck Induration, Week 12 (n=313,311,309,95)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.87" spread="0.05"/>
                    <measurement group_id="O2" value="0.49" spread="0.04"/>
                    <measurement group_id="O3" value="0.37" spread="0.04"/>
                    <measurement group_id="O4" value="1.41" spread="0.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Head/Neck Scaling, Baseline (n=329,329,335,107)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.29" spread="0.06"/>
                    <measurement group_id="O2" value="2.38" spread="0.06"/>
                    <measurement group_id="O3" value="2.28" spread="0.06"/>
                    <measurement group_id="O4" value="2.33" spread="0.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Head/Neck Scaling, Week 2 (n=326,326,331,106)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.75" spread="0.06"/>
                    <measurement group_id="O2" value="1.63" spread="0.06"/>
                    <measurement group_id="O3" value="1.60" spread="0.06"/>
                    <measurement group_id="O4" value="2.15" spread="0.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Head/Neck Scaling, Week 4 (n=320,323,328,102)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.38" spread="0.06"/>
                    <measurement group_id="O2" value="1.07" spread="0.06"/>
                    <measurement group_id="O3" value="1.16" spread="0.05"/>
                    <measurement group_id="O4" value="1.80" spread="0.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Head/Neck Scaling, Week 8 (n=315,319,323,99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.12" spread="0.06"/>
                    <measurement group_id="O2" value="0.70" spread="0.05"/>
                    <measurement group_id="O3" value="0.65" spread="0.05"/>
                    <measurement group_id="O4" value="1.66" spread="0.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Head/Neck Scaling, Week 12 (n=313,311,309,95)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.98" spread="0.06"/>
                    <measurement group_id="O2" value="0.60" spread="0.05"/>
                    <measurement group_id="O3" value="0.46" spread="0.05"/>
                    <measurement group_id="O4" value="1.51" spread="0.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Upper Limbs Erythema, Baseline (n=329,329,335,107)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.87" spread="0.04"/>
                    <measurement group_id="O2" value="2.87" spread="0.04"/>
                    <measurement group_id="O3" value="2.88" spread="0.04"/>
                    <measurement group_id="O4" value="2.92" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Upper Limbs Erythema, Week 2 (n=326,326,331,106)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.35" spread="0.04"/>
                    <measurement group_id="O2" value="2.18" spread="0.05"/>
                    <measurement group_id="O3" value="2.27" spread="0.05"/>
                    <measurement group_id="O4" value="2.75" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Upper Limbs Erythema, Week 4 (n=320,323,328,102)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.92" spread="0.05"/>
                    <measurement group_id="O2" value="1.73" spread="0.05"/>
                    <measurement group_id="O3" value="1.77" spread="0.05"/>
                    <measurement group_id="O4" value="2.61" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Upper Limbs Erythema, Week 8 (n=315,319,323,99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.55" spread="0.05"/>
                    <measurement group_id="O2" value="1.27" spread="0.05"/>
                    <measurement group_id="O3" value="1.25" spread="0.05"/>
                    <measurement group_id="O4" value="2.42" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Upper Limbs Erythema, Week 12 (n=313,311,309,95)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.45" spread="0.06"/>
                    <measurement group_id="O2" value="1.07" spread="0.05"/>
                    <measurement group_id="O3" value="0.94" spread="0.05"/>
                    <measurement group_id="O4" value="2.32" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Upper Limbs Induration Baseline(n=329,329,335,107)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.69" spread="0.04"/>
                    <measurement group_id="O2" value="2.76" spread="0.04"/>
                    <measurement group_id="O3" value="2.72" spread="0.04"/>
                    <measurement group_id="O4" value="2.79" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Upper Limbs Induration, Week 2 (n=326,326,331,106)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.17" spread="0.05"/>
                    <measurement group_id="O2" value="2.03" spread="0.05"/>
                    <measurement group_id="O3" value="2.13" spread="0.05"/>
                    <measurement group_id="O4" value="2.54" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Upper Limbs Induration, Week 4 (n=320,323,328,102)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.76" spread="0.05"/>
                    <measurement group_id="O2" value="1.54" spread="0.05"/>
                    <measurement group_id="O3" value="1.59" spread="0.05"/>
                    <measurement group_id="O4" value="2.36" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Upper Limbs Induration, Week 8 (n=315,319,323,99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.43" spread="0.06"/>
                    <measurement group_id="O2" value="1.13" spread="0.05"/>
                    <measurement group_id="O3" value="1.18" spread="0.05"/>
                    <measurement group_id="O4" value="2.12" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Upper Limbs Induration, Week 12 (n=313,311,309,95)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.31" spread="0.06"/>
                    <measurement group_id="O2" value="1.01" spread="0.05"/>
                    <measurement group_id="O3" value="0.81" spread="0.05"/>
                    <measurement group_id="O4" value="2.08" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Upper Limbs Scaling, Baseline (n=329,329,335,107)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.66" spread="0.04"/>
                    <measurement group_id="O2" value="2.72" spread="0.04"/>
                    <measurement group_id="O3" value="2.73" spread="0.04"/>
                    <measurement group_id="O4" value="2.63" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Upper Limbs Scaling, Week 2 (n=326,326,331,106)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.11" spread="0.05"/>
                    <measurement group_id="O2" value="2.00" spread="0.05"/>
                    <measurement group_id="O3" value="2.03" spread="0.05"/>
                    <measurement group_id="O4" value="2.35" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Upper Limbs Scaling, Week 4 (n=320,323,328,102)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.71" spread="0.05"/>
                    <measurement group_id="O2" value="1.50" spread="0.05"/>
                    <measurement group_id="O3" value="1.54" spread="0.05"/>
                    <measurement group_id="O4" value="2.22" spread="0.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Upper Limbs Scaling, Week 8 (n=315,319,323,99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.39" spread="0.06"/>
                    <measurement group_id="O2" value="1.11" spread="0.05"/>
                    <measurement group_id="O3" value="1.07" spread="0.05"/>
                    <measurement group_id="O4" value="1.98" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Upper Limbs Scaling, Week 12 (n=313,311,309,95)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.30" spread="0.06"/>
                    <measurement group_id="O2" value="1.00" spread="0.05"/>
                    <measurement group_id="O3" value="0.82" spread="0.05"/>
                    <measurement group_id="O4" value="1.95" spread="0.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Trunk Erythema, Baseline (n=329,329,335,107)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.95" spread="0.04"/>
                    <measurement group_id="O2" value="2.88" spread="0.04"/>
                    <measurement group_id="O3" value="2.91" spread="0.04"/>
                    <measurement group_id="O4" value="2.97" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Trunk Erythema, Week 2 (n=326,326,331,106)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.40" spread="0.05"/>
                    <measurement group_id="O2" value="2.20" spread="0.05"/>
                    <measurement group_id="O3" value="2.27" spread="0.05"/>
                    <measurement group_id="O4" value="2.75" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Trunk Erythema, Week 4 (n=320,323,328,102)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.03" spread="0.05"/>
                    <measurement group_id="O2" value="1.75" spread="0.05"/>
                    <measurement group_id="O3" value="1.76" spread="0.05"/>
                    <measurement group_id="O4" value="2.59" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Trunk Erythema, Week 8 (n=315,319,323,99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.71" spread="0.06"/>
                    <measurement group_id="O2" value="1.23" spread="0.05"/>
                    <measurement group_id="O3" value="1.24" spread="0.05"/>
                    <measurement group_id="O4" value="2.41" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Trunk Erythema, Week 12 (n=313,311,309,95)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.53" spread="0.06"/>
                    <measurement group_id="O2" value="0.97" spread="0.06"/>
                    <measurement group_id="O3" value="0.89" spread="0.05"/>
                    <measurement group_id="O4" value="2.33" spread="0.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Trunk Induration, Baseline (n=329,329,335,107)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.75" spread="0.04"/>
                    <measurement group_id="O2" value="2.70" spread="0.05"/>
                    <measurement group_id="O3" value="2.66" spread="0.05"/>
                    <measurement group_id="O4" value="2.66" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Trunk Induration, Week 2 (n=326,326,331,106)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.26" spread="0.05"/>
                    <measurement group_id="O2" value="2.01" spread="0.05"/>
                    <measurement group_id="O3" value="2.05" spread="0.05"/>
                    <measurement group_id="O4" value="2.40" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Trunk Induration, Week 4 (n=320,323,328,102)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.83" spread="0.05"/>
                    <measurement group_id="O2" value="1.50" spread="0.05"/>
                    <measurement group_id="O3" value="1.50" spread="0.05"/>
                    <measurement group_id="O4" value="2.26" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Trunk Induration, Week 8 (n=315,319,323,99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.50" spread="0.06"/>
                    <measurement group_id="O2" value="0.97" spread="0.05"/>
                    <measurement group_id="O3" value="0.98" spread="0.05"/>
                    <measurement group_id="O4" value="2.06" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Trunk Induration, Week 12 (n=313,311,309,95)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.33" spread="0.06"/>
                    <measurement group_id="O2" value="0.80" spread="0.05"/>
                    <measurement group_id="O3" value="0.66" spread="0.05"/>
                    <measurement group_id="O4" value="2.03" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Trunk Scaling, Baseline (n=329,329,335,107)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.64" spread="0.04"/>
                    <measurement group_id="O2" value="2.66" spread="0.05"/>
                    <measurement group_id="O3" value="2.57" spread="0.05"/>
                    <measurement group_id="O4" value="2.61" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Trunk Scaling, Week 2 (n=326,326,331,106)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.12" spread="0.05"/>
                    <measurement group_id="O2" value="1.92" spread="0.06"/>
                    <measurement group_id="O3" value="1.93" spread="0.05"/>
                    <measurement group_id="O4" value="2.36" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Trunk Scaling, Week 4 (n=320,323,328,102)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.73" spread="0.05"/>
                    <measurement group_id="O2" value="1.39" spread="0.05"/>
                    <measurement group_id="O3" value="1.44" spread="0.05"/>
                    <measurement group_id="O4" value="2.12" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Trunk Scaling, Week 8 (n=315,319,323,99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.47" spread="0.06"/>
                    <measurement group_id="O2" value="0.94" spread="0.05"/>
                    <measurement group_id="O3" value="0.90" spread="0.05"/>
                    <measurement group_id="O4" value="1.86" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Trunk Scaling, Week 12 (n=313,311,309,95)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.28" spread="0.06"/>
                    <measurement group_id="O2" value="0.74" spread="0.05"/>
                    <measurement group_id="O3" value="0.62" spread="0.05"/>
                    <measurement group_id="O4" value="1.91" spread="0.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lower Limbs Erythema, Baseline (n=329,329,335,107)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.12" spread="0.03"/>
                    <measurement group_id="O2" value="3.13" spread="0.04"/>
                    <measurement group_id="O3" value="3.14" spread="0.03"/>
                    <measurement group_id="O4" value="3.10" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lower Limbs Erythema, Week 2 (n=326,326,331,106)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.60" spread="0.04"/>
                    <measurement group_id="O2" value="2.44" spread="0.05"/>
                    <measurement group_id="O3" value="2.61" spread="0.05"/>
                    <measurement group_id="O4" value="2.92" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lower Limbs Erythema, Week 4 (n=320,323,328,102)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.17" spread="0.05"/>
                    <measurement group_id="O2" value="1.98" spread="0.05"/>
                    <measurement group_id="O3" value="2.15" spread="0.05"/>
                    <measurement group_id="O4" value="2.75" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lower Limbs Erythema, Week 8 (n=315,319,323,99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.77" spread="0.06"/>
                    <measurement group_id="O2" value="1.50" spread="0.05"/>
                    <measurement group_id="O3" value="1.62" spread="0.05"/>
                    <measurement group_id="O4" value="2.55" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lower Limbs Erythema, Week 12 (n=313,311,309,95)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.56" spread="0.06"/>
                    <measurement group_id="O2" value="1.21" spread="0.06"/>
                    <measurement group_id="O3" value="1.35" spread="0.05"/>
                    <measurement group_id="O4" value="2.45" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lower Limbs Induration Baseline(n=329,329,335,107)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.94" spread="0.04"/>
                    <measurement group_id="O2" value="2.97" spread="0.04"/>
                    <measurement group_id="O3" value="3.00" spread="0.04"/>
                    <measurement group_id="O4" value="2.92" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lower Limbs Induration, Week 2 (n=326,326,331,106)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.47" spread="0.04"/>
                    <measurement group_id="O2" value="2.26" spread="0.05"/>
                    <measurement group_id="O3" value="2.45" spread="0.04"/>
                    <measurement group_id="O4" value="2.69" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lower Limbs Induration, Week 4 (n=320,323,328,102)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.03" spread="0.05"/>
                    <measurement group_id="O2" value="1.72" spread="0.05"/>
                    <measurement group_id="O3" value="1.92" spread="0.05"/>
                    <measurement group_id="O4" value="2.54" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lower Limbs Induration, Week 8 (n=315,319,323,99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.58" spread="0.06"/>
                    <measurement group_id="O2" value="1.18" spread="0.05"/>
                    <measurement group_id="O3" value="1.38" spread="0.05"/>
                    <measurement group_id="O4" value="2.25" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lower Limbs Induration, Week 12 (n=313,311,309,95)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.40" spread="0.06"/>
                    <measurement group_id="O2" value="0.97" spread="0.05"/>
                    <measurement group_id="O3" value="1.10" spread="0.06"/>
                    <measurement group_id="O4" value="2.21" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lower Limbs Scaling, Baseline (n=329,329,335,107)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.91" spread="0.04"/>
                    <measurement group_id="O2" value="2.95" spread="0.04"/>
                    <measurement group_id="O3" value="2.98" spread="0.04"/>
                    <measurement group_id="O4" value="2.89" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lower Limbs Scaling, Week 2 (n=326,326,331,106)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.36" spread="0.05"/>
                    <measurement group_id="O2" value="2.25" spread="0.05"/>
                    <measurement group_id="O3" value="2.31" spread="0.05"/>
                    <measurement group_id="O4" value="2.62" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lower Limbs Scaling, Week 4 (n=320,323,328,102)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.98" spread="0.05"/>
                    <measurement group_id="O2" value="1.69" spread="0.06"/>
                    <measurement group_id="O3" value="1.81" spread="0.05"/>
                    <measurement group_id="O4" value="2.44" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lower Limbs Scaling, Week 8 (n=315,319,323,99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.60" spread="0.06"/>
                    <measurement group_id="O2" value="1.21" spread="0.06"/>
                    <measurement group_id="O3" value="1.32" spread="0.05"/>
                    <measurement group_id="O4" value="2.11" spread="0.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lower Limbs Scaling, Week 12 (n=313,311,309,95)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.39" spread="0.06"/>
                    <measurement group_id="O2" value="0.96" spread="0.06"/>
                    <measurement group_id="O3" value="1.08" spread="0.06"/>
                    <measurement group_id="O4" value="2.09" spread="0.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in PASI Component Scores by Body Region During the 12-Week Double Blind Treatment</title>
        <description>Combined assessment of lesion severity and area affected into single score; range=0(no disease)-72(maximal disease). Body divided into 4 sections=head, upper/lower limbs, trunk; each area scored by itself and scores combined for final PASI. For each section percent area of skin involved was estimated:0(0%)-6(90–100%) and severity estimated by clinical signs of erythema, induration, scaling; ranged 0-4: 0=none, 1=slight, 2=moderate, 3=marked, 4=very marked. Final PASI=sum of severity parameters for each section*area score*weighing factor (head=0.1, upper limbs=0.2, trunk=0.3, lower limbs=0.4). PASI score can vary in increments of 0.1; higher scores represent greater severity of psoriasis.</description>
        <time_frame>Weeks 2, 4, 8, and 12</time_frame>
        <population>FAS; OC</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg Twice Daily (BID)+Placebo Twice Weekly (BIW)</title>
            <description>Participants received CP-690,550 5 mg tablets, orally, BID, at approximately 12-hour intervals and placebo subcutaneous (SC) injections BIW at approximately 3- to 4-day intervals for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg BID + Placebo BIW</title>
            <description>Participants received CP-690,550 10 mg tablets, orally, BID, at approximately 12-hour intervals and placebo SC injections BIW at approximately 3- to 4-day intervals for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo BID + Etanercept 50 mg BIW</title>
            <description>Participants received matching placebo tablets, orally, BID, at approximately 12-hour intervals and etanercept 50 mg SC injections BIW at approximately 3- to 4-day intervals for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Placebo BID + Placebo BIW</title>
            <description>Participants received matching placebo tablets, orally, BID, at approximately 12-hour intervals and placebo SC injections BIW at approximately 3- to 4-day intervals for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in PASI Component Scores by Body Region During the 12-Week Double Blind Treatment</title>
          <description>Combined assessment of lesion severity and area affected into single score; range=0(no disease)-72(maximal disease). Body divided into 4 sections=head, upper/lower limbs, trunk; each area scored by itself and scores combined for final PASI. For each section percent area of skin involved was estimated:0(0%)-6(90–100%) and severity estimated by clinical signs of erythema, induration, scaling; ranged 0-4: 0=none, 1=slight, 2=moderate, 3=marked, 4=very marked. Final PASI=sum of severity parameters for each section*area score*weighing factor (head=0.1, upper limbs=0.2, trunk=0.3, lower limbs=0.4). PASI score can vary in increments of 0.1; higher scores represent greater severity of psoriasis.</description>
          <population>FAS; OC</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="326"/>
                <count group_id="O2" value="326"/>
                <count group_id="O3" value="331"/>
                <count group_id="O4" value="106"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Head/Neck Erythema, Week 2 (n=326,326,331,106)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.46" spread="0.04"/>
                    <measurement group_id="O2" value="-0.72" spread="0.05"/>
                    <measurement group_id="O3" value="-0.56" spread="0.04"/>
                    <measurement group_id="O4" value="-0.15" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Head/Neck Erythema, Week 4 (n=320,323,328,102)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.80" spread="0.06"/>
                    <measurement group_id="O2" value="-1.19" spread="0.06"/>
                    <measurement group_id="O3" value="-1.10" spread="0.05"/>
                    <measurement group_id="O4" value="-0.32" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Head/Neck Erythema, Week 8 (n=315,319,323,99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.09" spread="0.06"/>
                    <measurement group_id="O2" value="-1.59" spread="0.06"/>
                    <measurement group_id="O3" value="-1.63" spread="0.06"/>
                    <measurement group_id="O4" value="-0.54" spread="0.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Head/Neck Erythema, Week 12 (n=313,311,309,95)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.25" spread="0.07"/>
                    <measurement group_id="O2" value="-1.73" spread="0.07"/>
                    <measurement group_id="O3" value="-1.83" spread="0.06"/>
                    <measurement group_id="O4" value="-0.64" spread="0.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Head/Neck Induration, Week 2 (n=326,326,331,106)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.44" spread="0.04"/>
                    <measurement group_id="O2" value="-0.65" spread="0.05"/>
                    <measurement group_id="O3" value="-0.49" spread="0.04"/>
                    <measurement group_id="O4" value="-0.17" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Head/Neck Induration, Week 4 (n=320,323,328,102)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.83" spread="0.06"/>
                    <measurement group_id="O2" value="-1.15" spread="0.06"/>
                    <measurement group_id="O3" value="-0.95" spread="0.05"/>
                    <measurement group_id="O4" value="-0.39" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Head/Neck Induration, Week 8 (n=315,319,323,99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.08" spread="0.06"/>
                    <measurement group_id="O2" value="-1.50" spread="0.06"/>
                    <measurement group_id="O3" value="-1.41" spread="0.06"/>
                    <measurement group_id="O4" value="-0.58" spread="0.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Head/Neck Induration, Week 12 (n=313,311,309,95)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.19" spread="0.06"/>
                    <measurement group_id="O2" value="-1.61" spread="0.06"/>
                    <measurement group_id="O3" value="-1.57" spread="0.06"/>
                    <measurement group_id="O4" value="-0.71" spread="0.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Head/Neck Scaling, Week 2 (n=326,326,331,106)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.53" spread="0.04"/>
                    <measurement group_id="O2" value="-0.76" spread="0.05"/>
                    <measurement group_id="O3" value="-0.67" spread="0.05"/>
                    <measurement group_id="O4" value="-0.20" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Head/Neck Scaling, Week 4 (n=320,323,328,102)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.91" spread="0.06"/>
                    <measurement group_id="O2" value="-1.30" spread="0.07"/>
                    <measurement group_id="O3" value="-1.13" spread="0.06"/>
                    <measurement group_id="O4" value="-0.48" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Head/Neck Scaling, Week 8 (n=315,319,323,99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.16" spread="0.07"/>
                    <measurement group_id="O2" value="-1.70" spread="0.06"/>
                    <measurement group_id="O3" value="-1.62" spread="0.06"/>
                    <measurement group_id="O4" value="-0.69" spread="0.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Head/Neck Scaling, Week 12 (n=313,311,309,95)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.31" spread="0.07"/>
                    <measurement group_id="O2" value="-1.78" spread="0.07"/>
                    <measurement group_id="O3" value="-1.81" spread="0.07"/>
                    <measurement group_id="O4" value="-0.80" spread="0.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Upper Limbs Erythema, Week 2 (n=326,326,331,106)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.52" spread="0.04"/>
                    <measurement group_id="O2" value="-0.68" spread="0.04"/>
                    <measurement group_id="O3" value="-0.61" spread="0.04"/>
                    <measurement group_id="O4" value="-0.18" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Upper Limbs Erythema, Week 4 (n=320,323,328,102)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.94" spread="0.05"/>
                    <measurement group_id="O2" value="-1.13" spread="0.05"/>
                    <measurement group_id="O3" value="-1.11" spread="0.04"/>
                    <measurement group_id="O4" value="-0.26" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Upper Limbs Erythema, Week 8 (n=315,319,323,99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.31" spread="0.06"/>
                    <measurement group_id="O2" value="-1.60" spread="0.06"/>
                    <measurement group_id="O3" value="-1.62" spread="0.05"/>
                    <measurement group_id="O4" value="-0.49" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Upper Limbs Erythema, Week 12 (n=313,311,309,95)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.42" spread="0.07"/>
                    <measurement group_id="O2" value="-1.79" spread="0.06"/>
                    <measurement group_id="O3" value="-1.95" spread="0.06"/>
                    <measurement group_id="O4" value="-0.58" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Upper Limbs Induration, Week 2 (n=326,326,331,106)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.52" spread="0.04"/>
                    <measurement group_id="O2" value="-0.73" spread="0.04"/>
                    <measurement group_id="O3" value="-0.59" spread="0.04"/>
                    <measurement group_id="O4" value="-0.25" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Upper Limbs Induration, Week 4 (n=320,323,328,102)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.94" spread="0.06"/>
                    <measurement group_id="O2" value="-1.23" spread="0.05"/>
                    <measurement group_id="O3" value="-1.13" spread="0.05"/>
                    <measurement group_id="O4" value="-0.39" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Upper Limbs Induration, Week 8 (n=315,319,323,99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.26" spread="0.06"/>
                    <measurement group_id="O2" value="-1.65" spread="0.06"/>
                    <measurement group_id="O3" value="-1.54" spread="0.05"/>
                    <measurement group_id="O4" value="-0.67" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Upper Limbs Induration, Week 12 (n=313,311,309,95)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.39" spread="0.07"/>
                    <measurement group_id="O2" value="-1.77" spread="0.06"/>
                    <measurement group_id="O3" value="-1.92" spread="0.06"/>
                    <measurement group_id="O4" value="-0.68" spread="0.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Upper Limbs Scaling, Week 2 (n=326,326,331,106)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.56" spread="0.04"/>
                    <measurement group_id="O2" value="-0.72" spread="0.05"/>
                    <measurement group_id="O3" value="-0.69" spread="0.04"/>
                    <measurement group_id="O4" value="-0.28" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Upper Limbs Scaling, Week 4 (n=320,323,328,102)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.96" spread="0.05"/>
                    <measurement group_id="O2" value="-1.23" spread="0.06"/>
                    <measurement group_id="O3" value="-1.19" spread="0.05"/>
                    <measurement group_id="O4" value="-0.38" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Upper Limbs Scaling, Week 8 (n=315,319,323,99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.28" spread="0.06"/>
                    <measurement group_id="O2" value="-1.62" spread="0.06"/>
                    <measurement group_id="O3" value="-1.66" spread="0.06"/>
                    <measurement group_id="O4" value="-0.64" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Upper Limbs Scaling, Week 12 (n=313,311,309,95)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.36" spread="0.07"/>
                    <measurement group_id="O2" value="-1.73" spread="0.06"/>
                    <measurement group_id="O3" value="-1.92" spread="0.06"/>
                    <measurement group_id="O4" value="-0.65" spread="0.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Trunk Erythema, Week 2 (n=326,326,331,106)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.54" spread="0.04"/>
                    <measurement group_id="O2" value="-0.67" spread="0.04"/>
                    <measurement group_id="O3" value="-0.63" spread="0.04"/>
                    <measurement group_id="O4" value="-0.23" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Trunk Erythema, Week 4 (n=320,323,328,102)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.91" spread="0.05"/>
                    <measurement group_id="O2" value="-1.13" spread="0.05"/>
                    <measurement group_id="O3" value="-1.16" spread="0.05"/>
                    <measurement group_id="O4" value="-0.35" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Trunk Erythema, Week 8 (n=315,319,323,99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.23" spread="0.06"/>
                    <measurement group_id="O2" value="-1.66" spread="0.06"/>
                    <measurement group_id="O3" value="-1.67" spread="0.06"/>
                    <measurement group_id="O4" value="-0.59" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Trunk Erythema, Week 12 (n=313,311,309,95)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.41" spread="0.07"/>
                    <measurement group_id="O2" value="-1.90" spread="0.07"/>
                    <measurement group_id="O3" value="-2.03" spread="0.06"/>
                    <measurement group_id="O4" value="-0.67" spread="0.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Trunk Induration, Week 2 (n=326,326,331,106)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.49" spread="0.04"/>
                    <measurement group_id="O2" value="-0.69" spread="0.04"/>
                    <measurement group_id="O3" value="-0.61" spread="0.04"/>
                    <measurement group_id="O4" value="-0.27" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Trunk Induration, Week 4 (n=320,323,328,102)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.93" spread="0.06"/>
                    <measurement group_id="O2" value="-1.20" spread="0.06"/>
                    <measurement group_id="O3" value="-1.17" spread="0.05"/>
                    <measurement group_id="O4" value="-0.37" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Trunk Induration, Week 8 (n=315,319,323,99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.26" spread="0.06"/>
                    <measurement group_id="O2" value="-1.74" spread="0.06"/>
                    <measurement group_id="O3" value="-1.68" spread="0.06"/>
                    <measurement group_id="O4" value="-0.62" spread="0.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Trunk Induration, Week 12 (n=313,311,309,95)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.43" spread="0.07"/>
                    <measurement group_id="O2" value="-1.91" spread="0.07"/>
                    <measurement group_id="O3" value="-1.99" spread="0.06"/>
                    <measurement group_id="O4" value="-0.64" spread="0.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Trunk Scaling, Week 2 (n=326,326,331,106)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.52" spread="0.05"/>
                    <measurement group_id="O2" value="-0.74" spread="0.05"/>
                    <measurement group_id="O3" value="-0.64" spread="0.05"/>
                    <measurement group_id="O4" value="-0.25" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Trunk Scaling, Week 4 (n=320,323,328,102)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.92" spread="0.06"/>
                    <measurement group_id="O2" value="-1.27" spread="0.06"/>
                    <measurement group_id="O3" value="-1.15" spread="0.05"/>
                    <measurement group_id="O4" value="-0.47" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Trunk Scaling, Week 8 (n=315,319,323,99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.19" spread="0.06"/>
                    <measurement group_id="O2" value="-1.71" spread="0.06"/>
                    <measurement group_id="O3" value="-1.67" spread="0.06"/>
                    <measurement group_id="O4" value="-0.75" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Trunk Scaling, Week 12 (n=313,311,309,95)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.38" spread="0.07"/>
                    <measurement group_id="O2" value="-1.92" spread="0.06"/>
                    <measurement group_id="O3" value="-1.94" spread="0.06"/>
                    <measurement group_id="O4" value="-0.71" spread="0.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lower Limbs Erythema, Week 2 (n=326,326,331,106)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.52" spread="0.04"/>
                    <measurement group_id="O2" value="-0.69" spread="0.04"/>
                    <measurement group_id="O3" value="-0.53" spread="0.04"/>
                    <measurement group_id="O4" value="-0.20" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lower Limbs Erythema, Week 4 (n=320,323,328,102)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.95" spread="0.05"/>
                    <measurement group_id="O2" value="-1.15" spread="0.05"/>
                    <measurement group_id="O3" value="-1.00" spread="0.04"/>
                    <measurement group_id="O4" value="-0.32" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lower Limbs Erythema, Week 8 (n=315,319,323,99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.34" spread="0.06"/>
                    <measurement group_id="O2" value="-1.63" spread="0.05"/>
                    <measurement group_id="O3" value="-1.51" spread="0.05"/>
                    <measurement group_id="O4" value="-0.55" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lower Limbs Erythema, Week 12 (n=313,311,309,95)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.55" spread="0.07"/>
                    <measurement group_id="O2" value="-1.92" spread="0.07"/>
                    <measurement group_id="O3" value="-1.80" spread="0.06"/>
                    <measurement group_id="O4" value="-0.61" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lower Limbs Induration, Week 2 (n=326,326,331,106)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.47" spread="0.04"/>
                    <measurement group_id="O2" value="-0.71" spread="0.04"/>
                    <measurement group_id="O3" value="-0.56" spread="0.04"/>
                    <measurement group_id="O4" value="-0.24" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lower Limbs Induration, Week 4 (n=320,323,328,102)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.92" spread="0.05"/>
                    <measurement group_id="O2" value="-1.25" spread="0.05"/>
                    <measurement group_id="O3" value="-1.08" spread="0.05"/>
                    <measurement group_id="O4" value="-0.35" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lower Limbs Induration, Week 8 (n=315,319,323,99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.37" spread="0.06"/>
                    <measurement group_id="O2" value="-1.80" spread="0.06"/>
                    <measurement group_id="O3" value="-1.62" spread="0.06"/>
                    <measurement group_id="O4" value="-0.66" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lower Limbs Induration, Week 12 (n=313,311,309,95)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.56" spread="0.07"/>
                    <measurement group_id="O2" value="-2.01" spread="0.06"/>
                    <measurement group_id="O3" value="-1.91" spread="0.06"/>
                    <measurement group_id="O4" value="-0.67" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lower Limbs Scaling, Week 2 (n=326,326,331,106)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.55" spread="0.04"/>
                    <measurement group_id="O2" value="-0.69" spread="0.05"/>
                    <measurement group_id="O3" value="-0.67" spread="0.04"/>
                    <measurement group_id="O4" value="-0.27" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lower Limbs Scaling, Week 4 (n=320,323,328,102)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.94" spread="0.05"/>
                    <measurement group_id="O2" value="-1.26" spread="0.06"/>
                    <measurement group_id="O3" value="-1.18" spread="0.05"/>
                    <measurement group_id="O4" value="-0.43" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lower Limbs Scaling, Week 8 (n=315,319,323,99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.31" spread="0.06"/>
                    <measurement group_id="O2" value="-1.74" spread="0.06"/>
                    <measurement group_id="O3" value="-1.67" spread="0.06"/>
                    <measurement group_id="O4" value="-0.75" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lower Limbs Scaling, Week 12 (n=313,311,309,95)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.53" spread="0.07"/>
                    <measurement group_id="O2" value="-1.99" spread="0.06"/>
                    <measurement group_id="O3" value="-1.92" spread="0.07"/>
                    <measurement group_id="O4" value="-0.76" spread="0.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Percentage of Total Psoriatic BSA During the 12-Week Double-Blind Treatment</title>
        <description>Assessment of BSA with psoriasis performed separately for 4 body regions: head and neck, upper limbs, trunk (including axillae and groin), and lower limbs (including buttocks). The % surface area with psoriasis was estimated by means of the handprint method, where the full palmar hand of the participant (fully extended palm, fingers and thumb together) represented approximately 1% of the total BSA. The number of handprints of psoriatic skin in a body region was used to determine the extent (%) to which a body region was involved with psoriasis.</description>
        <time_frame>Baseline and Weeks 2, 4, 8, and 12</time_frame>
        <population>FAS; OC</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg Twice Daily (BID)+Placebo Twice Weekly (BIW)</title>
            <description>Participants received CP-690,550 5 mg tablets, orally, BID, at approximately 12-hour intervals and placebo subcutaneous (SC) injections BIW at approximately 3- to 4-day intervals for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg BID + Placebo BIW</title>
            <description>Participants received CP-690,550 10 mg tablets, orally, BID, at approximately 12-hour intervals and placebo SC injections BIW at approximately 3- to 4-day intervals for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo BID + Etanercept 50 mg BIW</title>
            <description>Participants received matching placebo tablets, orally, BID, at approximately 12-hour intervals and etanercept 50 mg SC injections BIW at approximately 3- to 4-day intervals for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Placebo BID + Placebo BIW</title>
            <description>Participants received matching placebo tablets, orally, BID, at approximately 12-hour intervals and placebo SC injections BIW at approximately 3- to 4-day intervals for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Percentage of Total Psoriatic BSA During the 12-Week Double-Blind Treatment</title>
          <description>Assessment of BSA with psoriasis performed separately for 4 body regions: head and neck, upper limbs, trunk (including axillae and groin), and lower limbs (including buttocks). The % surface area with psoriasis was estimated by means of the handprint method, where the full palmar hand of the participant (fully extended palm, fingers and thumb together) represented approximately 1% of the total BSA. The number of handprints of psoriatic skin in a body region was used to determine the extent (%) to which a body region was involved with psoriasis.</description>
          <population>FAS; OC</population>
          <units>percent psoriatic BSA</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="329"/>
                <count group_id="O2" value="329"/>
                <count group_id="O3" value="335"/>
                <count group_id="O4" value="107"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n=329,329,335,107)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.15" spread="0.98"/>
                    <measurement group_id="O2" value="31.74" spread="0.95"/>
                    <measurement group_id="O3" value="30.63" spread="1.00"/>
                    <measurement group_id="O4" value="31.88" spread="1.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2 (n=326,326,331,106)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.53" spread="0.96"/>
                    <measurement group_id="O2" value="28.12" spread="0.94"/>
                    <measurement group_id="O3" value="28.29" spread="0.97"/>
                    <measurement group_id="O4" value="32.03" spread="1.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (n=320,323,328,102)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.98" spread="0.96"/>
                    <measurement group_id="O2" value="22.88" spread="0.93"/>
                    <measurement group_id="O3" value="24.82" spread="0.95"/>
                    <measurement group_id="O4" value="32.47" spread="1.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (n=315,319,323,99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.74" spread="0.98"/>
                    <measurement group_id="O2" value="14.76" spread="0.89"/>
                    <measurement group_id="O3" value="15.42" spread="0.81"/>
                    <measurement group_id="O4" value="31.00" spread="1.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (n=313,311,309,95)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.04" spread="0.94"/>
                    <measurement group_id="O2" value="10.55" spread="0.77"/>
                    <measurement group_id="O3" value="10.60" spread="0.76"/>
                    <measurement group_id="O4" value="29.77" spread="2.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Percent Change From Baseline in Total Psoriatic BSA During the 12-Week Double-Blind Treatment</title>
        <description>Assessment of BSA with psoriasis performed separately for 4 body regions: head and neck, upper limbs, trunk (including axillae and groin), and lower limbs (including buttocks). The %surface area with psoriasis was estimated by means of the handprint method, where the full palmar hand of the participant(fully extended palm, fingers and thumb together) represented approximately 1% of the total BSA. The number of handprints of psoriatic skin in a body region was used to determine the extent (%) to which a body region was involved with psoriasis.</description>
        <time_frame>Weeks 2, 4, 8, and 12</time_frame>
        <population>FAS; OC</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg Twice Daily (BID)+Placebo Twice Weekly (BIW)</title>
            <description>Participants received CP-690,550 5 mg tablets, orally, BID, at approximately 12-hour intervals and placebo subcutaneous (SC) injections BIW at approximately 3- to 4-day intervals for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg BID + Placebo BIW</title>
            <description>Participants received CP-690,550 10 mg tablets, orally, BID, at approximately 12-hour intervals and placebo SC injections BIW at approximately 3- to 4-day intervals for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo BID + Etanercept 50 mg BIW</title>
            <description>Participants received matching placebo tablets, orally, BID, at approximately 12-hour intervals and etanercept 50 mg SC injections BIW at approximately 3- to 4-day intervals for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Placebo BID + Placebo BIW</title>
            <description>Participants received matching placebo tablets, orally, BID, at approximately 12-hour intervals and placebo SC injections BIW at approximately 3- to 4-day intervals for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Percent Change From Baseline in Total Psoriatic BSA During the 12-Week Double-Blind Treatment</title>
          <description>Assessment of BSA with psoriasis performed separately for 4 body regions: head and neck, upper limbs, trunk (including axillae and groin), and lower limbs (including buttocks). The %surface area with psoriasis was estimated by means of the handprint method, where the full palmar hand of the participant(fully extended palm, fingers and thumb together) represented approximately 1% of the total BSA. The number of handprints of psoriatic skin in a body region was used to determine the extent (%) to which a body region was involved with psoriasis.</description>
          <population>FAS; OC</population>
          <units>percent change from baseline</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="326"/>
                <count group_id="O2" value="326"/>
                <count group_id="O3" value="331"/>
                <count group_id="O4" value="106"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2 (n=326,326,331,106)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.54" spread="1.23"/>
                    <measurement group_id="O2" value="-11.71" spread="1.12"/>
                    <measurement group_id="O3" value="-7.54" spread="0.96"/>
                    <measurement group_id="O4" value="0.23" spread="1.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (n=320,323,328,102)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-19.90" spread="1.66"/>
                    <measurement group_id="O2" value="-29.17" spread="1.69"/>
                    <measurement group_id="O3" value="-19.60" spread="1.46"/>
                    <measurement group_id="O4" value="1.58" spread="2.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (n=315,319,323,99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-37.81" spread="2.81"/>
                    <measurement group_id="O2" value="-55.02" spread="1.93"/>
                    <measurement group_id="O3" value="-48.65" spread="1.91"/>
                    <measurement group_id="O4" value="-1.33" spread="3.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (n=313,311,309,95)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-47.66" spread="3.35"/>
                    <measurement group_id="O2" value="-67.51" spread="1.86"/>
                    <measurement group_id="O3" value="-64.91" spread="1.91"/>
                    <measurement group_id="O4" value="-6.68" spread="4.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Achieved a 50% Reduction in PASI Relative to Baseline (PASI50) During the 12-Week Double-Blind Treatment</title>
        <description>PASI quantifies severity of psoriasis based on both lesion severity and percent of BSA affected. PASI is a composite score by the investigator of degree of erythema, induration, and scaling (scored separately) for each of 4 body regions (head and neck, upper limbs, trunk [including axillae and groin], and lower limbs [including buttocks), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0; higher scores represent greater severity of psoriasis.</description>
        <time_frame>Weeks 2, 4, 8, and 12</time_frame>
        <population>FAS; OC</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg Twice Daily (BID)+Placebo Twice Weekly (BIW)</title>
            <description>Participants received CP-690,550 5 mg tablets, orally, BID, at approximately 12-hour intervals and placebo subcutaneous (SC) injections BIW at approximately 3- to 4-day intervals for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg BID + Placebo BIW</title>
            <description>Participants received CP-690,550 10 mg tablets, orally, BID, at approximately 12-hour intervals and placebo SC injections BIW at approximately 3- to 4-day intervals for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo BID + Etanercept 50 mg BIW</title>
            <description>Participants received matching placebo tablets, orally, BID, at approximately 12-hour intervals and etanercept 50 mg SC injections BIW at approximately 3- to 4-day intervals for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Placebo BID + Placebo BIW</title>
            <description>Participants received matching placebo tablets, orally, BID, at approximately 12-hour intervals and placebo SC injections BIW at approximately 3- to 4-day intervals for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Achieved a 50% Reduction in PASI Relative to Baseline (PASI50) During the 12-Week Double-Blind Treatment</title>
          <description>PASI quantifies severity of psoriasis based on both lesion severity and percent of BSA affected. PASI is a composite score by the investigator of degree of erythema, induration, and scaling (scored separately) for each of 4 body regions (head and neck, upper limbs, trunk [including axillae and groin], and lower limbs [including buttocks), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0; higher scores represent greater severity of psoriasis.</description>
          <population>FAS; OC</population>
          <units>percentage of participatns</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="326"/>
                <count group_id="O2" value="327"/>
                <count group_id="O3" value="331"/>
                <count group_id="O4" value="106"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2 (n=326,327,331,106)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.74"/>
                    <measurement group_id="O2" value="18.35"/>
                    <measurement group_id="O3" value="11.18"/>
                    <measurement group_id="O4" value="0.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (n=319,323,328,102)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.23"/>
                    <measurement group_id="O2" value="50.46"/>
                    <measurement group_id="O3" value="48.78"/>
                    <measurement group_id="O4" value="6.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (n=315,319, 323,99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.05"/>
                    <measurement group_id="O2" value="78.06"/>
                    <measurement group_id="O3" value="77.09"/>
                    <measurement group_id="O4" value="20.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (n=313,311,309,95)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.01"/>
                    <measurement group_id="O2" value="85.53"/>
                    <measurement group_id="O3" value="87.06"/>
                    <measurement group_id="O4" value="23.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Time to PASI50 Response During the 12-Week Double-Blind Treatment</title>
        <time_frame>Baseline up to Week 12</time_frame>
        <population>FAS; OC</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg Twice Daily (BID)+Placebo Twice Weekly (BIW)</title>
            <description>Participants received CP-690,550 5 mg tablets, orally, BID, at approximately 12-hour intervals and placebo subcutaneous (SC) injections BIW at approximately 3- to 4-day intervals for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg BID + Placebo BIW</title>
            <description>Participants received CP-690,550 10 mg tablets, orally, BID, at approximately 12-hour intervals and placebo SC injections BIW at approximately 3- to 4-day intervals for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo BID + Etanercept 50 mg BIW</title>
            <description>Participants received matching placebo tablets, orally, BID, at approximately 12-hour intervals and etanercept 50 mg SC injections BIW at approximately 3- to 4-day intervals for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Placebo BID + Placebo BIW</title>
            <description>Participants received matching placebo tablets, orally, BID, at approximately 12-hour intervals and placebo SC injections BIW at approximately 3- to 4-day intervals for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Median Time to PASI50 Response During the 12-Week Double-Blind Treatment</title>
          <population>FAS; OC</population>
          <units>weeks</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="329"/>
                <count group_id="O2" value="330"/>
                <count group_id="O3" value="335"/>
                <count group_id="O4" value="107"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.1">The lower (upper) bound of the 95% confidence interval (CI) was not estimable because the lower (upper) bound of the survival function using LogLog transformation was not below the median.</measurement>
                    <measurement group_id="O2" value="5.0" lower_limit="4.1" upper_limit="8.0"/>
                    <measurement group_id="O3" value="7.9" lower_limit="4.4" upper_limit="8.0"/>
                    <measurement group_id="O4" value="NA">Median and 95% CI were not estimable due to less than (&lt;)50% of events occurring.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Achieved a 90% Reduction in PASI Relative to Baseline (PASI90) During the 12-Week Double-Blind Treatment</title>
        <description>PASI quantifies severity of psoriasis based on both lesion severity and percent of BSA affected. PASI is a composite score by the investigator of degree of erythema, induration, and scaling (scored separately) for each of 4 body regions (head and neck, upper limbs, trunk [including axillae and groin], and lower limbs [including buttocks), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0; higher scores represent greater severity of psoriasis.</description>
        <time_frame>Weeks 2, 4, 8, and 12</time_frame>
        <population>FAS; OC</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg Twice Daily (BID)+Placebo Twice Weekly (BIW)</title>
            <description>Participants received CP-690,550 5 mg tablets, orally, BID, at approximately 12-hour intervals and placebo subcutaneous (SC) injections BIW at approximately 3- to 4-day intervals for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg BID + Placebo BIW</title>
            <description>Participants received CP-690,550 10 mg tablets, orally, BID, at approximately 12-hour intervals and placebo SC injections BIW at approximately 3- to 4-day intervals for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo BID + Etanercept 50 mg BIW</title>
            <description>Participants received matching placebo tablets, orally, BID, at approximately 12-hour intervals and etanercept 50 mg SC injections BIW at approximately 3- to 4-day intervals for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Placebo BID + Placebo BIW</title>
            <description>Participants received matching placebo tablets, orally, BID, at approximately 12-hour intervals and placebo SC injections BIW at approximately 3- to 4-day intervals for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Achieved a 90% Reduction in PASI Relative to Baseline (PASI90) During the 12-Week Double-Blind Treatment</title>
          <description>PASI quantifies severity of psoriasis based on both lesion severity and percent of BSA affected. PASI is a composite score by the investigator of degree of erythema, induration, and scaling (scored separately) for each of 4 body regions (head and neck, upper limbs, trunk [including axillae and groin], and lower limbs [including buttocks), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0; higher scores represent greater severity of psoriasis.</description>
          <population>FAS; OC</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="326"/>
                <count group_id="O2" value="327"/>
                <count group_id="O3" value="331"/>
                <count group_id="O4" value="106"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2 (n=326,327,331,106)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00"/>
                    <measurement group_id="O2" value="0.61"/>
                    <measurement group_id="O3" value="0.30"/>
                    <measurement group_id="O4" value="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (n=319,323,328,102)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.57"/>
                    <measurement group_id="O2" value="4.64"/>
                    <measurement group_id="O3" value="1.83"/>
                    <measurement group_id="O4" value="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (n=315,319,323,99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.06"/>
                    <measurement group_id="O2" value="26.02"/>
                    <measurement group_id="O3" value="15.79"/>
                    <measurement group_id="O4" value="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (n=313,311,309,95)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.04"/>
                    <measurement group_id="O2" value="38.26"/>
                    <measurement group_id="O3" value="34.95"/>
                    <measurement group_id="O4" value="1.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Time to Achieve PASI75 Response During the 12-Week Double-Blind Treatment</title>
        <time_frame>Baseline up to Week 12</time_frame>
        <population>FAS; OC</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg Twice Daily (BID)+Placebo Twice Weekly (BIW)</title>
            <description>Participants received CP-690,550 5 mg tablets, orally, BID, at approximately 12-hour intervals and placebo subcutaneous (SC) injections BIW at approximately 3- to 4-day intervals for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg BID + Placebo BIW</title>
            <description>Participants received CP-690,550 10 mg tablets, orally, BID, at approximately 12-hour intervals and placebo SC injections BIW at approximately 3- to 4-day intervals for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo BID + Etanercept 50 mg BIW</title>
            <description>Participants received matching placebo tablets, orally, BID, at approximately 12-hour intervals and etanercept 50 mg SC injections BIW at approximately 3- to 4-day intervals for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Placebo BID + Placebo BIW</title>
            <description>Participants received matching placebo tablets, orally, BID, at approximately 12-hour intervals and placebo SC injections BIW at approximately 3- to 4-day intervals for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Median Time to Achieve PASI75 Response During the 12-Week Double-Blind Treatment</title>
          <population>FAS; OC</population>
          <units>weeks</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="329"/>
                <count group_id="O2" value="330"/>
                <count group_id="O3" value="335"/>
                <count group_id="O4" value="107"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.6" lower_limit="12.4" upper_limit="13.1"/>
                    <measurement group_id="O2" value="8.6" lower_limit="8.1" upper_limit="12.1"/>
                    <measurement group_id="O3" value="12.1" lower_limit="11.1" upper_limit="12.1"/>
                    <measurement group_id="O4" value="NA">Median and 95% CI were not estimable due to &lt;50% of events occurring.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With a PASI Score Greater Than or Equal to (≥)125% of the Baseline PASI Score During the 12-Week Double-Blind Treatment</title>
        <time_frame>Weeks 2, 4, 8, and 12</time_frame>
        <population>FAS; OC</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg Twice Daily (BID)+Placebo Twice Weekly (BIW)</title>
            <description>Participants received CP-690,550 5 mg tablets, orally, BID, at approximately 12-hour intervals and placebo subcutaneous (SC) injections BIW at approximately 3- to 4-day intervals for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg BID + Placebo BIW</title>
            <description>Participants received CP-690,550 10 mg tablets, orally, BID, at approximately 12-hour intervals and placebo SC injections BIW at approximately 3- to 4-day intervals for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo BID + Etanercept 50 mg BIW</title>
            <description>Participants received matching placebo tablets, orally, BID, at approximately 12-hour intervals and etanercept 50 mg SC injections BIW at approximately 3- to 4-day intervals for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Placebo BID + Placebo BIW</title>
            <description>Participants received matching placebo tablets, orally, BID, at approximately 12-hour intervals and placebo SC injections BIW at approximately 3- to 4-day intervals for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a PASI Score Greater Than or Equal to (≥)125% of the Baseline PASI Score During the 12-Week Double-Blind Treatment</title>
          <population>FAS; OC</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="326"/>
                <count group_id="O2" value="327"/>
                <count group_id="O3" value="331"/>
                <count group_id="O4" value="106"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2 (n=326,327,331,106)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.92"/>
                    <measurement group_id="O2" value="0.61"/>
                    <measurement group_id="O3" value="0.30"/>
                    <measurement group_id="O4" value="4.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (n=319,323,328,102)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.19"/>
                    <measurement group_id="O2" value="0.93"/>
                    <measurement group_id="O3" value="0.91"/>
                    <measurement group_id="O4" value="8.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (n=315,319,323,99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.54"/>
                    <measurement group_id="O2" value="0.31"/>
                    <measurement group_id="O3" value="0.31"/>
                    <measurement group_id="O4" value="7.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (n=313,311,309,95)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.88"/>
                    <measurement group_id="O2" value="0.32"/>
                    <measurement group_id="O3" value="0.97"/>
                    <measurement group_id="O4" value="7.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Overall (n=327,329,334,107)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.59"/>
                    <measurement group_id="O2" value="1.82"/>
                    <measurement group_id="O3" value="1.80"/>
                    <measurement group_id="O4" value="15.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Itch Severity Item (ISI) Score During the 12-Week Double-Blind Treatment</title>
        <description>ISI assessed severity of itch (pruritus) due to psoriasis. ISI is a single item, horizontal numeric rating scale. Participants were asked to rate “your worst itching due to psoriasis over the past 24 hours” on a numeric rating scale anchored by the terms “No itching” (0) and “Worst possible itching” (10) at the ends.</description>
        <time_frame>Baseline, Weeks 2, 4, 8, and 12</time_frame>
        <population>FAS; OC</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg Twice Daily (BID)+Placebo Twice Weekly (BIW)</title>
            <description>Participants received CP-690,550 5 mg tablets, orally, BID, at approximately 12-hour intervals and placebo subcutaneous (SC) injections BIW at approximately 3- to 4-day intervals for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg BID + Placebo BIW</title>
            <description>Participants received CP-690,550 10 mg tablets, orally, BID, at approximately 12-hour intervals and placebo SC injections BIW at approximately 3- to 4-day intervals for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo BID + Etanercept 50 mg BIW</title>
            <description>Participants received matching placebo tablets, orally, BID, at approximately 12-hour intervals and etanercept 50 mg SC injections BIW at approximately 3- to 4-day intervals for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Placebo BID + Placebo BIW</title>
            <description>Participants received matching placebo tablets, orally, BID, at approximately 12-hour intervals and placebo SC injections BIW at approximately 3- to 4-day intervals for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Itch Severity Item (ISI) Score During the 12-Week Double-Blind Treatment</title>
          <description>ISI assessed severity of itch (pruritus) due to psoriasis. ISI is a single item, horizontal numeric rating scale. Participants were asked to rate “your worst itching due to psoriasis over the past 24 hours” on a numeric rating scale anchored by the terms “No itching” (0) and “Worst possible itching” (10) at the ends.</description>
          <population>FAS; OC</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="305"/>
                <count group_id="O2" value="308"/>
                <count group_id="O3" value="305"/>
                <count group_id="O4" value="107"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n=305,308,305,107)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.19" spread="0.16"/>
                    <measurement group_id="O2" value="5.26" spread="0.16"/>
                    <measurement group_id="O3" value="5.23" spread="0.15"/>
                    <measurement group_id="O4" value="5.15" spread="0.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2 (n=325,322,330,105)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.47" spread="0.15"/>
                    <measurement group_id="O2" value="2.87" spread="0.14"/>
                    <measurement group_id="O3" value="3.90" spread="0.15"/>
                    <measurement group_id="O4" value="4.90" spread="0.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (n=318,323,328,101)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.92" spread="0.15"/>
                    <measurement group_id="O2" value="1.86" spread="0.13"/>
                    <measurement group_id="O3" value="2.97" spread="0.13"/>
                    <measurement group_id="O4" value="4.65" spread="0.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (n=313,315,320,100)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.11" spread="0.14"/>
                    <measurement group_id="O2" value="1.22" spread="0.11"/>
                    <measurement group_id="O3" value="2.06" spread="0.13"/>
                    <measurement group_id="O4" value="4.74" spread="0.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (n=312,309,311,95)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.98" spread="0.14"/>
                    <measurement group_id="O2" value="1.25" spread="0.12"/>
                    <measurement group_id="O3" value="1.72" spread="0.13"/>
                    <measurement group_id="O4" value="4.75" spread="0.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in ISI Score During the 12-Week Double-Blind Treatment</title>
        <description>ISI assessed severity of itch (pruritus) due to psoriasis. ISI is a single item, horizontal numeric rating scale. Participants were asked to rate “your worst itching due to psoriasis over the past 24 hours” on a numeric rating scale anchored by the terms “No itching” (0) and “Worst possible itching” (10) at the ends.</description>
        <time_frame>Weeks 2, 4, 8, and 12</time_frame>
        <population>FAS; OC</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg Twice Daily (BID)+Placebo Twice Weekly (BIW)</title>
            <description>Participants received CP-690,550 5 mg tablets, orally, BID, at approximately 12-hour intervals and placebo subcutaneous (SC) injections BIW at approximately 3- to 4-day intervals for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg BID + Placebo BIW</title>
            <description>Participants received CP-690,550 10 mg tablets, orally, BID, at approximately 12-hour intervals and placebo SC injections BIW at approximately 3- to 4-day intervals for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo BID + Etanercept 50 mg BIW</title>
            <description>Participants received matching placebo tablets, orally, BID, at approximately 12-hour intervals and etanercept 50 mg SC injections BIW at approximately 3- to 4-day intervals for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Placebo BID + Placebo BIW</title>
            <description>Participants received matching placebo tablets, orally, BID, at approximately 12-hour intervals and placebo SC injections BIW at approximately 3- to 4-day intervals for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in ISI Score During the 12-Week Double-Blind Treatment</title>
          <description>ISI assessed severity of itch (pruritus) due to psoriasis. ISI is a single item, horizontal numeric rating scale. Participants were asked to rate “your worst itching due to psoriasis over the past 24 hours” on a numeric rating scale anchored by the terms “No itching” (0) and “Worst possible itching” (10) at the ends.</description>
          <population>FAS; OC</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="303"/>
                <count group_id="O2" value="300"/>
                <count group_id="O3" value="301"/>
                <count group_id="O4" value="105"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.73" spread="0.15"/>
                    <measurement group_id="O2" value="-2.39" spread="0.14"/>
                    <measurement group_id="O3" value="-1.22" spread="0.15"/>
                    <measurement group_id="O4" value="-0.26" spread="0.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.24" spread="0.18"/>
                    <measurement group_id="O2" value="-3.43" spread="0.17"/>
                    <measurement group_id="O3" value="-2.20" spread="0.15"/>
                    <measurement group_id="O4" value="-0.44" spread="0.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.01" spread="0.18"/>
                    <measurement group_id="O2" value="-4.02" spread="0.17"/>
                    <measurement group_id="O3" value="-3.13" spread="-0.17"/>
                    <measurement group_id="O4" value="-0.46" spread="0.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.18" spread="0.18"/>
                    <measurement group_id="O2" value="-3.96" spread="0.18"/>
                    <measurement group_id="O3" value="-3.46" spread="0.19"/>
                    <measurement group_id="O4" value="-0.43" spread="0.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving an ISI Score of 0 During the 12-Week Double-Blind Treatment</title>
        <description>ISI assessed severity of itch (pruritus) due to psoriasis. ISI is a single item, horizontal numeric rating scale. Participants were asked to rate “your worst itching due to psoriasis over the past 24 hours” on a numeric rating scale anchored by the terms “No itching” (0) and “Worst possible itching” (10) at the ends.</description>
        <time_frame>Weeks 2, 4, 8, and 12</time_frame>
        <population>FAS; OC</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg Twice Daily (BID)+Placebo Twice Weekly (BIW)</title>
            <description>Participants received CP-690,550 5 mg tablets, orally, BID, at approximately 12-hour intervals and placebo subcutaneous (SC) injections BIW at approximately 3- to 4-day intervals for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg BID + Placebo BIW</title>
            <description>Participants received CP-690,550 10 mg tablets, orally, BID, at approximately 12-hour intervals and placebo SC injections BIW at approximately 3- to 4-day intervals for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo BID + Etanercept 50 mg BIW</title>
            <description>Participants received matching placebo tablets, orally, BID, at approximately 12-hour intervals and etanercept 50 mg SC injections BIW at approximately 3- to 4-day intervals for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Placebo BID + Placebo BIW</title>
            <description>Participants received matching placebo tablets, orally, BID, at approximately 12-hour intervals and placebo SC injections BIW at approximately 3- to 4-day intervals for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving an ISI Score of 0 During the 12-Week Double-Blind Treatment</title>
          <description>ISI assessed severity of itch (pruritus) due to psoriasis. ISI is a single item, horizontal numeric rating scale. Participants were asked to rate “your worst itching due to psoriasis over the past 24 hours” on a numeric rating scale anchored by the terms “No itching” (0) and “Worst possible itching” (10) at the ends.</description>
          <population>FAS; OC</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="288"/>
                <count group_id="O2" value="281"/>
                <count group_id="O3" value="294"/>
                <count group_id="O4" value="98"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.42"/>
                    <measurement group_id="O2" value="13.88"/>
                    <measurement group_id="O3" value="10.54"/>
                    <measurement group_id="O4" value="1.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.66"/>
                    <measurement group_id="O2" value="34.28"/>
                    <measurement group_id="O3" value="14.09"/>
                    <measurement group_id="O4" value="2.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.45"/>
                    <measurement group_id="O2" value="47.83"/>
                    <measurement group_id="O3" value="28.67"/>
                    <measurement group_id="O4" value="6.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.64"/>
                    <measurement group_id="O2" value="51.85"/>
                    <measurement group_id="O3" value="40.07"/>
                    <measurement group_id="O4" value="6.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Dermatology Life Quality Index (DLQI) Score During the 12-Week Double-Blind Treatment</title>
        <description>The DLQI is a general dermatology questionnaire that consists of 10 items that assess health related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI questions are rated by the participant as 0 (not at all/not relevant) to 3 (very much) with a total score range of 0 (best) to 30 (worst); higher scores indicate poor quality of life.</description>
        <time_frame>Baseline and Weeks 4 and 12</time_frame>
        <population>FAS; OC</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg Twice Daily (BID)+Placebo Twice Weekly (BIW)</title>
            <description>Participants received CP-690,550 5 mg tablets, orally, BID, at approximately 12-hour intervals and placebo subcutaneous (SC) injections BIW at approximately 3- to 4-day intervals for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg BID + Placebo BIW</title>
            <description>Participants received CP-690,550 10 mg tablets, orally, BID, at approximately 12-hour intervals and placebo SC injections BIW at approximately 3- to 4-day intervals for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo BID + Etanercept 50 mg BIW</title>
            <description>Participants received matching placebo tablets, orally, BID, at approximately 12-hour intervals and etanercept 50 mg SC injections BIW at approximately 3- to 4-day intervals for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Placebo BID + Placebo BIW</title>
            <description>Participants received matching placebo tablets, orally, BID, at approximately 12-hour intervals and placebo SC injections BIW at approximately 3- to 4-day intervals for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Dermatology Life Quality Index (DLQI) Score During the 12-Week Double-Blind Treatment</title>
          <description>The DLQI is a general dermatology questionnaire that consists of 10 items that assess health related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI questions are rated by the participant as 0 (not at all/not relevant) to 3 (very much) with a total score range of 0 (best) to 30 (worst); higher scores indicate poor quality of life.</description>
          <population>FAS; OC</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="328"/>
                <count group_id="O2" value="326"/>
                <count group_id="O3" value="332"/>
                <count group_id="O4" value="106"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n=328,326,332,106)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.98" spread="0.39"/>
                    <measurement group_id="O2" value="13.32" spread="0.38"/>
                    <measurement group_id="O3" value="12.73" spread="0.38"/>
                    <measurement group_id="O4" value="12.27" spread="0.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (n=318,323,325,100)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.82" spread="0.36"/>
                    <measurement group_id="O2" value="5.95" spread="0.32"/>
                    <measurement group_id="O3" value="6.90" spread="0.35"/>
                    <measurement group_id="O4" value="10.51" spread="0.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (n=306,305,307,93)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.61" spread="0.36"/>
                    <measurement group_id="O2" value="3.47" spread="0.27"/>
                    <measurement group_id="O3" value="3.84" spread="0.30"/>
                    <measurement group_id="O4" value="10.33" spread="0.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in DLQI Score During the 12-Week Double-Blind Treatment</title>
        <description>The DLQI is a general dermatology questionnaire that consists of 10 items that assess health related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI questions are rated by the participant as 0 (not at all/not relevant) to 3 (very much) with a total score range of 0 (best) to 30 (worst); higher scores indicate poor quality of life. The minimally important difference for the DLQI has been estimated as a 2 to 5 point change from baseline.</description>
        <time_frame>Weeks 4 and 12</time_frame>
        <population>FAS; OC</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg Twice Daily (BID)+Placebo Twice Weekly (BIW)</title>
            <description>Participants received CP-690,550 5 mg tablets, orally, BID, at approximately 12-hour intervals and placebo subcutaneous (SC) injections BIW at approximately 3- to 4-day intervals for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg BID + Placebo BIW</title>
            <description>Participants received CP-690,550 10 mg tablets, orally, BID, at approximately 12-hour intervals and placebo SC injections BIW at approximately 3- to 4-day intervals for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo BID + Etanercept 50 mg BIW</title>
            <description>Participants received matching placebo tablets, orally, BID, at approximately 12-hour intervals and etanercept 50 mg SC injections BIW at approximately 3- to 4-day intervals for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Placebo BID + Placebo BIW</title>
            <description>Participants received matching placebo tablets, orally, BID, at approximately 12-hour intervals and placebo SC injections BIW at approximately 3- to 4-day intervals for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in DLQI Score During the 12-Week Double-Blind Treatment</title>
          <description>The DLQI is a general dermatology questionnaire that consists of 10 items that assess health related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI questions are rated by the participant as 0 (not at all/not relevant) to 3 (very much) with a total score range of 0 (best) to 30 (worst); higher scores indicate poor quality of life. The minimally important difference for the DLQI has been estimated as a 2 to 5 point change from baseline.</description>
          <population>FAS; OC</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="317"/>
                <count group_id="O2" value="319"/>
                <count group_id="O3" value="322"/>
                <count group_id="O4" value="99"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4 (n=317,319,322,99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.28" spread="0.35"/>
                    <measurement group_id="O2" value="-7.43" spread="0.36"/>
                    <measurement group_id="O3" value="-5.80" spread="0.33"/>
                    <measurement group_id="O4" value="-1.64" spread="0.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (n=305,301,305,93)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.33" spread="0.43"/>
                    <measurement group_id="O2" value="-9.72" spread="0.40"/>
                    <measurement group_id="O3" value="-8.97" spread="0.40"/>
                    <measurement group_id="O4" value="-1.85" spread="0.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean DLQI Subscale Scores During the 12-Week Double-Blind Treatment</title>
        <description>The DLQI is a general dermatology questionnaire that consists of 10 items that assess health related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI questions are rated by the participant as 0 (not at all/not relevant) to 3 (very much); higher scores indicate poor quality of life. The DLQI can be analyzed under 6 subscales by combining questions and is categorized as follows: symptoms and feelings (maximum score=6); daily activities (maximum score=6); leisure (maximum score=6); work and school (maximum score=3); personal relationships (maximum score=6); and treatment (maximum score=3).</description>
        <time_frame>Baseline and Weeks 4 and 12</time_frame>
        <population>FAS; OC</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg Twice Daily (BID)+Placebo Twice Weekly (BIW)</title>
            <description>Participants received CP-690,550 5 mg tablets, orally, BID, at approximately 12-hour intervals and placebo subcutaneous (SC) injections BIW at approximately 3- to 4-day intervals for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg BID + Placebo BIW</title>
            <description>Participants received CP-690,550 10 mg tablets, orally, BID, at approximately 12-hour intervals and placebo SC injections BIW at approximately 3- to 4-day intervals for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo BID + Etanercept 50 mg BIW</title>
            <description>Participants received matching placebo tablets, orally, BID, at approximately 12-hour intervals and etanercept 50 mg SC injections BIW at approximately 3- to 4-day intervals for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Placebo BID + Placebo BIW</title>
            <description>Participants received matching placebo tablets, orally, BID, at approximately 12-hour intervals and placebo SC injections BIW at approximately 3- to 4-day intervals for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean DLQI Subscale Scores During the 12-Week Double-Blind Treatment</title>
          <description>The DLQI is a general dermatology questionnaire that consists of 10 items that assess health related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI questions are rated by the participant as 0 (not at all/not relevant) to 3 (very much); higher scores indicate poor quality of life. The DLQI can be analyzed under 6 subscales by combining questions and is categorized as follows: symptoms and feelings (maximum score=6); daily activities (maximum score=6); leisure (maximum score=6); work and school (maximum score=3); personal relationships (maximum score=6); and treatment (maximum score=3).</description>
          <population>FAS; OC</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="328"/>
                <count group_id="O2" value="327"/>
                <count group_id="O3" value="332"/>
                <count group_id="O4" value="106"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Symptoms and Feelings,Baseline (n=328,327,332,106)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.44" spread="0.09"/>
                    <measurement group_id="O2" value="3.49" spread="0.08"/>
                    <measurement group_id="O3" value="3.47" spread="0.08"/>
                    <measurement group_id="O4" value="3.46" spread="0.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Symptoms and Feelings, Week 4 (n=318,323,324,100)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.11" spread="0.08"/>
                    <measurement group_id="O2" value="1.63" spread="0.07"/>
                    <measurement group_id="O3" value="1.94" spread="0.07"/>
                    <measurement group_id="O4" value="2.92" spread="0.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Symptoms and Feelings, Week 12 (n=306,304,307,93)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.60" spread="0.09"/>
                    <measurement group_id="O2" value="1.04" spread="0.07"/>
                    <measurement group_id="O3" value="1.16" spread="0.07"/>
                    <measurement group_id="O4" value="2.85" spread="0.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Daily Activities,Baseline (n=327,327,332,106)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.76" spread="0.10"/>
                    <measurement group_id="O2" value="2.85" spread="0.09"/>
                    <measurement group_id="O3" value="2.76" spread="0.09"/>
                    <measurement group_id="O4" value="2.52" spread="0.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Daily Activities, Week 4 (n=318,322,324,100)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.68" spread="0.08"/>
                    <measurement group_id="O2" value="1.30" spread="0.08"/>
                    <measurement group_id="O3" value="1.53" spread="0.08"/>
                    <measurement group_id="O4" value="2.28" spread="0.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Daily Activities, Week 12 (n=306,305,306,93)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.19" spread="0.08"/>
                    <measurement group_id="O2" value="0.70" spread="0.07"/>
                    <measurement group_id="O3" value="0.79" spread="0.07"/>
                    <measurement group_id="O4" value="2.17" spread="0.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leisure, Baseline (n=326,326,330,106)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.52" spread="0.11"/>
                    <measurement group_id="O2" value="2.67" spread="0.11"/>
                    <measurement group_id="O3" value="2.57" spread="0.11"/>
                    <measurement group_id="O4" value="2.25" spread="0.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leisure, Week 4 (n=318,322,325,100)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.50" spread="0.09"/>
                    <measurement group_id="O2" value="1.14" spread="0.08"/>
                    <measurement group_id="O3" value="1.33" spread="0.09"/>
                    <measurement group_id="O4" value="1.84" spread="0.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leisure, Week 12 (n=306,305,307,93)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.09" spread="0.09"/>
                    <measurement group_id="O2" value="0.70" spread="0.07"/>
                    <measurement group_id="O3" value="0.71" spread="0.07"/>
                    <measurement group_id="O4" value="1.90" spread="0.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Work and School,Baseline (n=328,327,331,106)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.12" spread="0.06"/>
                    <measurement group_id="O2" value="1.08" spread="0.06"/>
                    <measurement group_id="O3" value="1.06" spread="0.06"/>
                    <measurement group_id="O4" value="0.97" spread="0.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Work and School, Week 4 (n=318,323,325,100)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.56" spread="0.05"/>
                    <measurement group_id="O2" value="0.46" spread="0.05"/>
                    <measurement group_id="O3" value="0.54" spread="0.05"/>
                    <measurement group_id="O4" value="0.81" spread="0.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Work and School, Week 12 (n=306,304,307,92)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.41" spread="0.04"/>
                    <measurement group_id="O2" value="0.24" spread="0.04"/>
                    <measurement group_id="O3" value="0.32" spread="0.04"/>
                    <measurement group_id="O4" value="0.83" spread="0.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Personal Relationships,Baseline(n=328,326,332,106)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.95" spread="0.11"/>
                    <measurement group_id="O2" value="1.98" spread="0.10"/>
                    <measurement group_id="O3" value="1.67" spread="0.10"/>
                    <measurement group_id="O4" value="1.89" spread="0.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Personal Relationships, Week 4 (n=318,323,325,100)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.21" spread="0.09"/>
                    <measurement group_id="O2" value="0.90" spread="0.08"/>
                    <measurement group_id="O3" value="0.93" spread="0.08"/>
                    <measurement group_id="O4" value="1.64" spread="0.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Personal Relationships, Week 12 (n=306,305,307,93)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.85" spread="0.09"/>
                    <measurement group_id="O2" value="0.48" spread="0.06"/>
                    <measurement group_id="O3" value="0.52" spread="0.07"/>
                    <measurement group_id="O4" value="1.65" spread="0.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment, Baseline(n=328,327,332,106)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.22" spread="0.06"/>
                    <measurement group_id="O2" value="1.24" spread="0.06"/>
                    <measurement group_id="O3" value="1.23" spread="0.06"/>
                    <measurement group_id="O4" value="1.18" spread="0.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment, Week 4 (n=318,323,325,100)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.76" spread="0.05"/>
                    <measurement group_id="O2" value="0.52" spread="0.04"/>
                    <measurement group_id="O3" value="0.65" spread="0.04"/>
                    <measurement group_id="O4" value="1.02" spread="0.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment, Week 12 (n=306,305,307,93)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.45" spread="0.04"/>
                    <measurement group_id="O2" value="0.31" spread="0.03"/>
                    <measurement group_id="O3" value="0.33" spread="0.04"/>
                    <measurement group_id="O4" value="0.95" spread="0.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in DLQI Subscale Scores During the 12-Week Double-Blind Treatment</title>
        <description>The DLQI is a general dermatology questionnaire that consists of 10 items that assess health related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI questions are rated by the participant as 0 (not at all/not relevant) to 3 (very much); higher scores indicate poor quality of life. The DLQI can be analyzed under 6 subscales by combining questions and is categorized as follows: symptoms and feelings (maximum score=6); daily activities (maximum score=6); leisure (maximum score=6); work and school (maximum score=3); personal relationships (maximum score=6); and treatment (maximum score=3). The minimally important difference for the DLQI has been estimated as a 2 to 5 point change from baseline.</description>
        <time_frame>Weeks 4 and 12</time_frame>
        <population>FAS; OC</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg Twice Daily (BID)+Placebo Twice Weekly (BIW)</title>
            <description>Participants received CP-690,550 5 mg tablets, orally, BID, at approximately 12-hour intervals and placebo subcutaneous (SC) injections BIW at approximately 3- to 4-day intervals for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg BID + Placebo BIW</title>
            <description>Participants received CP-690,550 10 mg tablets, orally, BID, at approximately 12-hour intervals and placebo SC injections BIW at approximately 3- to 4-day intervals for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo BID + Etanercept 50 mg BIW</title>
            <description>Participants received matching placebo tablets, orally, BID, at approximately 12-hour intervals and etanercept 50 mg SC injections BIW at approximately 3- to 4-day intervals for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Placebo BID + Placebo BIW</title>
            <description>Participants received matching placebo tablets, orally, BID, at approximately 12-hour intervals and placebo SC injections BIW at approximately 3- to 4-day intervals for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in DLQI Subscale Scores During the 12-Week Double-Blind Treatment</title>
          <description>The DLQI is a general dermatology questionnaire that consists of 10 items that assess health related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI questions are rated by the participant as 0 (not at all/not relevant) to 3 (very much); higher scores indicate poor quality of life. The DLQI can be analyzed under 6 subscales by combining questions and is categorized as follows: symptoms and feelings (maximum score=6); daily activities (maximum score=6); leisure (maximum score=6); work and school (maximum score=3); personal relationships (maximum score=6); and treatment (maximum score=3). The minimally important difference for the DLQI has been estimated as a 2 to 5 point change from baseline.</description>
          <population>FAS; OC</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="317"/>
                <count group_id="O2" value="320"/>
                <count group_id="O3" value="321"/>
                <count group_id="O4" value="99"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Symptoms and Feelings, Week 4 (n=317,320,321,99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.34" spread="0.09"/>
                    <measurement group_id="O2" value="-1.87" spread="0.08"/>
                    <measurement group_id="O3" value="-1.53" spread="0.08"/>
                    <measurement group_id="O4" value="-0.53" spread="0.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Symptoms and Feelings, Week 12 (n=305,301,305,93)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.81" spread="0.10"/>
                    <measurement group_id="O2" value="-2.41" spread="0.10"/>
                    <measurement group_id="O3" value="-2.30" spread="0.10"/>
                    <measurement group_id="O4" value="-0.62" spread="0.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Daily Activities, Week 4 (n=316,319,321,99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.13" spread="0.09"/>
                    <measurement group_id="O2" value="-1.57" spread="0.09"/>
                    <measurement group_id="O3" value="-1.21" spread="0.09"/>
                    <measurement group_id="O4" value="-0.28" spread="0.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Daily Activities, Week 12 (n=304,302,304,93)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.58" spread="0.10"/>
                    <measurement group_id="O2" value="-2.14" spread="0.10"/>
                    <measurement group_id="O3" value="-1.96" spread="0.10"/>
                    <measurement group_id="O4" value="-0.34" spread="0.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leisure, Week 4 (n=316,318,320,99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.03" spread="0.10"/>
                    <measurement group_id="O2" value="-1.54" spread="0.10"/>
                    <measurement group_id="O3" value="-1.24" spread="0.10"/>
                    <measurement group_id="O4" value="-0.39" spread="0.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leisure, Week 12 (n=303,301,303,93)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.41" spread="0.11"/>
                    <measurement group_id="O2" value="-1.95" spread="0.11"/>
                    <measurement group_id="O3" value="-1.90" spread="0.11"/>
                    <measurement group_id="O4" value="-0.31" spread="0.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Work and School, Week 4 (n=317,320,321,99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.56" spread="0.06"/>
                    <measurement group_id="O2" value="-0.63" spread="0.06"/>
                    <measurement group_id="O3" value="-0.52" spread="0.06"/>
                    <measurement group_id="O4" value="-0.13" spread="0.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Work and School, Week 12 (n=305,301,304,92)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.69" spread="0.07"/>
                    <measurement group_id="O2" value="-0.86" spread="0.06"/>
                    <measurement group_id="O3" value="-0.77" spread="0.07"/>
                    <measurement group_id="O4" value="-0.12" spread="0.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Personal Relationships, Week 4 (n=317,319,322,99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.76" spread="0.09"/>
                    <measurement group_id="O2" value="-1.09" spread="0.09"/>
                    <measurement group_id="O3" value="-0.73" spread="0.08"/>
                    <measurement group_id="O4" value="-0.18" spread="0.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Personal Relationships, Week 12 (n=305,301,305,93)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.10" spread="0.11"/>
                    <measurement group_id="O2" value="-1.46" spread="0.10"/>
                    <measurement group_id="O3" value="-1.17" spread="0.09"/>
                    <measurement group_id="O4" value="-0.20" spread="0.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment, Week 4 (n=317,320,322,99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.47" spread="0.06"/>
                    <measurement group_id="O2" value="-0.72" spread="0.06"/>
                    <measurement group_id="O3" value="-0.58" spread="0.06"/>
                    <measurement group_id="O4" value="-0.12" spread="0.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment, Week 12 (n=305,302,305,93)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.75" spread="0.06"/>
                    <measurement group_id="O2" value="-0.91" spread="0.06"/>
                    <measurement group_id="O3" value="-0.91" spread="0.06"/>
                    <measurement group_id="O4" value="-0.24" spread="0.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving DLQI Response ≥5 During the 12-Week Double-Blind Treatment</title>
        <description>The DLQI is a general dermatology questionnaire that consists of 10 items that assess health related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI questions are rated by the participant as 0 (not at all/not relevant) to 3 (very much) with a total score range of 0 (best) to 30 (worst); higher scores indicate poor quality of life.</description>
        <time_frame>Weeks 4 and 12</time_frame>
        <population>FAS; OC</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg Twice Daily (BID)+Placebo Twice Weekly (BIW)</title>
            <description>Participants received CP-690,550 5 mg tablets, orally, BID, at approximately 12-hour intervals and placebo subcutaneous (SC) injections BIW at approximately 3- to 4-day intervals for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg BID + Placebo BIW</title>
            <description>Participants received CP-690,550 10 mg tablets, orally, BID, at approximately 12-hour intervals and placebo SC injections BIW at approximately 3- to 4-day intervals for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo BID + Etanercept 50 mg BIW</title>
            <description>Participants received matching placebo tablets, orally, BID, at approximately 12-hour intervals and etanercept 50 mg SC injections BIW at approximately 3- to 4-day intervals for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Placebo BID + Placebo BIW</title>
            <description>Participants received matching placebo tablets, orally, BID, at approximately 12-hour intervals and placebo SC injections BIW at approximately 3- to 4-day intervals for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving DLQI Response ≥5 During the 12-Week Double-Blind Treatment</title>
          <description>The DLQI is a general dermatology questionnaire that consists of 10 items that assess health related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI questions are rated by the participant as 0 (not at all/not relevant) to 3 (very much) with a total score range of 0 (best) to 30 (worst); higher scores indicate poor quality of life.</description>
          <population>FAS; OC</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="279"/>
                <count group_id="O2" value="283"/>
                <count group_id="O3" value="282"/>
                <count group_id="O4" value="82"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.93"/>
                    <measurement group_id="O2" value="71.38"/>
                    <measurement group_id="O3" value="61.35"/>
                    <measurement group_id="O4" value="36.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.54"/>
                    <measurement group_id="O2" value="85.28"/>
                    <measurement group_id="O3" value="81.34"/>
                    <measurement group_id="O4" value="35.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving DLQI Response ≤1 During the 12-Week Double-Blind Treatment</title>
        <description>The DLQI is a general dermatology questionnaire that consists of 10 items that assess health related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI questions are rated by the participant as 0 (not at all/not relevant) to 3 (very much) with a total score range of 0 (best) to 30 (worst); higher scores indicate poor quality of life.</description>
        <time_frame>Weeks 4 and 12</time_frame>
        <population>FAS; OC</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg Twice Daily (BID)+Placebo Twice Weekly (BIW)</title>
            <description>Participants received CP-690,550 5 mg tablets, orally, BID, at approximately 12-hour intervals and placebo subcutaneous (SC) injections BIW at approximately 3- to 4-day intervals for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg BID + Placebo BIW</title>
            <description>Participants received CP-690,550 10 mg tablets, orally, BID, at approximately 12-hour intervals and placebo SC injections BIW at approximately 3- to 4-day intervals for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo BID + Etanercept 50 mg BIW</title>
            <description>Participants received matching placebo tablets, orally, BID, at approximately 12-hour intervals and etanercept 50 mg SC injections BIW at approximately 3- to 4-day intervals for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Placebo BID + Placebo BIW</title>
            <description>Participants received matching placebo tablets, orally, BID, at approximately 12-hour intervals and placebo SC injections BIW at approximately 3- to 4-day intervals for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving DLQI Response ≤1 During the 12-Week Double-Blind Treatment</title>
          <description>The DLQI is a general dermatology questionnaire that consists of 10 items that assess health related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI questions are rated by the participant as 0 (not at all/not relevant) to 3 (very much) with a total score range of 0 (best) to 30 (worst); higher scores indicate poor quality of life.</description>
          <population>FAS; OC</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="306"/>
                <count group_id="O2" value="312"/>
                <count group_id="O3" value="316"/>
                <count group_id="O4" value="95"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.07"/>
                    <measurement group_id="O2" value="21.79"/>
                    <measurement group_id="O3" value="15.51"/>
                    <measurement group_id="O4" value="7.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.22"/>
                    <measurement group_id="O2" value="51.36"/>
                    <measurement group_id="O3" value="47.18"/>
                    <measurement group_id="O4" value="8.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Time to DLQI Response</title>
        <description>The DLQI is a general dermatology questionnaire that consists of 10 items that assess health related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI questions are rated by the participant as 0 (not at all/not relevant) to 3 (very much) with a total score range of 0 (best) to 30 (worst); higher scores indicate poor quality of life. DLQI Response was defined as a 5-point reduction in the total DLQI score.</description>
        <time_frame>Weeks 4 and 12</time_frame>
        <population>Data were not analyzed as the endpoint of proportion of participants achieving a 5-point reduction from baseline in DLQI provided similar information.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg Twice Daily (BID)+Placebo Twice Weekly (BIW)</title>
            <description>Participants received CP-690,550 5 mg tablets, orally, BID, at approximately 12-hour intervals and placebo subcutaneous (SC) injections BIW at approximately 3- to 4-day intervals for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg BID + Placebo BIW</title>
            <description>Participants received CP-690,550 10 mg tablets, orally, BID, at approximately 12-hour intervals and placebo SC injections BIW at approximately 3- to 4-day intervals for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo BID + Etanercept 50 mg BIW</title>
            <description>Participants received matching placebo tablets, orally, BID, at approximately 12-hour intervals and etanercept 50 mg SC injections BIW at approximately 3- to 4-day intervals for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Placebo BID + Placebo BIW</title>
            <description>Participants received matching placebo tablets, orally, BID, at approximately 12-hour intervals and placebo SC injections BIW at approximately 3- to 4-day intervals for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Median Time to DLQI Response</title>
          <description>The DLQI is a general dermatology questionnaire that consists of 10 items that assess health related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI questions are rated by the participant as 0 (not at all/not relevant) to 3 (very much) with a total score range of 0 (best) to 30 (worst); higher scores indicate poor quality of life. DLQI Response was defined as a 5-point reduction in the total DLQI score.</description>
          <population>Data were not analyzed as the endpoint of proportion of participants achieving a 5-point reduction from baseline in DLQI provided similar information.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Short Form 36 (SF-36) Mental Component Summary (MCS) and Physical Component Summary (PCS) Scores at Baseline and Week 12</title>
        <description>The SF-36 is a general health status questionnaire that assesses 8 domains of functional health and well being: Physical Functioning, Role Limitations due to Physical Health Problems, Bodily Pain, Social Functioning, Mental Health, Role Limitations due to Emotional Problems, Vitality, and General Health Perceptions. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning). A PCS score and MCS score are based on a normalized sum of the 8 scale scores; PCS/MCS summary concept score = (raw score*10) plus 50. Higher scores indicate a better health related quality of life.</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>FAS; OC</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg Twice Daily (BID)+Placebo Twice Weekly (BIW)</title>
            <description>Participants received CP-690,550 5 mg tablets, orally, BID, at approximately 12-hour intervals and placebo subcutaneous (SC) injections BIW at approximately 3- to 4-day intervals for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg BID + Placebo BIW</title>
            <description>Participants received CP-690,550 10 mg tablets, orally, BID, at approximately 12-hour intervals and placebo SC injections BIW at approximately 3- to 4-day intervals for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo BID + Etanercept 50 mg BIW</title>
            <description>Participants received matching placebo tablets, orally, BID, at approximately 12-hour intervals and etanercept 50 mg SC injections BIW at approximately 3- to 4-day intervals for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Placebo BID + Placebo BIW</title>
            <description>Participants received matching placebo tablets, orally, BID, at approximately 12-hour intervals and placebo SC injections BIW at approximately 3- to 4-day intervals for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Short Form 36 (SF-36) Mental Component Summary (MCS) and Physical Component Summary (PCS) Scores at Baseline and Week 12</title>
          <description>The SF-36 is a general health status questionnaire that assesses 8 domains of functional health and well being: Physical Functioning, Role Limitations due to Physical Health Problems, Bodily Pain, Social Functioning, Mental Health, Role Limitations due to Emotional Problems, Vitality, and General Health Perceptions. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning). A PCS score and MCS score are based on a normalized sum of the 8 scale scores; PCS/MCS summary concept score = (raw score*10) plus 50. Higher scores indicate a better health related quality of life.</description>
          <population>FAS; OC</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="327"/>
                <count group_id="O2" value="327"/>
                <count group_id="O3" value="327"/>
                <count group_id="O4" value="105"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline Physical Health Score (n=327,327,327,105)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.4" spread="0.5"/>
                    <measurement group_id="O2" value="48.3" spread="0.5"/>
                    <measurement group_id="O3" value="47.5" spread="0.5"/>
                    <measurement group_id="O4" value="46.8" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 Physical Health Score (n=303,304,307,95)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.7" spread="0.5"/>
                    <measurement group_id="O2" value="53.6" spread="0.4"/>
                    <measurement group_id="O3" value="52.5" spread="0.5"/>
                    <measurement group_id="O4" value="47.8" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline Mental Health Score (n=327,327,327,105)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.0" spread="0.6"/>
                    <measurement group_id="O2" value="41.2" spread="0.6"/>
                    <measurement group_id="O3" value="42.0" spread="0.7"/>
                    <measurement group_id="O4" value="39.8" spread="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 Mental Health Score (n=303,304,307,95)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.0" spread="0.6"/>
                    <measurement group_id="O2" value="49.3" spread="0.5"/>
                    <measurement group_id="O3" value="47.8" spread="0.6"/>
                    <measurement group_id="O4" value="41.7" spread="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean SF-36 Domain Scores at Baseline and Week 12</title>
        <description>The SF-36 is a general health status questionnaire that assesses 8 domains of functional health and well being: Physical Functioning, Role Limitations due to Physical Health Problems, Bodily Pain, Social Functioning, Mental Health, Role Limitations due to Emotional Problems, Vitality, and General Health Perceptions. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning). Higher scores indicate a better health related quality of life.</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>FAS; OC</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg Twice Daily (BID)+Placebo Twice Weekly (BIW)</title>
            <description>Participants received CP-690,550 5 mg tablets, orally, BID, at approximately 12-hour intervals and placebo subcutaneous (SC) injections BIW at approximately 3- to 4-day intervals for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg BID + Placebo BIW</title>
            <description>Participants received CP-690,550 10 mg tablets, orally, BID, at approximately 12-hour intervals and placebo SC injections BIW at approximately 3- to 4-day intervals for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo BID + Etanercept 50 mg BIW</title>
            <description>Participants received matching placebo tablets, orally, BID, at approximately 12-hour intervals and etanercept 50 mg SC injections BIW at approximately 3- to 4-day intervals for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Placebo BID + Placebo BIW</title>
            <description>Participants received matching placebo tablets, orally, BID, at approximately 12-hour intervals and placebo SC injections BIW at approximately 3- to 4-day intervals for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean SF-36 Domain Scores at Baseline and Week 12</title>
          <description>The SF-36 is a general health status questionnaire that assesses 8 domains of functional health and well being: Physical Functioning, Role Limitations due to Physical Health Problems, Bodily Pain, Social Functioning, Mental Health, Role Limitations due to Emotional Problems, Vitality, and General Health Perceptions. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning). Higher scores indicate a better health related quality of life.</description>
          <population>FAS; OC</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="328"/>
                <count group_id="O2" value="328"/>
                <count group_id="O3" value="330"/>
                <count group_id="O4" value="106"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline Physical Functioning (n=328,328,330,106)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.3" spread="0.5"/>
                    <measurement group_id="O2" value="49.0" spread="0.5"/>
                    <measurement group_id="O3" value="48.6" spread="0.5"/>
                    <measurement group_id="O4" value="46.7" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 Physical Functioning (n=306,305,308,95)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.9" spread="0.5"/>
                    <measurement group_id="O2" value="53.1" spread="0.4"/>
                    <measurement group_id="O3" value="52.2" spread="0.4"/>
                    <measurement group_id="O4" value="48.1" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline Role Physical (n=328,328,330,106)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.4" spread="0.6"/>
                    <measurement group_id="O2" value="45.9" spread="0.6"/>
                    <measurement group_id="O3" value="45.5" spread="0.6"/>
                    <measurement group_id="O4" value="44.4" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 Role Physical (n=307,305,308,95)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.5" spread="0.5"/>
                    <measurement group_id="O2" value="52.5" spread="0.4"/>
                    <measurement group_id="O3" value="51.2" spread="0.5"/>
                    <measurement group_id="O4" value="46.1" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline Bodily Pain (n=328,329,331,107)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.5" spread="0.7"/>
                    <measurement group_id="O2" value="45.6" spread="0.7"/>
                    <measurement group_id="O3" value="44.0" spread="0.7"/>
                    <measurement group_id="O4" value="43.6" spread="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 Bodily Pain (n=306,305,307,95)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.7" spread="0.6"/>
                    <measurement group_id="O2" value="54.6" spread="0.5"/>
                    <measurement group_id="O3" value="52.4" spread="0.6"/>
                    <measurement group_id="O4" value="45.7" spread="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline General Health (n=328,328,330,106)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.4" spread="0.5"/>
                    <measurement group_id="O2" value="42.8" spread="0.5"/>
                    <measurement group_id="O3" value="43.5" spread="0.6"/>
                    <measurement group_id="O4" value="42.4" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 General Health (n=305,304,308,95)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.2" spread="0.5"/>
                    <measurement group_id="O2" value="48.5" spread="0.5"/>
                    <measurement group_id="O3" value="47.9" spread="0.5"/>
                    <measurement group_id="O4" value="42.6" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline Vitality (n=328,329,331,107)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.9" spread="0.5"/>
                    <measurement group_id="O2" value="48.5" spread="0.6"/>
                    <measurement group_id="O3" value="48.3" spread="0.5"/>
                    <measurement group_id="O4" value="46.5" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 Vitality (n=306,305,307,95)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.4" spread="0.5"/>
                    <measurement group_id="O2" value="54.4" spread="0.5"/>
                    <measurement group_id="O3" value="52.9" spread="0.5"/>
                    <measurement group_id="O4" value="47.9" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline Social Functioning (n=328,329,331,107)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.6" spread="0.6"/>
                    <measurement group_id="O2" value="41.1" spread="0.6"/>
                    <measurement group_id="O3" value="42.3" spread="0.7"/>
                    <measurement group_id="O4" value="40.7" spread="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 Social Functioning (n=306,305,307,95)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.8" spread="0.6"/>
                    <measurement group_id="O2" value="50.6" spread="0.5"/>
                    <measurement group_id="O3" value="49.3" spread="0.5"/>
                    <measurement group_id="O4" value="42.0" spread="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline Role-Emotional (n=328,329,331,107)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.2" spread="0.7"/>
                    <measurement group_id="O2" value="42.4" spread="0.7"/>
                    <measurement group_id="O3" value="43.1" spread="0.7"/>
                    <measurement group_id="O4" value="40.4" spread="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 Role-Emotional (n=306,305,307,95)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.6" spread="0.5"/>
                    <measurement group_id="O2" value="50.2" spread="0.5"/>
                    <measurement group_id="O3" value="48.6" spread="0.6"/>
                    <measurement group_id="O4" value="43.3" spread="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline Mental Health (n=328,329,331,107)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.0" spread="0.6"/>
                    <measurement group_id="O2" value="41.5" spread="0.6"/>
                    <measurement group_id="O3" value="41.7" spread="0.7"/>
                    <measurement group_id="O4" value="39.5" spread="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 Mental Health (n=306,305,307,95)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.6" spread="0.6"/>
                    <measurement group_id="O2" value="48.9" spread="0.5"/>
                    <measurement group_id="O3" value="47.5" spread="0.6"/>
                    <measurement group_id="O4" value="41.4" spread="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline Health Transition (n=328,329,331,107)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.2" spread="0.0"/>
                    <measurement group_id="O2" value="3.2" spread="0.0"/>
                    <measurement group_id="O3" value="3.1" spread="0.0"/>
                    <measurement group_id="O4" value="3.2" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 Health Transition (n=306,305,307,95)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6" spread="0.0"/>
                    <measurement group_id="O2" value="2.6" spread="0.0"/>
                    <measurement group_id="O3" value="2.5" spread="0.0"/>
                    <measurement group_id="O4" value="3.0" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in SF-36 MCS and PCS Scores</title>
        <description>The SF-36 is a general health status questionnaire that assesses 8 domains of functional health and well being: Physical Functioning, Role Limitations due to Physical Health Problems, Bodily Pain, Social Functioning, Mental Health, Role Limitations due to Emotional Problems, Vitality, and General Health Perceptions. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning). A PCS score and MCS score are based on a normalized sum of the 8 scale scores; PCS/MCS summary concept score = (raw score*10) plus 50. Higher scores indicate a better health related quality of life.</description>
        <time_frame>Week 12</time_frame>
        <population>FAS; OC</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg Twice Daily (BID)+Placebo Twice Weekly (BIW)</title>
            <description>Participants received CP-690,550 5 mg tablets, orally, BID, at approximately 12-hour intervals and placebo subcutaneous (SC) injections BIW at approximately 3- to 4-day intervals for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg BID + Placebo BIW</title>
            <description>Participants received CP-690,550 10 mg tablets, orally, BID, at approximately 12-hour intervals and placebo SC injections BIW at approximately 3- to 4-day intervals for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo BID + Etanercept 50 mg BIW</title>
            <description>Participants received matching placebo tablets, orally, BID, at approximately 12-hour intervals and etanercept 50 mg SC injections BIW at approximately 3- to 4-day intervals for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Placebo BID + Placebo BIW</title>
            <description>Participants received matching placebo tablets, orally, BID, at approximately 12-hour intervals and placebo SC injections BIW at approximately 3- to 4-day intervals for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in SF-36 MCS and PCS Scores</title>
          <description>The SF-36 is a general health status questionnaire that assesses 8 domains of functional health and well being: Physical Functioning, Role Limitations due to Physical Health Problems, Bodily Pain, Social Functioning, Mental Health, Role Limitations due to Emotional Problems, Vitality, and General Health Perceptions. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning). A PCS score and MCS score are based on a normalized sum of the 8 scale scores; PCS/MCS summary concept score = (raw score*10) plus 50. Higher scores indicate a better health related quality of life.</description>
          <population>FAS; OC</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="301"/>
                <count group_id="O2" value="302"/>
                <count group_id="O3" value="301"/>
                <count group_id="O4" value="93"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Physical Health Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.1" spread="0.4"/>
                    <measurement group_id="O2" value="5.0" spread="0.5"/>
                    <measurement group_id="O3" value="5.2" spread="0.5"/>
                    <measurement group_id="O4" value="0.8" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mental Health Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.0" spread="0.6"/>
                    <measurement group_id="O2" value="7.6" spread="0.6"/>
                    <measurement group_id="O3" value="5.8" spread="0.6"/>
                    <measurement group_id="O4" value="1.5" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in SF-36 Domain Scores</title>
        <description>The SF-36 is a general health status questionnaire that assesses 8 domains of functional health and well being: Physical Functioning, Role Limitations due to Physical Health Problems, Bodily Pain, Social Functioning, Mental Health, Role Limitations due to Emotional Problems, Vitality, and General Health Perceptions. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning). Higher scores indicate a better health related quality of life.</description>
        <time_frame>Week 12</time_frame>
        <population>FAS; OC</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg Twice Daily (BID)+Placebo Twice Weekly (BIW)</title>
            <description>Participants received CP-690,550 5 mg tablets, orally, BID, at approximately 12-hour intervals and placebo subcutaneous (SC) injections BIW at approximately 3- to 4-day intervals for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg BID + Placebo BIW</title>
            <description>Participants received CP-690,550 10 mg tablets, orally, BID, at approximately 12-hour intervals and placebo SC injections BIW at approximately 3- to 4-day intervals for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo BID + Etanercept 50 mg BIW</title>
            <description>Participants received matching placebo tablets, orally, BID, at approximately 12-hour intervals and etanercept 50 mg SC injections BIW at approximately 3- to 4-day intervals for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Placebo BID + Placebo BIW</title>
            <description>Participants received matching placebo tablets, orally, BID, at approximately 12-hour intervals and placebo SC injections BIW at approximately 3- to 4-day intervals for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in SF-36 Domain Scores</title>
          <description>The SF-36 is a general health status questionnaire that assesses 8 domains of functional health and well being: Physical Functioning, Role Limitations due to Physical Health Problems, Bodily Pain, Social Functioning, Mental Health, Role Limitations due to Emotional Problems, Vitality, and General Health Perceptions. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning). Higher scores indicate a better health related quality of life.</description>
          <population>FAS; OC</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="305"/>
                <count group_id="O2" value="304"/>
                <count group_id="O3" value="304"/>
                <count group_id="O4" value="94"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Physical Functioning</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.5" spread="0.4"/>
                    <measurement group_id="O2" value="3.7" spread="0.4"/>
                    <measurement group_id="O3" value="3.7" spread="0.5"/>
                    <measurement group_id="O4" value="1.1" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Role Physical</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.1" spread="0.5"/>
                    <measurement group_id="O2" value="6.3" spread="0.6"/>
                    <measurement group_id="O3" value="6.1" spread="0.5"/>
                    <measurement group_id="O4" value="1.3" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bodily Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.0" spread="0.7"/>
                    <measurement group_id="O2" value="8.5" spread="0.6"/>
                    <measurement group_id="O3" value="8.6" spread="0.7"/>
                    <measurement group_id="O4" value="1.6" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>General Health</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5" spread="0.5"/>
                    <measurement group_id="O2" value="5.5" spread="0.5"/>
                    <measurement group_id="O3" value="4.4" spread="0.5"/>
                    <measurement group_id="O4" value="0.2" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vitality</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.2" spread="0.5"/>
                    <measurement group_id="O2" value="5.4" spread="0.5"/>
                    <measurement group_id="O3" value="4.6" spread="0.5"/>
                    <measurement group_id="O4" value="1.3" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Social Functioning</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.0" spread="0.7"/>
                    <measurement group_id="O2" value="9.2" spread="0.6"/>
                    <measurement group_id="O3" value="7.3" spread="0.6"/>
                    <measurement group_id="O4" value="0.7" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Role - Emotional</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.4" spread="0.6"/>
                    <measurement group_id="O2" value="7.2" spread="0.6"/>
                    <measurement group_id="O3" value="5.8" spread="0.7"/>
                    <measurement group_id="O4" value="2.3" spread="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mental Health</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.5" spread="0.6"/>
                    <measurement group_id="O2" value="7.0" spread="0.6"/>
                    <measurement group_id="O3" value="5.9" spread="0.6"/>
                    <measurement group_id="O4" value="1.4" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Health Transition</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.5" spread="0.1"/>
                    <measurement group_id="O2" value="-0.6" spread="0.1"/>
                    <measurement group_id="O3" value="-0.6" spread="0.1"/>
                    <measurement group_id="O4" value="-0.2" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants in Each Patient Global Assessment of Psoriasis (PtGA) Category During the 12-Week Double-Blind Treatment</title>
        <description>The PtGA asks the participant to evaluate the overall cutaneous disease at that point in time on a single item, 5-point scale (0=clear; 1=almost clear; 2=mild; 3=moderate; 4=severe).</description>
        <time_frame>Baseline and Weeks 2, 4, and 8</time_frame>
        <population>FAS; OC</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg Twice Daily (BID)+Placebo Twice Weekly (BIW)</title>
            <description>Participants received CP-690,550 5 mg tablets, orally, BID, at approximately 12-hour intervals and placebo subcutaneous (SC) injections BIW at approximately 3- to 4-day intervals for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg BID + Placebo BIW</title>
            <description>Participants received CP-690,550 10 mg tablets, orally, BID, at approximately 12-hour intervals and placebo SC injections BIW at approximately 3- to 4-day intervals for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo BID + Etanercept 50 mg BIW</title>
            <description>Participants received matching placebo tablets, orally, BID, at approximately 12-hour intervals and etanercept 50 mg SC injections BIW at approximately 3- to 4-day intervals for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Placebo BID + Placebo BIW</title>
            <description>Participants received matching placebo tablets, orally, BID, at approximately 12-hour intervals and placebo SC injections BIW at approximately 3- to 4-day intervals for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants in Each Patient Global Assessment of Psoriasis (PtGA) Category During the 12-Week Double-Blind Treatment</title>
          <description>The PtGA asks the participant to evaluate the overall cutaneous disease at that point in time on a single item, 5-point scale (0=clear; 1=almost clear; 2=mild; 3=moderate; 4=severe).</description>
          <population>FAS; OC</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="328"/>
                <count group_id="O2" value="328"/>
                <count group_id="O3" value="330"/>
                <count group_id="O4" value="107"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Clear, Baseline (n=328,328,330,107)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Almost Clear, Baseline (n=328,328,330,107)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.3"/>
                    <measurement group_id="O3" value="0.3"/>
                    <measurement group_id="O4" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mild, Baseline (n=328,328,330,107)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.4"/>
                    <measurement group_id="O2" value="1.5"/>
                    <measurement group_id="O3" value="4.2"/>
                    <measurement group_id="O4" value="3.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate, Baseline (n=328,328,330,107)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.3"/>
                    <measurement group_id="O2" value="30.2"/>
                    <measurement group_id="O3" value="28.5"/>
                    <measurement group_id="O4" value="23.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe, Baseline (n=328,328,330,107)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.3"/>
                    <measurement group_id="O2" value="68.0"/>
                    <measurement group_id="O3" value="67.0"/>
                    <measurement group_id="O4" value="72.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Clear, Week 2 (n=324,322,331,106)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.3"/>
                    <measurement group_id="O4" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Almost Clear, Week 2 (n=324,322,331,106)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2"/>
                    <measurement group_id="O2" value="4.3"/>
                    <measurement group_id="O3" value="1.2"/>
                    <measurement group_id="O4" value="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mild, Week 2 (n=324,322,331,106)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.3"/>
                    <measurement group_id="O2" value="14.9"/>
                    <measurement group_id="O3" value="11.8"/>
                    <measurement group_id="O4" value="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate, Week 2 (n=324,322,331,106)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.4"/>
                    <measurement group_id="O2" value="54.3"/>
                    <measurement group_id="O3" value="52.0"/>
                    <measurement group_id="O4" value="38.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe, Week 2 (n=324,322,331,106)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.8"/>
                    <measurement group_id="O2" value="26.4"/>
                    <measurement group_id="O3" value="34.7"/>
                    <measurement group_id="O4" value="57.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Clear, Week 4 (n=319,323,324,100)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3"/>
                    <measurement group_id="O2" value="0.6"/>
                    <measurement group_id="O3" value="0.3"/>
                    <measurement group_id="O4" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Almost Clear, Week 4 (n=319,323,324,100)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.9"/>
                    <measurement group_id="O2" value="17.0"/>
                    <measurement group_id="O3" value="9.3"/>
                    <measurement group_id="O4" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mild, Week 4 (n=319,323,324,100)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.6"/>
                    <measurement group_id="O2" value="30.7"/>
                    <measurement group_id="O3" value="26.5"/>
                    <measurement group_id="O4" value="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate, Week 4 (n=319,323,324,100)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.7"/>
                    <measurement group_id="O2" value="36.8"/>
                    <measurement group_id="O3" value="43.5"/>
                    <measurement group_id="O4" value="35.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe, Week 4 (n=319,323,324,100)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.5"/>
                    <measurement group_id="O2" value="14.9"/>
                    <measurement group_id="O3" value="20.4"/>
                    <measurement group_id="O4" value="60.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Clear, Week 8 (n=313,317,315,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.9"/>
                    <measurement group_id="O2" value="4.7"/>
                    <measurement group_id="O3" value="3.5"/>
                    <measurement group_id="O4" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Almost Clear, Week 8 (n=313,317,315,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.9"/>
                    <measurement group_id="O2" value="38.2"/>
                    <measurement group_id="O3" value="29.8"/>
                    <measurement group_id="O4" value="4.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mild, Week 8 (n=313,317,315,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.5"/>
                    <measurement group_id="O2" value="27.1"/>
                    <measurement group_id="O3" value="33.0"/>
                    <measurement group_id="O4" value="7.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate, Week 8 (n=313,317,315,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.3"/>
                    <measurement group_id="O2" value="22.1"/>
                    <measurement group_id="O3" value="24.8"/>
                    <measurement group_id="O4" value="38.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe, Week 8 (n=313,317,315,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.3"/>
                    <measurement group_id="O2" value="7.9"/>
                    <measurement group_id="O3" value="8.9"/>
                    <measurement group_id="O4" value="50.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With a PtGA Response During the 12-Week Double-Blind Treatment</title>
        <description>The PtGA asks the participant to evaluate the overall cutaneous disease at that point in time on a single item, 5-point scale (0=clear; 1=almost clear; 2=mild; 3=moderate; 4=severe). Response defined as score of 0 or 1.</description>
        <time_frame>Weeks 2, 4, 8, and 12</time_frame>
        <population>FAS; OC</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg Twice Daily (BID)+Placebo Twice Weekly (BIW)</title>
            <description>Participants received CP-690,550 5 mg tablets, orally, BID, at approximately 12-hour intervals and placebo subcutaneous (SC) injections BIW at approximately 3- to 4-day intervals for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg BID + Placebo BIW</title>
            <description>Participants received CP-690,550 10 mg tablets, orally, BID, at approximately 12-hour intervals and placebo SC injections BIW at approximately 3- to 4-day intervals for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo BID + Etanercept 50 mg BIW</title>
            <description>Participants received matching placebo tablets, orally, BID, at approximately 12-hour intervals and etanercept 50 mg SC injections BIW at approximately 3- to 4-day intervals for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Placebo BID + Placebo BIW</title>
            <description>Participants received matching placebo tablets, orally, BID, at approximately 12-hour intervals and placebo SC injections BIW at approximately 3- to 4-day intervals for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a PtGA Response During the 12-Week Double-Blind Treatment</title>
          <description>The PtGA asks the participant to evaluate the overall cutaneous disease at that point in time on a single item, 5-point scale (0=clear; 1=almost clear; 2=mild; 3=moderate; 4=severe). Response defined as score of 0 or 1.</description>
          <population>FAS; OC</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="324"/>
                <count group_id="O2" value="322"/>
                <count group_id="O3" value="331"/>
                <count group_id="O4" value="106"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2 (n=324,322,331,106)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.54"/>
                    <measurement group_id="O2" value="4.35"/>
                    <measurement group_id="O3" value="1.51"/>
                    <measurement group_id="O4" value="0.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (n=319,323,324,100)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.21"/>
                    <measurement group_id="O2" value="17.65"/>
                    <measurement group_id="O3" value="9.57"/>
                    <measurement group_id="O4" value="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (n=313,317,315,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.81"/>
                    <measurement group_id="O2" value="42.90"/>
                    <measurement group_id="O3" value="33.33"/>
                    <measurement group_id="O4" value="4.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (n=306,304,309,95)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.68"/>
                    <measurement group_id="O2" value="56.25"/>
                    <measurement group_id="O3" value="53.07"/>
                    <measurement group_id="O4" value="1.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants in Each Patient Satisfaction With Study Medication (PSSM) Category During the 12-Week Double-Blind Treatment</title>
        <description>The PSSM is a single, 7 point item that evaluates overall participant satisfaction with the study treatment. Response options range from “very dissatisfied” to “very satisfied” with the study medication.</description>
        <time_frame>Week 12</time_frame>
        <population>FAS; OC</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg Twice Daily (BID)+Placebo Twice Weekly (BIW)</title>
            <description>Participants received CP-690,550 5 mg tablets, orally, BID, at approximately 12-hour intervals and placebo subcutaneous (SC) injections BIW at approximately 3- to 4-day intervals for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg BID + Placebo BIW</title>
            <description>Participants received CP-690,550 10 mg tablets, orally, BID, at approximately 12-hour intervals and placebo SC injections BIW at approximately 3- to 4-day intervals for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo BID + Etanercept 50 mg BIW</title>
            <description>Participants received matching placebo tablets, orally, BID, at approximately 12-hour intervals and etanercept 50 mg SC injections BIW at approximately 3- to 4-day intervals for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Placebo BID + Placebo BIW</title>
            <description>Participants received matching placebo tablets, orally, BID, at approximately 12-hour intervals and placebo SC injections BIW at approximately 3- to 4-day intervals for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants in Each Patient Satisfaction With Study Medication (PSSM) Category During the 12-Week Double-Blind Treatment</title>
          <description>The PSSM is a single, 7 point item that evaluates overall participant satisfaction with the study treatment. Response options range from “very dissatisfied” to “very satisfied” with the study medication.</description>
          <population>FAS; OC</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="307"/>
                <count group_id="O2" value="305"/>
                <count group_id="O3" value="306"/>
                <count group_id="O4" value="95"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Very satisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.0"/>
                    <measurement group_id="O2" value="68.5"/>
                    <measurement group_id="O3" value="62.4"/>
                    <measurement group_id="O4" value="15.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Somewhat satisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.0"/>
                    <measurement group_id="O2" value="17.4"/>
                    <measurement group_id="O3" value="23.5"/>
                    <measurement group_id="O4" value="15.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Slightly satisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.7"/>
                    <measurement group_id="O2" value="5.2"/>
                    <measurement group_id="O3" value="7.2"/>
                    <measurement group_id="O4" value="11.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neither satisfied nor dissatisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.6"/>
                    <measurement group_id="O2" value="2.3"/>
                    <measurement group_id="O3" value="2.0"/>
                    <measurement group_id="O4" value="11.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Slightly dissatisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6"/>
                    <measurement group_id="O2" value="1.6"/>
                    <measurement group_id="O3" value="2.0"/>
                    <measurement group_id="O4" value="4.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Somewhat dissatisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.6"/>
                    <measurement group_id="O2" value="3.0"/>
                    <measurement group_id="O3" value="2.0"/>
                    <measurement group_id="O4" value="12.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Very dissatisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.5"/>
                    <measurement group_id="O2" value="2.0"/>
                    <measurement group_id="O3" value="1.0"/>
                    <measurement group_id="O4" value="28.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving PSSM Response of 'Very Satisfied' or 'Somewhat Satisfied' at Week 12</title>
        <description>The PSSM is a single, 7 point item that evaluates overall participant satisfaction with the study treatment. Response options range from “very dissatisfied” to “very satisfied” with the study medication.</description>
        <time_frame>Week 12</time_frame>
        <population>FAS; OC</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg Twice Daily (BID)+Placebo Twice Weekly (BIW)</title>
            <description>Participants received CP-690,550 5 mg tablets, orally, BID, at approximately 12-hour intervals and placebo subcutaneous (SC) injections BIW at approximately 3- to 4-day intervals for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg BID + Placebo BIW</title>
            <description>Participants received CP-690,550 10 mg tablets, orally, BID, at approximately 12-hour intervals and placebo SC injections BIW at approximately 3- to 4-day intervals for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo BID + Etanercept 50 mg BIW</title>
            <description>Participants received matching placebo tablets, orally, BID, at approximately 12-hour intervals and etanercept 50 mg SC injections BIW at approximately 3- to 4-day intervals for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Placebo BID + Placebo BIW</title>
            <description>Participants received matching placebo tablets, orally, BID, at approximately 12-hour intervals and placebo SC injections BIW at approximately 3- to 4-day intervals for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving PSSM Response of 'Very Satisfied' or 'Somewhat Satisfied' at Week 12</title>
          <description>The PSSM is a single, 7 point item that evaluates overall participant satisfaction with the study treatment. Response options range from “very dissatisfied” to “very satisfied” with the study medication.</description>
          <population>FAS; OC</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="307"/>
                <count group_id="O2" value="305"/>
                <count group_id="O3" value="306"/>
                <count group_id="O4" value="95"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.01"/>
                    <measurement group_id="O2" value="85.90"/>
                    <measurement group_id="O3" value="85.95"/>
                    <measurement group_id="O4" value="31.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean European Quality of Life 5 Dimension (EQ-5D) Health State Utility Score During the 12-Week Double-Blind Treatment</title>
        <description>EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problems); 3 indicates worst health state (&quot;confined to bed&quot;). Scoring formula developed by EuroQol Group assigns a utility value for each domain in the profile. Score is transformed and results in a total score range -0.594 to 1.000; higher score indicates a better health state.</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>FAS; OC</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg Twice Daily (BID)+Placebo Twice Weekly (BIW)</title>
            <description>Participants received CP-690,550 5 mg tablets, orally, BID, at approximately 12-hour intervals and placebo subcutaneous (SC) injections BIW at approximately 3- to 4-day intervals for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg BID + Placebo BIW</title>
            <description>Participants received CP-690,550 10 mg tablets, orally, BID, at approximately 12-hour intervals and placebo SC injections BIW at approximately 3- to 4-day intervals for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo BID + Etanercept 50 mg BIW</title>
            <description>Participants received matching placebo tablets, orally, BID, at approximately 12-hour intervals and etanercept 50 mg SC injections BIW at approximately 3- to 4-day intervals for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Placebo BID + Placebo BIW</title>
            <description>Participants received matching placebo tablets, orally, BID, at approximately 12-hour intervals and placebo SC injections BIW at approximately 3- to 4-day intervals for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean European Quality of Life 5 Dimension (EQ-5D) Health State Utility Score During the 12-Week Double-Blind Treatment</title>
          <description>EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problems); 3 indicates worst health state (&quot;confined to bed&quot;). Scoring formula developed by EuroQol Group assigns a utility value for each domain in the profile. Score is transformed and results in a total score range -0.594 to 1.000; higher score indicates a better health state.</description>
          <population>FAS; OC</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="325"/>
                <count group_id="O2" value="326"/>
                <count group_id="O3" value="330"/>
                <count group_id="O4" value="104"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" spread="0.0"/>
                    <measurement group_id="O2" value="0.7" spread="0.0"/>
                    <measurement group_id="O3" value="0.7" spread="0.0"/>
                    <measurement group_id="O4" value="0.6" spread="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" spread="0.0"/>
                    <measurement group_id="O2" value="0.9" spread="0.0"/>
                    <measurement group_id="O3" value="0.9" spread="0.0"/>
                    <measurement group_id="O4" value="0.7" spread="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Least Squares (LS) Mean Change From Baseline in EQ-5D Health State Utility Score During the 12-Week Double-Blind Treatment</title>
        <description>EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problems); 3 indicates worst health state (&quot;confined to bed&quot;). Scoring formula developed by EuroQol Group assigns a utility value for each domain in the profile. Score is transformed and results in a total score range -0.594 to 1.000; higher score indicates a better health state.</description>
        <time_frame>Week 12</time_frame>
        <population>FAS; OC</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg Twice Daily (BID)+Placebo Twice Weekly (BIW)</title>
            <description>Participants received CP-690,550 5 mg tablets, orally, BID, at approximately 12-hour intervals and placebo subcutaneous (SC) injections BIW at approximately 3- to 4-day intervals for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg BID + Placebo BIW</title>
            <description>Participants received CP-690,550 10 mg tablets, orally, BID, at approximately 12-hour intervals and placebo SC injections BIW at approximately 3- to 4-day intervals for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo BID + Etanercept 50 mg BIW</title>
            <description>Participants received matching placebo tablets, orally, BID, at approximately 12-hour intervals and etanercept 50 mg SC injections BIW at approximately 3- to 4-day intervals for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Placebo BID + Placebo BIW</title>
            <description>Participants received matching placebo tablets, orally, BID, at approximately 12-hour intervals and placebo SC injections BIW at approximately 3- to 4-day intervals for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Least Squares (LS) Mean Change From Baseline in EQ-5D Health State Utility Score During the 12-Week Double-Blind Treatment</title>
          <description>EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problems); 3 indicates worst health state (&quot;confined to bed&quot;). Scoring formula developed by EuroQol Group assigns a utility value for each domain in the profile. Score is transformed and results in a total score range -0.594 to 1.000; higher score indicates a better health state.</description>
          <population>FAS; OC</population>
          <units>scores on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="301"/>
                <count group_id="O2" value="300"/>
                <count group_id="O3" value="303"/>
                <count group_id="O4" value="92"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.14" spread="0.011"/>
                    <measurement group_id="O2" value="0.21" spread="0.011"/>
                    <measurement group_id="O3" value="0.19" spread="0.011"/>
                    <measurement group_id="O4" value="0.03" spread="0.021"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean EQ-5D Visual Analog Score (VAS) During the 12-Week Double-Blind Treatment</title>
        <description>EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single index value. The VAS component rates current health state on a scale from 0 mm (worst imaginable health state) to 100 mm (best imaginable health state); higher scores indicate a better health state.</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>FAS; OC</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg Twice Daily (BID)+Placebo Twice Weekly (BIW)</title>
            <description>Participants received CP-690,550 5 mg tablets, orally, BID, at approximately 12-hour intervals and placebo subcutaneous (SC) injections BIW at approximately 3- to 4-day intervals for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg BID + Placebo BIW</title>
            <description>Participants received CP-690,550 10 mg tablets, orally, BID, at approximately 12-hour intervals and placebo SC injections BIW at approximately 3- to 4-day intervals for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo BID + Etanercept 50 mg BIW</title>
            <description>Participants received matching placebo tablets, orally, BID, at approximately 12-hour intervals and etanercept 50 mg SC injections BIW at approximately 3- to 4-day intervals for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Placebo BID + Placebo BIW</title>
            <description>Participants received matching placebo tablets, orally, BID, at approximately 12-hour intervals and placebo SC injections BIW at approximately 3- to 4-day intervals for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean EQ-5D Visual Analog Score (VAS) During the 12-Week Double-Blind Treatment</title>
          <description>EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single index value. The VAS component rates current health state on a scale from 0 mm (worst imaginable health state) to 100 mm (best imaginable health state); higher scores indicate a better health state.</description>
          <population>FAS; OC</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="315"/>
                <count group_id="O2" value="318"/>
                <count group_id="O3" value="312"/>
                <count group_id="O4" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n=315,318,312,100)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.3" spread="1.3"/>
                    <measurement group_id="O2" value="63.3" spread="1.3"/>
                    <measurement group_id="O3" value="64.2" spread="1.3"/>
                    <measurement group_id="O4" value="60.5" spread="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (n=298,294,297,91)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.3" spread="1.1"/>
                    <measurement group_id="O2" value="81.1" spread="1.0"/>
                    <measurement group_id="O3" value="80.0" spread="1.0"/>
                    <measurement group_id="O4" value="65.1" spread="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in EQ-5D VAS at Week 12</title>
        <description>EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single index value. The VAS component rates current health state on a scale from 0 mm (worst imaginable health state) to 100 mm (best imaginable health state); higher scores indicate a better health state.</description>
        <time_frame>Week 12</time_frame>
        <population>FAS; OC</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg Twice Daily (BID)+Placebo Twice Weekly (BIW)</title>
            <description>Participants received CP-690,550 5 mg tablets, orally, BID, at approximately 12-hour intervals and placebo subcutaneous (SC) injections BIW at approximately 3- to 4-day intervals for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg BID + Placebo BIW</title>
            <description>Participants received CP-690,550 10 mg tablets, orally, BID, at approximately 12-hour intervals and placebo SC injections BIW at approximately 3- to 4-day intervals for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo BID + Etanercept 50 mg BIW</title>
            <description>Participants received matching placebo tablets, orally, BID, at approximately 12-hour intervals and etanercept 50 mg SC injections BIW at approximately 3- to 4-day intervals for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Placebo BID + Placebo BIW</title>
            <description>Participants received matching placebo tablets, orally, BID, at approximately 12-hour intervals and placebo SC injections BIW at approximately 3- to 4-day intervals for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in EQ-5D VAS at Week 12</title>
          <description>EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single index value. The VAS component rates current health state on a scale from 0 mm (worst imaginable health state) to 100 mm (best imaginable health state); higher scores indicate a better health state.</description>
          <population>FAS; OC</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="289"/>
                <count group_id="O2" value="288"/>
                <count group_id="O3" value="285"/>
                <count group_id="O4" value="88"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.6" spread="1.4"/>
                    <measurement group_id="O2" value="16.6" spread="1.5"/>
                    <measurement group_id="O3" value="15.7" spread="1.4"/>
                    <measurement group_id="O4" value="3.0" spread="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Dimension Health State EQ-5D Score During the 12-Week Double-Blind Treatment</title>
        <description>EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 dimensions: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression. The score for each of the 5 dimensions can range from 1 to 3; 1 indicates better health state (no problems); 3 indicates worst health state (&quot;confined to bed&quot;).</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>FAS; OC</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg Twice Daily (BID)+Placebo Twice Weekly (BIW)</title>
            <description>Participants received CP-690,550 5 mg tablets, orally, BID, at approximately 12-hour intervals and placebo subcutaneous (SC) injections BIW at approximately 3- to 4-day intervals for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg BID + Placebo BIW</title>
            <description>Participants received CP-690,550 10 mg tablets, orally, BID, at approximately 12-hour intervals and placebo SC injections BIW at approximately 3- to 4-day intervals for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo BID + Etanercept 50 mg BIW</title>
            <description>Participants received matching placebo tablets, orally, BID, at approximately 12-hour intervals and etanercept 50 mg SC injections BIW at approximately 3- to 4-day intervals for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Placebo BID + Placebo BIW</title>
            <description>Participants received matching placebo tablets, orally, BID, at approximately 12-hour intervals and placebo SC injections BIW at approximately 3- to 4-day intervals for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Dimension Health State EQ-5D Score During the 12-Week Double-Blind Treatment</title>
          <description>EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 dimensions: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression. The score for each of the 5 dimensions can range from 1 to 3; 1 indicates better health state (no problems); 3 indicates worst health state (&quot;confined to bed&quot;).</description>
          <population>FAS; OC</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="326"/>
                <count group_id="O2" value="327"/>
                <count group_id="O3" value="330"/>
                <count group_id="O4" value="104"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Mobility, Baseline (n=326,327,330,104)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" spread="0.0"/>
                    <measurement group_id="O2" value="1.3" spread="0.0"/>
                    <measurement group_id="O3" value="1.3" spread="0.0"/>
                    <measurement group_id="O4" value="1.3" spread="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mobility, Week 12 (n=306,304,307,95)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" spread="0.0"/>
                    <measurement group_id="O2" value="1.1" spread="0.0"/>
                    <measurement group_id="O3" value="1.2" spread="0.0"/>
                    <measurement group_id="O4" value="1.3" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Self Care, Baseline (n=327,327,330,104)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" spread="0.0"/>
                    <measurement group_id="O2" value="1.1" spread="0.0"/>
                    <measurement group_id="O3" value="1.1" spread="0.0"/>
                    <measurement group_id="O4" value="1.2" spread="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Self Care, Week 12 (n=306,304,307,95)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" spread="0.0"/>
                    <measurement group_id="O2" value="1.0" spread="0.0"/>
                    <measurement group_id="O3" value="1.1" spread="0.0"/>
                    <measurement group_id="O4" value="1.2" spread="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Usual Activities, Baseline (n=327,327,330,104)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" spread="0.0"/>
                    <measurement group_id="O2" value="1.4" spread="0.0"/>
                    <measurement group_id="O3" value="1.4" spread="0.0"/>
                    <measurement group_id="O4" value="1.5" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Usual Activities, Week 12 (n=307,304,307,95)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" spread="0.0"/>
                    <measurement group_id="O2" value="1.1" spread="0.0"/>
                    <measurement group_id="O3" value="1.2" spread="0.0"/>
                    <measurement group_id="O4" value="1.3" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain/Discomfort, Baseline (n=327,328,330,104)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8" spread="0.0"/>
                    <measurement group_id="O2" value="1.8" spread="0.0"/>
                    <measurement group_id="O3" value="1.9" spread="0.0"/>
                    <measurement group_id="O4" value="1.8" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain/Discomfort, Week 12 (n=307,304,307,95)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" spread="0.0"/>
                    <measurement group_id="O2" value="1.3" spread="0.0"/>
                    <measurement group_id="O3" value="1.4" spread="0.0"/>
                    <measurement group_id="O4" value="1.7" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anxiety/Depression, Baseline (n=326,327,330,104)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" spread="0.0"/>
                    <measurement group_id="O2" value="1.7" spread="0.0"/>
                    <measurement group_id="O3" value="1.6" spread="0.0"/>
                    <measurement group_id="O4" value="1.7" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anxiety/Depression, Week 12 (n=305,304,307,95)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" spread="0.0"/>
                    <measurement group_id="O2" value="1.3" spread="0.0"/>
                    <measurement group_id="O3" value="1.3" spread="0.0"/>
                    <measurement group_id="O4" value="1.5" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in EQ-5D Dimension Health State Score at Week 12</title>
        <description>EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 dimensions: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression. The score for each of the 5 dimensions can range from 1 to 3; 1 indicates better health state (no problems); 3 indicates worst health state (&quot;confined to bed&quot;).</description>
        <time_frame>Week 12</time_frame>
        <population>FAS; OC</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg Twice Daily (BID)+Placebo Twice Weekly (BIW)</title>
            <description>Participants received CP-690,550 5 mg tablets, orally, BID, at approximately 12-hour intervals and placebo subcutaneous (SC) injections BIW at approximately 3- to 4-day intervals for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg BID + Placebo BIW</title>
            <description>Participants received CP-690,550 10 mg tablets, orally, BID, at approximately 12-hour intervals and placebo SC injections BIW at approximately 3- to 4-day intervals for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo BID + Etanercept 50 mg BIW</title>
            <description>Participants received matching placebo tablets, orally, BID, at approximately 12-hour intervals and etanercept 50 mg SC injections BIW at approximately 3- to 4-day intervals for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Placebo BID + Placebo BIW</title>
            <description>Participants received matching placebo tablets, orally, BID, at approximately 12-hour intervals and placebo SC injections BIW at approximately 3- to 4-day intervals for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in EQ-5D Dimension Health State Score at Week 12</title>
          <description>EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 dimensions: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression. The score for each of the 5 dimensions can range from 1 to 3; 1 indicates better health state (no problems); 3 indicates worst health state (&quot;confined to bed&quot;).</description>
          <population>FAS; OC</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="305"/>
                <count group_id="O2" value="302"/>
                <count group_id="O3" value="303"/>
                <count group_id="O4" value="92"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Mobility</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" spread="0.0"/>
                    <measurement group_id="O2" value="-0.1" spread="0.0"/>
                    <measurement group_id="O3" value="-0.1" spread="0.0"/>
                    <measurement group_id="O4" value="-0.0" spread="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Self-Care</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" spread="0.0"/>
                    <measurement group_id="O2" value="-0.1" spread="0.0"/>
                    <measurement group_id="O3" value="-0.1" spread="0.0"/>
                    <measurement group_id="O4" value="-0.1" spread="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Usual Activities</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" spread="0.0"/>
                    <measurement group_id="O2" value="-0.3" spread="0.0"/>
                    <measurement group_id="O3" value="-0.2" spread="0.0"/>
                    <measurement group_id="O4" value="-0.1" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain/Discomfort</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4" spread="0.0"/>
                    <measurement group_id="O2" value="-0.5" spread="0.0"/>
                    <measurement group_id="O3" value="-0.5" spread="0.0"/>
                    <measurement group_id="O4" value="-0.1" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anxiety/Depression</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2" spread="0.0"/>
                    <measurement group_id="O2" value="-0.4" spread="0.0"/>
                    <measurement group_id="O3" value="-0.3" spread="0.0"/>
                    <measurement group_id="O4" value="-0.1" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Interacting With Healthcare Professionals During the 12-Week Double-Blind Treatment</title>
        <description>The Psoriasis Health Care Resource Utilization (Ps-HCRU) questionnaire is a short questionnaire designed to assess healthcare resource use and the impact of psoriasis on work. The first section assesses direct costs associated with healthcare resource use (interactions with healthcare providers such as general practitioners [GPs], primary care physicians [PCPs], or family medicine physicians [FMP], emergency room visits, and hospitalizations), and the second section assesses indirect costs associated with absenteeism due to psoriasis and the impact of psoriasis on productivity at work.</description>
        <time_frame>Baseline (BL) and Week 12</time_frame>
        <population>FAS; OC</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg Twice Daily (BID)+Placebo Twice Weekly (BIW)</title>
            <description>Participants received CP-690,550 5 mg tablets, orally, BID, at approximately 12-hour intervals and placebo subcutaneous (SC) injections BIW at approximately 3- to 4-day intervals for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg BID + Placebo BIW</title>
            <description>Participants received CP-690,550 10 mg tablets, orally, BID, at approximately 12-hour intervals and placebo SC injections BIW at approximately 3- to 4-day intervals for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo BID + Etanercept 50 mg BIW</title>
            <description>Participants received matching placebo tablets, orally, BID, at approximately 12-hour intervals and etanercept 50 mg SC injections BIW at approximately 3- to 4-day intervals for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Placebo BID + Placebo BIW</title>
            <description>Participants received matching placebo tablets, orally, BID, at approximately 12-hour intervals and placebo SC injections BIW at approximately 3- to 4-day intervals for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Interacting With Healthcare Professionals During the 12-Week Double-Blind Treatment</title>
          <description>The Psoriasis Health Care Resource Utilization (Ps-HCRU) questionnaire is a short questionnaire designed to assess healthcare resource use and the impact of psoriasis on work. The first section assesses direct costs associated with healthcare resource use (interactions with healthcare providers such as general practitioners [GPs], primary care physicians [PCPs], or family medicine physicians [FMP], emergency room visits, and hospitalizations), and the second section assesses indirect costs associated with absenteeism due to psoriasis and the impact of psoriasis on productivity at work.</description>
          <population>FAS; OC</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="255"/>
                <count group_id="O2" value="251"/>
                <count group_id="O3" value="261"/>
                <count group_id="O4" value="79"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline, GP/PCP/FMP (n=230,220,224,77)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8"/>
                    <measurement group_id="O2" value="0.9"/>
                    <measurement group_id="O3" value="1.3"/>
                    <measurement group_id="O4" value="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline, Dermatologist (n=230,220,224,77)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.9"/>
                    <measurement group_id="O2" value="4.5"/>
                    <measurement group_id="O3" value="7.5"/>
                    <measurement group_id="O4" value="10.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline, Rheumatologist (n=230,220,224,77)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline, Cardiologist (n=230,220,224,77)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4"/>
                    <measurement group_id="O2" value="0.4"/>
                    <measurement group_id="O3" value="0.4"/>
                    <measurement group_id="O4" value="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline, Gastroenterologist (n=230,220,224,77)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline, Psychiatrist (n=230,220,224,77)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.4"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline, Surgeon (n=230,220,224,77)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline, Nurse (n=230,220,224,77)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3"/>
                    <measurement group_id="O2" value="1.3"/>
                    <measurement group_id="O3" value="0.8"/>
                    <measurement group_id="O4" value="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline, Other (n=230,220,224,77)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1"/>
                    <measurement group_id="O2" value="0.9"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12, GP/PCP/FMP (n=255,251,261,79)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.1"/>
                    <measurement group_id="O2" value="6.7"/>
                    <measurement group_id="O3" value="8.4"/>
                    <measurement group_id="O4" value="8.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12, Dermatologist (n=255,251,261,79)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.2"/>
                    <measurement group_id="O2" value="4.3"/>
                    <measurement group_id="O3" value="5.7"/>
                    <measurement group_id="O4" value="7.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12, Rheumatologist (n=255,251,261,79)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7"/>
                    <measurement group_id="O2" value="1.1"/>
                    <measurement group_id="O3" value="0.7"/>
                    <measurement group_id="O4" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12, Cardiologist (n=255,251,261,79)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5"/>
                    <measurement group_id="O2" value="1.9"/>
                    <measurement group_id="O3" value="2.6"/>
                    <measurement group_id="O4" value="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12, Gastroenterologist (n=255,251,261,79)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1"/>
                    <measurement group_id="O2" value="1.5"/>
                    <measurement group_id="O3" value="1.5"/>
                    <measurement group_id="O4" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12, Psychiatrist (n=255,251,261,79)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.7"/>
                    <measurement group_id="O3" value="1.5"/>
                    <measurement group_id="O4" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12, Surgeon (n=255,251,261,79)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3"/>
                    <measurement group_id="O2" value="0.3"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12, Nurse (n=255,251,261,79)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1"/>
                    <measurement group_id="O2" value="1.9"/>
                    <measurement group_id="O3" value="2.6"/>
                    <measurement group_id="O4" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12, Other (n=255,251,261,79)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.6"/>
                    <measurement group_id="O2" value="5.1"/>
                    <measurement group_id="O3" value="6.8"/>
                    <measurement group_id="O4" value="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Reporting Healthcare Resource Use Events During the 12-Week Double-Blind Treatment</title>
        <time_frame>Week 12</time_frame>
        <population>FAS; OC</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg Twice Daily (BID)+Placebo Twice Weekly (BIW)</title>
            <description>Participants received CP-690,550 5 mg tablets, orally, BID, at approximately 12-hour intervals and placebo subcutaneous (SC) injections BIW at approximately 3- to 4-day intervals for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg BID + Placebo BIW</title>
            <description>Participants received CP-690,550 10 mg tablets, orally, BID, at approximately 12-hour intervals and placebo SC injections BIW at approximately 3- to 4-day intervals for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo BID + Etanercept 50 mg BIW</title>
            <description>Participants received matching placebo tablets, orally, BID, at approximately 12-hour intervals and etanercept 50 mg SC injections BIW at approximately 3- to 4-day intervals for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Placebo BID + Placebo BIW</title>
            <description>Participants received matching placebo tablets, orally, BID, at approximately 12-hour intervals and placebo SC injections BIW at approximately 3- to 4-day intervals for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Reporting Healthcare Resource Use Events During the 12-Week Double-Blind Treatment</title>
          <population>FAS; OC</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="230"/>
                <count group_id="O2" value="225"/>
                <count group_id="O3" value="238"/>
                <count group_id="O4" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.43"/>
                    <measurement group_id="O2" value="9.78"/>
                    <measurement group_id="O3" value="10.08"/>
                    <measurement group_id="O4" value="8.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Employed or Not Employed and the Impact of Psoriasis on Work</title>
        <description>Psoriasis Health Care Resource Utilization Questionnaire is a short questionnaire designed to assess healthcare resource use and the impact of psoriasis on work. The questionnaire assesses employment status of participant (employed: yes or no) and if currently employed it asks the participant if they were absent or on sick leave from work due to psoriasis; if unemployed it asks the participant if the unemployment is due to psoriasis.</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>FAS; OC</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg Twice Daily (BID)+Placebo Twice Weekly (BIW)</title>
            <description>Participants received CP-690,550 5 mg tablets, orally, BID, at approximately 12-hour intervals and placebo subcutaneous (SC) injections BIW at approximately 3- to 4-day intervals for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg BID + Placebo BIW</title>
            <description>Participants received CP-690,550 10 mg tablets, orally, BID, at approximately 12-hour intervals and placebo SC injections BIW at approximately 3- to 4-day intervals for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo BID + Etanercept 50 mg BIW</title>
            <description>Participants received matching placebo tablets, orally, BID, at approximately 12-hour intervals and etanercept 50 mg SC injections BIW at approximately 3- to 4-day intervals for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Placebo BID + Placebo BIW</title>
            <description>Participants received matching placebo tablets, orally, BID, at approximately 12-hour intervals and placebo SC injections BIW at approximately 3- to 4-day intervals for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Employed or Not Employed and the Impact of Psoriasis on Work</title>
          <description>Psoriasis Health Care Resource Utilization Questionnaire is a short questionnaire designed to assess healthcare resource use and the impact of psoriasis on work. The questionnaire assesses employment status of participant (employed: yes or no) and if currently employed it asks the participant if they were absent or on sick leave from work due to psoriasis; if unemployed it asks the participant if the unemployment is due to psoriasis.</description>
          <population>FAS; OC</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="230"/>
                <count group_id="O2" value="219"/>
                <count group_id="O3" value="224"/>
                <count group_id="O4" value="77"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline, employed</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.8"/>
                    <measurement group_id="O2" value="71.2"/>
                    <measurement group_id="O3" value="72.3"/>
                    <measurement group_id="O4" value="71.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline, absent/sick leave due to psoriasis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.3"/>
                    <measurement group_id="O2" value="21.0"/>
                    <measurement group_id="O3" value="22.3"/>
                    <measurement group_id="O4" value="23.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline, not employed</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.2"/>
                    <measurement group_id="O2" value="28.8"/>
                    <measurement group_id="O3" value="27.7"/>
                    <measurement group_id="O4" value="28.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline, unemployed due to psoriasis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.6"/>
                    <measurement group_id="O2" value="7.3"/>
                    <measurement group_id="O3" value="6.3"/>
                    <measurement group_id="O4" value="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12, employed</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.2"/>
                    <measurement group_id="O2" value="73.8"/>
                    <measurement group_id="O3" value="69.1"/>
                    <measurement group_id="O4" value="68.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12, absent/sick leave due to psoriasis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.2"/>
                    <measurement group_id="O2" value="14.7"/>
                    <measurement group_id="O3" value="15.7"/>
                    <measurement group_id="O4" value="17.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12, not employed</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.8"/>
                    <measurement group_id="O2" value="26.2"/>
                    <measurement group_id="O3" value="30.9"/>
                    <measurement group_id="O4" value="31.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12, unemployed due to psoriasis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0"/>
                    <measurement group_id="O2" value="4.9"/>
                    <measurement group_id="O3" value="4.7"/>
                    <measurement group_id="O4" value="4.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Reporting Work-Impacted Events During the 12-Week Double-Blind Treatment</title>
        <description>Psoriasis Health Care Resource Utilization Questionnaire is a short questionnaire designed to assess healthcare resource use and the impact of psoriasis on work.</description>
        <time_frame>Week 12</time_frame>
        <population>FAS; OC</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg Twice Daily (BID)+Placebo Twice Weekly (BIW)</title>
            <description>Participants received CP-690,550 5 mg tablets, orally, BID, at approximately 12-hour intervals and placebo subcutaneous (SC) injections BIW at approximately 3- to 4-day intervals for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg BID + Placebo BIW</title>
            <description>Participants received CP-690,550 10 mg tablets, orally, BID, at approximately 12-hour intervals and placebo SC injections BIW at approximately 3- to 4-day intervals for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo BID + Etanercept 50 mg BIW</title>
            <description>Participants received matching placebo tablets, orally, BID, at approximately 12-hour intervals and etanercept 50 mg SC injections BIW at approximately 3- to 4-day intervals for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Placebo BID + Placebo BIW</title>
            <description>Participants received matching placebo tablets, orally, BID, at approximately 12-hour intervals and placebo SC injections BIW at approximately 3- to 4-day intervals for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Reporting Work-Impacted Events During the 12-Week Double-Blind Treatment</title>
          <description>Psoriasis Health Care Resource Utilization Questionnaire is a short questionnaire designed to assess healthcare resource use and the impact of psoriasis on work.</description>
          <population>FAS; OC</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="158"/>
                <count group_id="O2" value="164"/>
                <count group_id="O3" value="164"/>
                <count group_id="O4" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.97"/>
                    <measurement group_id="O2" value="30.49"/>
                    <measurement group_id="O3" value="34.15"/>
                    <measurement group_id="O4" value="56.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Psoriasis Quality of Life 12 (PQOL-12) Score During the 12-Week Double-Blind Treatment</title>
        <description>The PQOL-12 is a 12-item questionnaire; 8 of the items on the Koo-Menter Psoriasis Index 12-item Quality of Life Questionnaire (PQOL-12) focus on emotional issues associated with psoriasis (self conscious, helpless, embarrassed, ability to enjoy life). The last 4 items deal with physical symptoms (pain or soreness, itch, physical irritation) and choice of clothing. The recall period is over the past month. The questions are answered on a scale from 0 to 10 with 0 being best and 10 being worst. Scores from each question are summed to give a total score (range 0 -120); higher scores indicate greater impairment to quality of life.</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>FAS; OC</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg Twice Daily (BID)+Placebo Twice Weekly (BIW)</title>
            <description>Participants received CP-690,550 5 mg tablets, orally, BID, at approximately 12-hour intervals and placebo subcutaneous (SC) injections BIW at approximately 3- to 4-day intervals for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg BID + Placebo BIW</title>
            <description>Participants received CP-690,550 10 mg tablets, orally, BID, at approximately 12-hour intervals and placebo SC injections BIW at approximately 3- to 4-day intervals for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo BID + Etanercept 50 mg BIW</title>
            <description>Participants received matching placebo tablets, orally, BID, at approximately 12-hour intervals and etanercept 50 mg SC injections BIW at approximately 3- to 4-day intervals for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Placebo BID + Placebo BIW</title>
            <description>Participants received matching placebo tablets, orally, BID, at approximately 12-hour intervals and placebo SC injections BIW at approximately 3- to 4-day intervals for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Psoriasis Quality of Life 12 (PQOL-12) Score During the 12-Week Double-Blind Treatment</title>
          <description>The PQOL-12 is a 12-item questionnaire; 8 of the items on the Koo-Menter Psoriasis Index 12-item Quality of Life Questionnaire (PQOL-12) focus on emotional issues associated with psoriasis (self conscious, helpless, embarrassed, ability to enjoy life). The last 4 items deal with physical symptoms (pain or soreness, itch, physical irritation) and choice of clothing. The recall period is over the past month. The questions are answered on a scale from 0 to 10 with 0 being best and 10 being worst. Scores from each question are summed to give a total score (range 0 -120); higher scores indicate greater impairment to quality of life.</description>
          <population>FAS; OC</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="323"/>
                <count group_id="O2" value="326"/>
                <count group_id="O3" value="331"/>
                <count group_id="O4" value="105"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n=323,326,331,105)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.4" spread="1.5"/>
                    <measurement group_id="O2" value="77.0" spread="1.5"/>
                    <measurement group_id="O3" value="75.7" spread="1.5"/>
                    <measurement group_id="O4" value="74.9" spread="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (n=303,303,306,92)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.0" spread="1.8"/>
                    <measurement group_id="O2" value="29.2" spread="1.6"/>
                    <measurement group_id="O3" value="31.0" spread="1.7"/>
                    <measurement group_id="O4" value="65.5" spread="3.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in PQOL-12 Score During the 12-Week Double-Blind Treatment</title>
        <description>The PQOL-12 is a 12-item questionnaire; 8 of the items on the PQOL-12) focus on emotional issues associated with psoriasis (self conscious, helpless, embarrassed, ability to enjoy life). The last 4 items deal with physical symptoms (pain or soreness, itch, physical irritation) and choice of clothing. The recall period is over the past month. The questions are answered on a scale from 0 to 10 with 0 being best and 10 being worst. Scores from each question are summed to give a total score (range 0 -120); higher scores indicate greater impairment to quality of life.</description>
        <time_frame>Week 12</time_frame>
        <population>FAS; OC</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg Twice Daily (BID)+Placebo Twice Weekly (BIW)</title>
            <description>Participants received CP-690,550 5 mg tablets, orally, BID, at approximately 12-hour intervals and placebo subcutaneous (SC) injections BIW at approximately 3- to 4-day intervals for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg BID + Placebo BIW</title>
            <description>Participants received CP-690,550 10 mg tablets, orally, BID, at approximately 12-hour intervals and placebo SC injections BIW at approximately 3- to 4-day intervals for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo BID + Etanercept 50 mg BIW</title>
            <description>Participants received matching placebo tablets, orally, BID, at approximately 12-hour intervals and etanercept 50 mg SC injections BIW at approximately 3- to 4-day intervals for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Placebo BID + Placebo BIW</title>
            <description>Participants received matching placebo tablets, orally, BID, at approximately 12-hour intervals and placebo SC injections BIW at approximately 3- to 4-day intervals for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in PQOL-12 Score During the 12-Week Double-Blind Treatment</title>
          <description>The PQOL-12 is a 12-item questionnaire; 8 of the items on the PQOL-12) focus on emotional issues associated with psoriasis (self conscious, helpless, embarrassed, ability to enjoy life). The last 4 items deal with physical symptoms (pain or soreness, itch, physical irritation) and choice of clothing. The recall period is over the past month. The questions are answered on a scale from 0 to 10 with 0 being best and 10 being worst. Scores from each question are summed to give a total score (range 0 -120); higher scores indicate greater impairment to quality of life.</description>
          <population>FAS; OC</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="299"/>
                <count group_id="O2" value="299"/>
                <count group_id="O3" value="303"/>
                <count group_id="O4" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-35.2" spread="1.9"/>
                    <measurement group_id="O2" value="-47.9" spread="1.8"/>
                    <measurement group_id="O3" value="-44.3" spread="1.8"/>
                    <measurement group_id="O4" value="-9.6" spread="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>The same event may appear as both an adverse event (AE) and a serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.</desc>
      <group_list>
        <group group_id="E1">
          <title>CP-690,550 5 mg BID</title>
          <description>Participants received CP-690,550 5 mg tablets, orally, BID at approximately 12-hour intervals and placebo SC injections BIW at approximately 3- to 4-day intervals for 12 weeks.</description>
        </group>
        <group group_id="E2">
          <title>CP-690,550 10 mg BID</title>
          <description>Participants received CP-690,550 10 mg tablets, orally, BID at approximately 12-hour intervals and placebo SC injections BIW at approximately 3- to 4-day intervals for 12 weeks.</description>
        </group>
        <group group_id="E3">
          <title>Etanercept 50 mg BIW</title>
          <description>Participants received matching placebo tablets, orally, BID at approximately 12-hour intervals and etanercept 50 mg SC injections BIW at approximately 3- to 4-day intervals for 12 weeks.</description>
        </group>
        <group group_id="E4">
          <title>Placebo</title>
          <description>Participants received matching placebo tablets, orally, BID at approximately 12-hour intervals and placebo SC injections BIW at approximately 3- to 4-day intervals for 12 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (v16.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="330"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="335"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="335"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Uveitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="335"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="335"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Jaundice</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="335"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="335"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="335"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Extradural abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="335"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Paronychia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="335"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Perineal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="335"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="335"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Foot fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="335"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Lower limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="335"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Poisoning</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="335"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="335"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Thoracic vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="335"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Gastric cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="335"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Ischaemic cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="335"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="335"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal colic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="335"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="335"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Psoriasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="330"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="335"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA (v16.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="103" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="121" subjects_at_risk="330"/>
                <counts group_id="E3" subjects_affected="109" subjects_at_risk="335"/>
                <counts group_id="E4" subjects_affected="34" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="335"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="330"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="335"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="335"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Injection site reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="335"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Folliculitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="330"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="335"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="330"/>
                <counts group_id="E3" subjects_affected="25" subjects_at_risk="335"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="330"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="335"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="330"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="335"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood cholesterol increased</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="330"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="335"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="330"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="335"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dyslipidaemia</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="330"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="335"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Hypercholesterolaemia</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="330"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="335"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="330"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="335"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="330"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="335"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="335"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Psoriasis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="335"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="330"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="335"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Clinical interpretation regarding sub-phenotypes of psoriasis (e.g., scalp psoriasis) should not be made based on the reported assessments by body regions. For example, the body region of head does not reflect solely scalp psoriasis.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Pfizer ClinicalTrials.gov Call Center</name_or_title>
      <organization>Pfizer, Inc.</organization>
      <phone>1-800-718-1021</phone>
      <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

